Method for controlling membrane potential-dependent ion channel through type i taste receptors (T1RS)
Patent Information
- Application Number
- JP2024527046
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-17
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-06-09
AI Technical Summary
Current treatments for neurological diseases such as Alzheimer's and neuropathic pain lack effective methods to control voltage-gated sodium channels (VGSC) activity, which contributes to neuronal hyperactivity and excitability, due to the difficulty in selectively targeting these channels without affecting heart function.
The method involves using Type I taste receptors (T1Rs) to control VGSC activity through ligands that bind to T1R3, specifically inhibiting amyloid β peptide binding to these receptors, thereby modulating VGSC activity and reducing neuronal overactivity.
This approach effectively suppresses VGSC activity, alleviating neuropathic pain and preventing neuronal death, offering a therapeutic option for Alzheimer's disease and other neurodegenerative conditions by targeting T1R3 with substances like DichlorProp and antibodies.
Abstract
Description
Method for controlling voltage-dependent ion channels via type I taste receptors (T1Rs)
[0001] The present invention is based on the first discovery that Type I taste receptors, which are umami and sweet taste receptors, are involved in not only taste perception but also cytoskeletal polymerization / depolymerization and the regulation of ion channels such as voltage-gated sodium channels (VGSCs) and voltage-gated potassium channels (VGKCs). The present invention relates to a method for regulating VGSCs and VGKCs via umami and sweet GPCR receptors (Type I taste receptors, "T1Rs" gene family) present in neurons and cardiomyocytes. The present invention also relates to a ligand substance that specifically binds to Type I taste receptors (e.g., T1R3) and can regulate VGSC-activated currents amplified by the binding of sweet amino acids or umami substances to Type I taste receptors on the neuronal surface, as well as a screening method for such a substance. Furthermore, the present invention relates to a pharmaceutical composition for the prevention and / or treatment of neurological disorders caused by the amplification of VGSC-activated currents induced by sweet amino acids or umami substances via Type I taste receptors on the neuronal surface, which contains the ligand substance as an active ingredient, and a screening method for such a pharmaceutical composition.
[0002] The present invention is also based on the discovery that Type I taste receptors are activated not only by amino acids and sweet substances, but also by amyloid beta peptide, and are involved in regulating the polymerization state of the cytoskeleton and regulating VGSC and VGKC. This strongly suggests that Type I taste receptors (T1R1, T1R2, T1R3) may act as receptors for amyloid beta peptide, affecting and influencing neuronal function, morphology, and the like, in neuronal dysfunction, which has been widely reported in neurodegenerative diseases such as Alzheimer's disease. That is, the present invention relates to a method for regulating VGSC via Type I taste receptors (the "T1Rs" gene family) present in neurons, etc. In particular, the present invention relates to a method for inhibiting voltage-gated sodium channels (VGSCs) using an amyloid beta peptide binding inhibitor, which is a T1R3 binding inhibitor that acts on the gustatory GPCR receptor "T1R3" in neurons. The present invention also relates to therapeutic agents for Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) using these T1R3 binding inhibitors of amyloid β peptide, and a screening method for the same.
[0003] Furthermore, the present invention relates to a method for inhibiting voltage-gated sodium channels (VGSCs) via the T1R2 / T1R3 sweet taste GPCR receptor, and to a pain treatment formulation using an Aβ peptide binding inhibitor such as an agonist or antagonist of the sweet taste GPCR receptor (T1R2 / T1R3), for neuropathic pain that occurs when an anticancer drug (Paclitaxel) is used in cancer treatment, and a screening method for the same.
[0004] During pain and epileptic seizures, frequent action potentials are observed in neurons. This phenomenon is due to neuronal hyperactivity. Therefore, the primary function of analgesics and antiepileptic drugs is to suppress frequent action potentials. It has also been reported that epileptic seizure-like symptoms due to neuronal hyperactivity occur in brain regions such as the hippocampus of patients with neurodegenerative diseases, particularly Alzheimer's disease (AD). It is believed that neuronal cell death occurs after this period of hyperactivity. Therefore, the development of drugs that suppress neuronal hyperactivity could also be effective as therapeutic agents for improving the symptoms of AD patients.
[0005] Furthermore, changes in amyloid beta peptide in cerebrospinal fluid (CSF) are known to occur in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and other neurodegenerative dementias (Bibl et al., (2007)). Amyloid beta peptide in CSF is used as a biomarker for AD and other conditions. Overexpression of amyloid precursor protein (APP) has been reported to increase sodium channel activity. Specifically, experiments using iPS-derived neurons have demonstrated that amyloid beta peptide induces neuronal hyperactivity and amplifies sodium channels. It has been reported that this hyperactivity can be suppressed by inhibiting BACE1, which cleaves APP and produces amyloid beta peptide (Non-Patent Document 1). However, the mechanism by which amyloid beta peptide enhances sodium channels remains unknown.
[0006] In addition, voltage-dependent Na + The VGSC channel is composed of many types of Na + There are channels in the blood that are widely distributed outside the brain. They play an especially important role in supporting cardiac contraction and nerve function, so blocking them carelessly can be life-threatening. + Drug discovery targeting the channel molecule itself + Selectively inhibiting the channel is difficult.
[0007] On the other hand, the activity (kinetics) of voltage-gated sodium channels (VGSCs) is known to be regulated by the activity of G proteins. G protein activation affects the amplitude and activation threshold of VGSC currents, thereby controlling the susceptibility (threshold) of action potentials. Many GPCR-type receptors on the cell membrane are known to activate serine / threonine kinases (PKA / PKC) through G proteins, thereby modifying VGSC activity. Activation of pertussis toxin-sensitive Gαi and Gαo shifts the SS curve of VGSCs toward hyperpolarization, and activation of Gαi and Gαo by thrombin further enhances this shift (Ma et al., 1994).
[0008] Furthermore, in umami and sweet taste GPCR receptors (Type I taste receptors, "T1Rs" gene family) present in neurons, Gαi binds to T1R1 / T1R3 (Husted et al., 2017) and T1R2 / T1R3 (Yang et al., 2020), suggesting that the action of T1R GPCRs on VGSCs also involves a Gαi-mediated mechanism. In addition to the action of G protein α subunits on VGSCs, the action of Gβγ has also been reported. Ma et al. (1997) reported that binding of Gβ2γ3, Gβ1γ3, or Gβ5γ3 to the carboxyl terminus of VGSCs delays the inactivation of VGSCs. However, this delayed inactivation effect is dependent on the Gβγ subtype, and no such effect is observed with Gβ1γ1 (Ma et al., 1997). This action is thought to be a direct action of Gβ2γ3 on VGSC, since the action of Gβ2γ3 can be reversed by adding adenylyl cyclase 2 and the Gβγ-binding motif, Gln-XX-Glu-Arg, present at the carboxyl end of VGSC. An example of Gβγ directly acting on an ion channel to control its activity is activation of GPCR coupled with Gi / Go, resulting in activated Gβγ directly acting on GIRK (G-protein activated Inwardly Rectifying Kinase). + ) and regulates its activity (Oliveira et al., 2019).
[0009] (2005) investigated the delay in inactivation of VGSC currents by Gβγ in different VGSCs (Nav1.1, Nav1.2, Nav1.4, and Nav1.5) and reported that the delay in inactivation by Gβγ occurred only in Nav1.1 and Nav1.2, but not in Nav1.4 or Nav1.5. Therefore, the delay in VGSC inactivation by Aβ1-42 is thought to be due to the action of a different Gβγ type or a different mechanism.
[0010] Additionally, it has been reported that T1R3 GPCR couples with Gαs, causing depolymerization of microtubules, resulting in activation of the Rho / ROCK pathway via Gα12 / 13 (Masubuchi et al., 2017), and that T1R1 / T1R3 (Husted et al., 2017) and T1R2 / T1R3 (Yang et al., 2020) both bind to Gαi.
[0011] On the other hand, in the central nervous system, numerous studies have reported that activation of PKA / PKC results in the phosphorylation of VGSCs, thereby suppressing VGSC activity. For example, PKA activation has been shown to suppress VGSCs in hippocampal pyramidal neurons (Cantrell et al. (1996)), 5-HT2a / c receptors in cortical pyramidal neurons (Carr et al. (2002)), and D1-class dopamine receptors in hippocampal pyramidal neurons and striatal medium spiny neurons (Cantrell et al. (1997); Surmeier et al. (1992)). PKC activation, which is mediated by D2 dopamine receptor activation (Carr et al. (2003)), has been shown to suppress VGSCs in striatal medium spiny neurons and cholinergic interneurons.
[0012] Furthermore, because VGSCs play a key role in action potential generation in both the peripheral and central nervous systems, changes in VGSC activation thresholds significantly affect nerve excitability and are deeply involved in the pathogenesis of neuropathic pain. A typical example of neuropathic pain is chemotherapy (paclitaxel)-induced neuropathic pain, which occurs when the anticancer drug paclitaxel is used for cancer treatment. Paclitaxel increases the expression of VGSCs in the dorsal root ganglion (DRG) neuronal cell bodies, which are inhibited by ProTx II, a VGSC blocker specific for Nav1.7. This results in an increase in the frequency of spontaneous firing of sensory neuron action potentials in peripheral nerves, leading to neuropathic pain (Non-Patent Document 3). Neuropathic pain is estimated to affect 6% to 17% of the general population and is associated with reduced quality of life (QOL) and functional impairment (North, RY, et al., (2018)). In 2016, an estimated 20.4% of American adults reported chronic pain, with 8.0% reporting severe chronic pain that affected their daily lives (Dahlhamer J., et al. (2016)). Statistics in Japan showed that the prevalence of chronic pain was 16.6%, and the prevalence of chronic pain associated with a decline in quality of life (QOL) was 3.2% (Inoue, S., et al. (2017)).
[0013] Diseases and conditions such as failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and diabetic polyneuropathy are known to cause chronic neuropathic pain syndromes (Huygen, Frank, et al. (2019)). Typical causes of neuropathic pain include peripheral neuropathy, such as diabetic neuropathy and postherpetic neuralgia. Neuropathic pain in peripheral nerves (primary sensory neurons) increases the excitability of primary sensory neurons, resulting in chronic pain. Increased excitability of primary sensory neurons also affects central excitability, making pain intractable. Chronic pain and neuropathy during and after chemotherapy significantly impact patients' quality of life (QOL) (Xiao et al. (2008), Authier et al. (2009), Quintao, et al. (2019)). Chemotherapy-induced peripheral neuropathic pain is one of the most serious side effects of anticancer drugs, including platinum- and taxane-derived drugs (oxaliplatin, cisplatin, carboplatin, and paclitaxel). Due to its severity, chemotherapy-induced peripheral neuropathic pain can even lead to treatment discontinuation and potentially increase the risk of death (Quintao, et al. (2019)). Electrophysiological studies have demonstrated that chronic pain and neuropathy are caused by spontaneous action potential activity observed in sensory afferent nerves, and that chemotherapy-induced painful peripheral neuropathy is thought to be caused by abnormal activity of spontaneous afferent nerves.
[0014] In recent years, the quality of life of patients has become more important in the medical field, and there is a general trend to actively control pain. + The VGSC exists in the cell membrane of sensory neurons and has the function of opening and closing depending on the membrane potential to allow ions to pass through. +It is a channel with high selectivity for ions and plays an important role in the generation of action potentials, so it has long been known as an important drug target in the treatment of pain. VGSCs not only generate action potentials in the peripheral and central nervous system, but also greatly affect nerve excitability, such as suppressing excitability by controlling the VGSC activation threshold, and are deeply involved in the pathogenesis of neuropathic pain. Since nerve cells transmit pain signals to the central nervous system using electrical pulses called action potentials, pain can be blocked by inhibiting VGSCs. Therefore, Na + Channel (VGSC) blockers are important potential analgesic drugs.
[0015] However, VGSCs support cardiac contraction and nerve function, so blocking them carelessly can be life-threatening. + The presence of channels and their structures are similar, + In drug discovery targeting the channel molecule itself, the target Na + It is difficult to selectively inhibit the Na channel. + It is extremely difficult to develop a drug that can subtly adjust the channel, such as by restoring a slightly hypersensitive response to normal, rather than completely suppressing it. In other words, a system is needed that can continuously provide substances that act specifically on VGSCs on peripheral neurons and appropriately adjust their degree of activity.
[0016] Furthermore, as mentioned above, it has been reported that amyloid beta peptide expression increases in brain regions where AD has developed, and that overexpression of amyloid precursor protein (APP) increases VGSC activity. Therefore, if we can clarify the receptors expressed in brain regions through which amyloid beta peptide enhances VGSC activity and by what mechanism, and if we can find a substance that inhibits the binding of amyloid beta peptide to the receptor that enhances VGSC activity, it is expected that this will lead to the development of pharmaceuticals that can treat or prevent the onset or worsening of AD.
[0017] However, according to Shakoor et al. (2017), "Although we have been able to treat the symptoms of over 500 genetically engineered mice that develop Alzheimer's disease, the results of mouse models have not translated to the treatment of human dementia." This complicates Alzheimer's disease research and drug discovery, as it is unclear how amyloid beta peptide affects or inhibits the function of human (neuron) cells and what receptors it possesses. Therefore, to effectively treat and prevent AD, it is urgent to identify the GPCR receptors present on the surface of neurons in human cerebrospinal fluid (CSF) that activate VGSC currents by acting as ligands with amyloid beta peptide, causing central nervous system hyperactivity.
[0018] Ghatak,et al., ELife 8 (November 29, 2019).https: / / doi.org / 10.7554 / eLife.50333.Li, et al. (2002)Proceedings of the National Academy of Sciences 99, no. 7: 4692-96. https: / / doi.org / 10.1073 / pnas.072090199.Li, et al. (2018) The Journal of Neuroscience 38, no. 5: 1124-36. https: / / doi.org / 10.1523 / JNEUROSCI.0899-17.2017.Maillet, et al. (2015) Chemical Senses 40, no. 8: 577-86. https: / / doi.org / 10.1093 / chemse / bjv045.Martin, et al. (2017) Journal of Biological Chemistry 292, no. 27: 11508-30. https: / / doi.org / 10.1074 / jbc.M116.773820.Martinez, et al. (1993) Journal of Neural Transmission - Parkinson’s Disease and Dementia Section 6, no. 1: 1-9. https: / / doi.org / 10.1007 / BF02252617.Mattheisen, et al. (2018) Cell Reports 23, no. 9 (May 2018): 2770-81. https: / / doi.org / 10.1016 / j.celrep.2018.04.109.Vetter, et al. (2012) Biochemical Pharmacology 83, no. 11: 1562-71. https: / / doi.org / 10.1016 / j.bcp.2012.02.022.Xu, et al. (2015) Journal of Biological Chemistry 290, no. 27 (July 3, 2015): 16619-32.https: / / doi.org / 10.1074 / jbc.M115.638932.
[0019] The present invention provides an effective method for controlling VGSC activity in neurons by indirectly enhancing or inhibiting VGSC activity in neurons via T1Rs receptors, which are GPCR-type taste receptors such as sweet taste receptors (T1R2 / T1R3). The present invention also aims to indirectly and efficiently inhibit central nervous system hyperactivity caused by enhanced voltage-gated sodium channel (VGSC) activity due to amyloid beta peptide (Aβ) and / or amyloid precursor protein (APP), which are overexpressed in brain regions of patients with Alzheimer's disease (AD) and ALS, thereby preventing neuronal cell death and ameliorating epileptiform symptoms caused by neural hyperactivity, thereby treating or preventing AD and ALS. Another objective of the present invention is to treat or prevent neuropathic pain caused by enhanced VGSC activity in peripheral nerves by indirectly inhibiting VGSC activity via T1Rs receptors and restoring the overactive state of nerves to normal. To achieve this, the challenge is to identify a GPCR-type receptor that has amyloid β peptide as a ligand and that enhances the VGSC current in neurons through the receptor, thereby causing neural hyperactivity.
[0020] Type I taste receptors, consisting of T1R1, T1R2, and T1R3 GPCRs that sense umami and sweetness, are expressed not only in the oral cavity, where taste is sensed, but also in many tissues, including the nervous system. They are known to function as amino acid sensors for umami and other tastes, in addition to T1R2 / T1R3, which sense sweetness. The present inventors have discovered a novel biological phenomenon in which Type I taste receptors are activated by umami-containing amino acids and sweet substances, and regulate not only taste perception but also cytoskeletal polymerization / depolymerization, voltage-gated sodium channels (VGSCs), and voltage-gated potassium channels (VGKCs). Furthermore, they have discovered that Type I taste receptors are activated not only by amino acids and sweet substances, but also by amyloid beta peptides, and are involved in the regulation of cytoskeletal polymerization and the regulation of VGSCs and VGKCs. This strongly suggests that the neuronal dysfunction caused by amyloid beta peptide, which has been widely reported in neurodegenerative diseases such as Alzheimer's disease, may be due to Type I taste receptors (T1R1, T1R2, T1R3) acting as receptors for amyloid beta peptide, acting on and influencing neuronal function, morphology, etc. The present invention is based on these findings, and is specifically described below.
[0021] <Alzheimer's Disease and Gustatory Receptors> Sensory abnormalities, such as taste and smell, have been reported in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as neuropsychiatric disorders including ADHD and schizophrenia (Field et al., (2015)). In patients with mild cognitive impairment, olfactory discrimination impairment, particularly in patients who are not aware of olfactory impairment, may be clinically useful as an early diagnostic marker for Alzheimer's disease. It has also been reported that olfactory impairment is observed early in Alzheimer's disease and amyotrophic lateral sclerosis (ALS), and olfactory and gustatory dysfunction is observed early in Parkinson's disease, and may be useful as a biomarker for early disease development (Field et al. (2015)). Li et al. (2002) reported that T1R2 / T1R3 recognizes sweetness, including artificial sweeteners, and T1R1 / T1R3 recognizes umami (monosodium glutamate; MSG), and that the T1R1 / T1R3 response to MSG is enhanced by other umami 5'-ribonucleotides, IMP and GMP (Non-Patent Document 2). Meanwhile, Martin et al. analyzed the functional role of T1R3 using T1R3-KO mice and found that the T1R3 subunit is widely expressed throughout the brain and is abundant in the hypothalamus, hippocampus, and cortex (Non-Patent Document 5). This suggests that the sweet taste receptor system plays an important role in central nervous system tissues other than the tongue, supporting synaptic function, memory acquisition, and social behavior.
[0022] Furthermore, the present inventors have focused on the relationship between Alzheimer's disease (AD) and taste receptors, particularly sweet or umami taste receptors containing the T1R3 subunit, which are widely expressed in the central nervous system, including the hippocampus and cortex. Using human neuroblastoma SH-SY5Y cells (functionally expressing Nav1.2, Nav1.3, and Nav1.7; see Non-Patent Document 8) and HEK cells stably expressing Nav1.5 (endogenously expressing T1R1, T1R2, and T1R3), they observed the sodium channel activation effects of taste stimuli. By reducing the expression of the T1R1 and T1R3 genes with a silencer vector, they confirmed that the effects of taste stimuli on sodium channel currents are indeed mediated by the taste receptor GPCR. In SH-SY5Y cells, Nav1.7 is most abundant, followed by Nav1.3 >> Nav1.2 > Nav1.4 > Nav1.5 mRNA expression, and the functionally expressed genes that generate voltage-gated sodium channel (VGSC) currents are TTX-sensitive Nav1.7, Nav1.2, and Nav1.3 (Non-patent Document 8).
[0023] Next, to elucidate the mechanism by which amyloid beta (Aβ) peptides, which are overexpressed in the hippocampus and other areas of Alzheimer's disease (AD) and ALS patients, enhance voltage-gated sodium channels (VGSCs), we first conducted detailed experiments using Aβ25-35 peptide (ANASPEC). Experiments using SH-SY5Y cells and HEK cells demonstrated that Aβ25-35 peptides indirectly enhance the activity of VGSCs by binding to T1R3. Specifically, administration of Aβ25-35 peptide to SH-SY5Y cells enhanced the activity of Nav1.3 and Nav1.7 in VGSCs. On the other hand, we confirmed that the amyloid beta (Aβ) peptide's enhancing effect on Nav1.5 activity was not observed when HEK Nav1.5-expressing cells were first transfected with a T1R3-KO vector to reduce the amount of T1R3 expression in the cells. This indicates that the binding of Aβ25-35 peptide to T1R3 receptors expressed in neurons in cerebrospinal fluid (CSF) is the cause of VGCS activation, and strongly suggests that T1R3 binding inhibitors, such as T1R3 antagonists that bind to T1R3 competitively with Aβ25-35 peptide, can suppress the enhancement of VGSC by Aβ25-35 peptide.
[0024] Furthermore, in the present invention, it has been observed that Aβ peptides other than Aβ25-35 peptide, such as Aβ1-38 (Peptide Institute), Aβ1-40 (Wako Pure Chemical Industries, Ltd.), and Aβ1-42 (Wako Pure Chemical Industries, Ltd.), also regulate the activity of sodium channels (VGSCs) via sweet taste receptors (T1R2 / T1R3, T1R3 / T1R3) or umami taste receptors (T1R1 / T1R1, T1R1 / T1R3). Furthermore, the present inventors recently demonstrated that the action of these Aβ peptides on VGSCs does not occur in cells in which T1R3 expression is silenced (data not shown). This leads to the conclusion that, not only in the case of Aβ25-35, for which binding to T1R3 has been confirmed, but also in the case of other Aβ peptides, the regulation of VGSC activity is due to binding to T1R3, or that the presence of T1R3 is at least essential for the regulation of VGSC activity by Aβ peptides. For example, even if the action of an Aβ peptide (such as Aβ1-42) on an umami taste receptor (T1R1 / T1R1, T1R1 / T1R3) occurs through binding to T1R1, it can be inferred that the loss of the action of T1R3 on the umami taste receptor prevents the Aβ peptide from binding to T1R1, or that signal transmission from the bound T1R1 to VGSCs is impaired, resulting in the inhibition of the regulation of VGSC activity by the Aβ peptide. Because all four Aβ peptides used in the above experiments contain the Aβ25-35 sequence (Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met; SEQ ID NO: 1), it can be said that the Aβ25-35 sequence in the Aβ peptide is the region active in binding to T1R3, and that Aβ peptides containing this sequence are highly likely to have binding activity to T1R3. In this case, understanding the physical relationship between the amino acid sequence structure and T1R3 will likely elucidate the mechanism of action of Aβ peptides on T1R3, providing important information that will lead to the discovery of compounds and peptides that inhibit the action of Aβ peptides on T1R3.In particular, the second half of the Aβ25-35 sequence (Ala-Ile-Ile-Gly-Leu-Met) has hydrophobic side chains, except for Gly, and therefore does not participate in hydrogen bonds that bind the ligand and receptor (O'Hara et al. (1993), Hampson et al. (1999)). Therefore, the first half of the Aβ25-35 sequence, Gly-Ser-Asn-Lys-Gly, especially Ser-Asn-Lys, is thought to be important for the binding of Aβ25-35 to T1R3.
[0025] As described above, the present invention first discovered that Type I taste receptors (T1R1, T1R2, and T1R3) are receptors for amyloid beta peptide, making drug discovery targeting the amyloid beta peptide receptor possible. Previously, mouse models of Alzheimer's disease have not been useful for developing therapeutic drugs for human dementia. One of the major reasons is thought to be species differences in the sensitivity of Type I taste receptors to umami and sweet ligands. While mice have significantly different umami and sweet sensitivity than humans, only apes, such as chimpanzees, gorillas, orangutans, long-tailed macaques, baboons, and rhesus macaques, possess sensitivity similar to that of humans (Li et al. (2011) , Toda et al. (2021) ). Therefore, in order to use animals other than the aforementioned apes for drug discovery screening, in vivo drug discovery would be impossible without replacing Type I taste receptors with human-type receptors. Therefore, the cells used in the in vitro experiments of the present invention are limited to human-derived cells, animal-derived cells that endogenously express human Type I taste receptors, or cells in which Type I taste receptors with amino acid sequences specific to humans have been expressed by gene transfer or other methods.
[0026] <Sweet taste receptor (T1R2 / T1R3, or T1R3 / T1R3) binding substance> As a candidate for a substance that inhibits the binding of Aβ25-35 peptide to T1R3, lactisole, a known T1R3 antagonist that binds to T1R3 and has a sweet taste inhibitory effect, and its structural analogues chlorofibrate and dicloprop ((R)-2-(2,4-dichlorophenoxy)propanoic acid: DichlorProp), were tested for VGSC activity using T1R3-expressing cells, and it was confirmed that both inhibited VGSC activity. Furthermore, it was confirmed that dicloprop was the most effective at inhibiting VGSC compared to lactisole and clofibrate. The IC values of these compounds were then used to test the sweet taste inhibitory effect. 50 The order of the compounds was lactizol > clofibrate > dicloprop, with dicloprop inhibiting the sodium channel at the lowest concentration. These compounds have a VGSC inhibitory effect due to their T1R3 antagonist-like action. These experimental results were similar to those reported in (Non-Patent Document 4), which compared the degree of sucralose-induced inhibition of responses in an intracellular calcium assay using an experimental system overexpressing T1R2 / T1R3 and G16-gust44. Jiang et al. reported that lactitol binds to TMD3, TMD5, and TMD6 of TR3 (Jiang et al. (2005)). This suggests that lactitol may limit the change to an activated conformation of T1R3 induced by amyloid beta, a T1R3 agonist, as well as sweet substances.
[0027] Next, we investigated the effect of sweet-sensing T1R2 / T1R3 receptors on enhancing or inhibiting VGSC activity. We found that sweet-sensing T1R2 / T1R3 receptors enhance VGSC activity when exposed to sweet amino acids contained in CSF, such as L-glutamine (L-Gln) and L-serine (L-Ser). Martinez et al. reported that the concentrations of many amino acids in cerebrospinal fluid are altered in patients with Alzheimer's and vascular dementia (Non-Patent Document 6). In particular, Smith et al. measured the amino acid levels in the cerebrospinal fluid of patients with epileptic seizures and dementia (12 patients) and patients with epileptic seizures only (10 patients) compared with healthy individuals (23 patients). They reported that L-glutamine concentrations were statistically significantly elevated in patients with epileptic seizures only (715 + 145 nmol / ml) and patients with epilepsy and dementia (733 + 165 nmol / ml) compared with normal individuals (497 + 147 nmol / ml) (Smith et al. (1985)). This report suggests that changes in amino acid concentrations in cerebrospinal fluid (CSF) may affect neural hyperactivity in conditions such as epilepsy and dementia. From the above, it is suggested that sweet amino acids such as glutamine and serine are a group of substances that exhibit the effect of enhancing VGSC via the T1R2 / T1R3 receptor, similar to the Aβ25-35 peptide, in contrast to the T1R3 antagonists such as lactisole mentioned above, and that they may be T1R2 / T1R3 agonists, but at the same time, they may also be T1R1 / T1R3 agonists.
[0028] Substances that have an enhancing or inhibiting effect on VGSCs via "T1Rs" receptors such as sweet taste receptors (T1R2 / T1R3, T1R3 / T1R3) act on sweet taste receptors (T1R2 / T1R3) to enhance VGSC (sodium channel) current. In the present invention, a group of substances such as sweet amino acids such as glutamine and serine are referred to as "Group 1." The groups of substances that belong to "Group 1" are as follows: "Group 1": Agonist-like effects that act on sweet taste receptors (T1R2 / T1R3) and amplify VGSC current are observed not only with sweet amino acids such as serine and glutamine, but also with sodium lactate. According to Shirahata et al. (2005), it has been suggested that the strength of the binding relationship between Ankyrin G, which binds to VGSC, and VGSC may be a key player in controlling the left or right shift of the IV curve. Therefore, it is possible that glutamine, serine, etc. promote the polymerization of microfilaments via T1R2 / T1R3, strengthening the binding with Ankyrin G and thereby enhancing VGSC.
[0029] "Group 2": A group of peptides that act on sweet taste receptors (T1R2 / T1R3), including the amyloid beta (Aβ) 25-35 peptide, which is believed to be one of the causative substances of dementia. Similar to "Group 1," this group has an agonist-like effect that amplifies VGSC currents.
[0030] "Group 3": This group includes artificial sweeteners that act on sweet taste receptors (T1R2 / T1R3) and exhibit antagonistic effects that inhibit VGSC currents. Among artificial sweeteners, saccharin and aspartame act only on T1R2, while sucralose, which is structurally similar to sucrose, has been reported to act on both T1R2 and T1R3 (Neiers et al. (2016)). Overexpression of T1R2 has been confirmed to have an effect on VGSCs similar to that induced by artificial sweetener stimulation. In summary, in the T1R2 / T1R3 heterodimer, stimulation of T1R3 enhances VGSCs, while stimulation of T1R2 suppresses them. In other words, it is highly likely that the groups of substances belonging to "Group 1" and "Group 2" stimulate T1R3 out of T1R2 / T1R3, and the group of substances belonging to "Group 3" stimulate T1R2.
[0031] "Group 4": Substances reported to act on the umami receptor (T1R1 / T1R3) include glutamic acid and monosodium glutamate (MSG), known as amino acid seasonings, and nucleotides (NMP: nucleoside monophosphate), such as IMP (inosine monophosphate) and GMP (guanosine monophosphate), known as nucleic acid seasonings. Among these, MSG delays the inactivation of VGSC currents, while IMP transiently enhances VGSC currents, subsequently shifting the IV curve toward negative potentials by approximately 10 mV over time. Similar changes in VGSCs are also observed in MSG / IMP mixtures. GMP alone enhances VGSCs but does not affect the inactivation process or the nature of the IV curve. IMP and GMP, which are used as nucleic acid-based umami seasonings, have a structure in which the 5' position is phosphorylated, so to avoid confusion, in this specification they are not simply referred to as inosinic acid and guanylic acid, but are referred to in Japanese as inosinic acid and guanosine phosphate, respectively.
[0032] Unlike the Aβ25-35 peptide, which acts as a T1R3 agonist, the amyloid beta (Aβ) 1-42 peptide (12.5 nM-1 μM) acts on the T1R1 / T1R3 umami receptor, similar to the effects of MSG and IMP, and belongs to "Group 4." It delays the inactivation of VGSCs and shifts the activation threshold 5-10 mV toward hyperpolarization. In experiments using Nav1.5, the effect of Aβ1-42 in delaying the inactivation process is weaker than that of MSG, but closely resembles that of IMP. Its effect is equivalent to that of MSG in SH-SY5Y.
[0033] We investigated the effects of saccharin and aspartame, two artificial sweeteners that act on sweet T1R2 / T1R3 receptors, on VGSCs. The degree of VGSC reduction varied with each artificial sweetener, with significant intercellular variability. The mechanism of VGSC inhibition by artificial sweeteners, unlike direct VGSC channel inhibition by lidocaine, was found to be due to a left-shift (negative potential) of the steady-state (SS) inactivation curve, thereby reducing VGSC availability (the number of VGSCs that can be activated by voltage stimulation) and decreasing the number of activated VGSCs. Since experimental results of VGSC inhibition by artificial sweeteners showed cell-to-cell variability, we considered the possibility of cell-to-cell variability in the expression levels of T1R2 / T1R3 receptors and attempted overexpression of T1R2 / T1R3 receptors, but no improvement in cell-to-cell variability was observed. Therefore, when we overexpressed only T1R2, we confirmed the inhibition of VGSC current based on a shift in the steady-state inactivation curve (SS inactivation curve) toward negative voltage, as in the above-mentioned experimental results. This confirms that T1R2 is a drug discovery target for VGSC inhibition in cells that express a large amount of T1R2. These T1R2 binding inhibitors are classified as "Group 3."
[0034] Unlike sweet substances, umami substances, including monosodium glutamate (MSG), are sensed by the umami receptor (T1R1 / T1R3), an amino acid sensor. Other umami substances, such as inosine monophosphate (IMP) and guanosine monophosphate (GMP), are known to stimulate the umami receptor (T1R1 / T1R3) independently, in addition to enhancing the umami effect of monosodium glutamate (MSG). To investigate the possibility that the umami receptor (T1R1 / T1R3) functions as an amino acid sensor in CSF and regulates VGSC activity, we used patch clamp techniques to examine the effects of endogenously expressed umami receptors (T1R1 / T1R3) on VGSC activity in HEK cells or SH-SY5Y cells activated by monosodium glutamate (MSG), IMP, or GMP. We found that, depending on the umami substance, it can enhance VGSC currents, shift the threshold potential for VGSC activation in the hyperpolarized direction (approximately 10 mV), and slow the rate of inactivation of VGSC currents via T1R1. This demonstrated for the first time that umami substances regulate VGSC activity, demonstrating for the first time that VGSCs are downstream effectors, just as they are in taste perception (Example 4, Figures 35, 36A, B, and 36C). Furthermore, we confirmed that the effect of amyloid beta (Aβ) 1-42 peptide on VGSCs differs from that of amyloid beta (Aβ) 25-35 peptide, and also acts on umami receptors (T1R1 / T1R3), and its effect is similar to that of MSG and IMP (Figure 37). Furthermore, when we investigated the effects of lysine and aspartic acid, whose concentrations are higher in the CSF of Alzheimer's disease patients than in healthy individuals, on VGSC, we confirmed that they delay the inactivation of VGSC, just like MSG (Data not shown).
[0035] We observed that umami taste receptor (T1R1 / T1R3)-expressing cells, in which VGSCs were suppressed by artificial sweeteners such as aspartame, were first treated with monosodium glutamate (MSG) or MSG2.5 (a mixed composition of MSG, IMP, and GMP: Ajinomoto®), partially reversed the suppression of VGSC currents caused by aspartame (shifting the VGSC IV curve to the right (positive direction)). Furthermore, we found that the effect of monosodium glutamate on T1R1 occurs independently of the effect of "Group 3" substances such as aspartame, which inactivate VGSCs via T1R2, and therefore functions as an antagonist to the inactivation of VGSCs via T1R2. In other words, the enhancement of VGSCs by umami substances such as monosodium glutamate through T1R1 is thought to be an effect on VGSCs independent of their effects via T1R2 and T1R3. This is supported by the fact that in experiments using HEK-Nav1.5 cells in which T1R3 was silenced, the effect of MSG2.5 on T1R1 was observed to be the same as in control cells. This group of substances that target the umami receptors (T1R1 / T1R3) is called "Group 4."
[0036] As described below, Aβ25-35 peptide inhibits VGSC currents at high concentrations. In other words, the enhancement of VGSC currents caused by low concentrations of Aβ25-35 peptide disappears at high concentrations and returns to control levels. This is the same phenomenon observed when T1R2 is activated by stimulation with artificial sweeteners. While it is necessary to suppress the enhancement of VGSC currents (neuronal hyperactivity) caused by low concentrations of Aβ25-35 peptide, the inhibition of VGSC currents by high concentrations of Aβ25-35 peptide corresponds to the point at which the nerve is no longer able to transmit information. In this case, the action of monosodium glutamate and other agents on VGSCs via T1R1 (shifting the activation threshold of VGSCs in the negative direction) shifts the membrane potential threshold required for VGSC activation toward hyperpolarization compared to before T1R1 activation, bringing it closer to the resting membrane potential, allowing VGSCs to be activated by a small shift in membrane potential toward depolarization from the resting membrane potential. As a result, action potentials become more likely to occur, which may play an important role in partially restoring function.
[0037] Aβ peptides, Aβ25-35 and Aβ1-42, exhibit completely different behaviors. Furthermore, even when focusing solely on Aβ25-35, desensitization occurs at high concentrations, and consistent VGSC enhancement activity is not always observed. Therefore, identifying the type and concentration of Aβ peptides is essential. Aβ1-42 has been reported as a major peptide in the central nervous system (Agarwal et al., 2011, Lue et al., 1999, Mo et al., 2015), and is therefore presumed to be a major cause of disease symptoms such as AD. Like MSG, Aβ1-42 delays VGSC inactivation, and the degree of this delay becomes significant in a concentration-dependent manner, resulting in persistent VGSC opening. The ratio of Aβ1-40 to Aβ1-42 has been reported as a diagnostic marker for Alzheimer's disease. It has been reported that Aβ1-42 levels in CSF are lower in patients with Alzheimer's disease than in healthy individuals (Agarwal et al., 2011, Lue et al., 1999, Mo et al., 2015). In this case, Aβ1-40 may shift the VGSC S-S curve toward hyperpolarization, thereby reducing neuronal activity. Clinically, it is known that as AD progresses, the ratio of Aβ1-40 / Aβ1-42 in CSF changes, with Aβ1-40 increasing (Lehmann et al. (2020)). Lue et al. (1999) measured soluble and insoluble Aβ1-40 and Aβ1-42 concentrations in the entorhinal cortex, a component of the medial temporal lobe memory system, and the superior frontal gyrus, which occupies approximately one-third of the lateral frontal lobe and is responsible for higher cognitive functions, where Alzheimer's disease pathology is observed from the early stages. They compared these concentrations between healthy individuals and those with Alzheimer's disease. They found that Aβ1-42 was decreased in the cerebrospinal fluid of patients with Alzheimer's disease, but that Aβ1-42 concentrations in the entorhinal cortex and superior frontal gyrus, as well as Aβ1-40, were increased in brains with Alzheimer's disease, both soluble and insoluble.It is particularly noteworthy that soluble Aβ1-42 was detected in the entorhinal cortex and superior frontal gyrus, whereas it was not detected in healthy individuals. Table 1 below compares the concentrations of soluble and insoluble Aβ1-40 and Aβ1-42 measured in the entorhinal cortex and superior frontal gyrus of healthy individuals and AD patients, as shown in Lue et al. (1999).
[0038]
[0039] In addition to the above, Aβ1-42 also tends to inhibit outward potassium currents, as seen in the series of compounds in "Group 4," so it is highly likely that its activity will be inhibited not only in neurons but also in cardiomyocytes. In this case, even in cardiomyocytes, it activates membrane voltage-dependent calcium channels, and at the same time, sodium / calcium (Na) is activated to expel excessively accumulated intracellular sodium. + / Ca 2+ The calcium-dependent cell death occurs when the NCX exchange mechanism is reversed and calcium is transported into the cell. Administration of Aβ1-42 depolymerizes microtubules (Pianu et al. (2014)) (Figure 33), and administration of Aβ25-35 depolymerizes microfilaments (Figure 34). Loss of the cytoskeleton is also thought to contribute to the progression of cell death.
[0040] The VGSC effect of MSG or a mixture of MSG with IMP or GMP could not be confirmed in experiments using T1R1-silenced cells, confirming that it is mediated by the umami taste receptor (T1R1 / T1R3) rather than the glutamate GPCR receptor (metabotropic glutamate receptor). This MSG-mediated slowing of VGSC inactivation through the umami taste receptor is thought to have a physiologically important role. Specifically, this delayed inactivation is important for the generation of high-frequency action potentials, burst action potentials, and the integration of multiple synaptic inputs. Therefore, T1R1 / T1R3 or T1R1 homodimers are effective targets for therapeutic development when treating neural activity and synaptic integration. Vanderstichele et al. (2016) reported that the concentration of Aβ1-40 in the cerebrospinal fluid of patients with Alzheimer's disease (dementia) was measured to be 1.9 μM, and Lehmann et al. (2020) also reported that the concentration of Aβ1-40 in the cerebrospinal fluid was 2.85 μM.
[0041] Furthermore, Mattheisen et al. (2018) reported that cinacalcet, an agonist of the calcium-sensing receptor (CaSR), and NPS-2143, an antagonist of the CaSR, have an inhibitory effect on VGSCs, and that this inhibitory effect is mediated by an unknown GPCR different from "CaSR." The present inventors suspected that the VGSC inhibitory effect of cinacalcet may also be mediated by a sweet taste receptor containing "T1R3." They observed the effects of cinacalcet and NPS-2143 on VGSCs using HEK-Nav1.5-expressing cells in which T1R3 was silenced, but no VGSC inhibitory effect was observed. This strongly suggests that cinacalcet and NPS-2143 exert their inhibitory effect on VGSC via sweet taste receptors containing T1R3. Furthermore, when experiments were performed in which cinacalcet and NPS-2143 were applied to SH-SY5Y cells, it was confirmed that they inhibited sodium channel currents in the same way as in experiments with HEK-Nav1.5-expressing cells. Based on the above, calcium-sensing receptor (CaSR) agonists and antagonists such as cinacalcet and NPS-2143 can also be considered as a type of substance that inhibits the binding of sweet taste receptors containing T1R3, and therefore belong to the above-mentioned "Group 3."
[0042] As mentioned above, excessive cranial nerve activity such as epileptiform seizures has been observed in AD patients (especially in the early stages) in electroencephalograms, and it has been reported that VGSCs are one of the main causes of this. However, in the present invention, it has been discovered for the first time that VGSCs (Na + It has been revealed that the inhibition of sweet taste GPCR receptors, especially "T1R3", plays an important role in the inhibition of Na+ by sweet taste inhibitors (lactisol, clofibrate, dicloprop). + Dicloprop was by far the most potent in terms of channel inhibitory effect (inhibition of neural hyperactivity) (dicloprop >> clofibrate > lactisol).
[0043] Furthermore, we investigated the effect of Aβ peptides on enhancing VGSC activity using an anti-T1R3 (229-258) antibody (anti-N-terminal T1R3 Venus Flytrap Domain (VFD, 229-258 aa) polyclonal antibody (AP16368a, Abcepta, Inc.)), which is a potential T1R3 binding inhibitor. We found that pre-treatment of neurons with the anti-T1R3 antibody inhibited the enhancement of VGSC activity by the Aβ25-35 peptide and prevented the binding of Aβ peptide to neurons. Furthermore, we confirmed that the VGSC current enhanced by the Aβ25-35 peptide was restored to control levels by the T1R3 antibody (data not shown).
[0044] <Various T1R3 Antibodies and Aβ Peptide Binding Sites on the T1R3 Protein> The three antibodies used in the present invention, anti-T1R3(229-258) antibody, anti-T1R3(303-396) antibody, and anti-T1R3(400-570) antibody, are polyclonal antibodies raised against the 229-258 aa, 303-396 aa, and 400-570 aa regions of the T1R3 protein, respectively. Experimental results show that the anti-T1R3(229-258) antibody inhibits the binding of Aβ25-35 peptide, the anti-T1R3(303-396) antibody inhibits the binding of Aβ1-40 peptide, and the anti-T1R3(400-570) antibody inhibits the binding of Aβ1-42 peptide to T1R3. As a result, it was found that these antibodies inhibited the enhancement of T1R3-mediated VGSC currents caused by each Aβ peptide and improved changes in cell morphology and dynamics. This indicates that these T1R3 antibodies, or anti-T1R3 antibodies having an epitope comprising at least 8 consecutive amino acids from the amino acid sequences of each peptide used as an epitope for producing these antibodies, are inhibitors of the binding of each Aβ peptide to neurons and the like, and can also serve as inhibitors of the pathophysiological effects caused by each Aβ peptide in neurons and the like, and are therefore promising as therapeutic agents for AD.
[0045] <Inhibitory mechanism of T1R3 binding inhibitors (Group 3) on VGSC> The action and inhibitory mechanism of dichlorprop on VGSC closely resembles that of TBB (4,5,6,7-tetrabromobenzotriazole), a casein kinase inhibitor that inhibits casein kinase 2 (CK2). Therefore, the inhibitory action of dichlorprop via T1R3 is thought to have an inhibitory mechanism similar to that of casein kinase 2. Inhibition of CK2 by TBB suppresses the phosphorylation of VGSC, which is essential for the binding of VGSC to ankyrin G, and inhibits its binding to ankyrin G. Protein phosphatases also dephosphorylate VGSC in a manner similar to that of TBB. It has been reported that KCNQ2 channels, which bind to ankyrin G like VGSCs, anchor both CK2 and protein phosphatase 1 to the channel itself (Kang et al., 2014). Furthermore, Pradhan et al. (2017) reported that Gβ1 binds to the catalytic subunit of protein phosphatase 1 in platelets. This suggests that the delayed inactivation of VGSCs by the umami taste receptor T1R (T1R GPCR) may occur through a mechanism that regulates the degree of phosphorylation at the ankyrin G binding site of VGSCs via Gβ.
[0046] As mentioned above, when MSG (monosodium glutamate), IMP (inosine monophosphate), GMP (guanosine monophosphate), and MSG2.5 (a mixture of 97.5% MSG and 1.25% IMP and GMP contained in Ajinomoto (registered trademark)) which are well-known umami substances, act on the umami receptor (T1R1 / T1R3), sodium channel currents of VGSCs are activated, in contrast to sweet substances acting on the sweet receptor (T1R2 / T1R3). When monosodium glutamate (MSG) was administered to VGSCs in a state where VGSCs were suppressed by more than 80% by the action of dichlorprop, the negative shift in the inactivation curve of VGSC magnitude caused by the action of dichlorprop was partially restored. This indicates that MSG, which acts through T1R1, suppresses VGSCs via a pathway different from that of dichlorprop, which acts through T1R3.
[0047] <Regulation mechanism of VGSC activity by T1R3 binding inhibitors> Paclitaxel (Taxol), which has the effect of stabilizing the cytoskeleton (microtubules), is used as an anticancer drug in the treatment of breast cancer. However, it is known that neuropathic pain occurs as a side effect. Because this pain is strongly suggested to be caused by neural overactivity, we investigated whether paclitaxel (Taxol) enhances VGSC activity. As a result, we found that VGSC activity was also enhanced by treating VGSC-expressing cells with paclitaxel (Taxol). This suggests that neuropathic pain, which occurs as a side effect of the anticancer drug paclitaxel (Taxol), is also caused by enhanced VGSC activity, similar to cranial neural overactivity. Therefore, it is expected that VGSC inhibitors acting via T1R3 will have analgesic effects on neuropathic pain. This suggests that T1R3 binding inhibitors such as dicloprop are effective in treating neuropathic pain.
[0048] <Considerations on the Regulatory Mechanism of T1R3 Binding Inhibitors on VGSC Activity> Based on the above, the regulatory mechanism of T1R3 binding inhibitors on VGSC activity can be considered as follows. However, the regulatory mechanism of T1R3 binding inhibitors on VGSC activity in the present invention is not limited to the restrictive mechanism discussed below. When a sweet taste receptor (T1R2 / T1R3) is activated by a ligand, it modifies the cytoskeletal structure, and this structural change modulates the activity of VGSC. VGSCs are known to bind to the cytoskeleton via ankyrin G / spectrin. In particular, it has been known that the binding of ankyrin G to VGSCs requires the phosphorylation by casein kinase 2 (CK2) of an ankyrin binding site conserved in many voltage-gated sodium channels in the intracellular loop between domains II and III of VGSCs (Brechet et al. (2008), Non-Patent Document 9). Specifically, the cytoskeleton binds to VGSCs via ankyrin G / spectrin, and the binding of ankyrin G to VGSCs is necessary for the localization of VGSCs to the cell membrane surface. This binding of ankyrin G to VGSCs plays an important role in densely expressing VGSCs at the axon initial point of neurons, such as the nodes of Ranvier. It has been reported that knockout of ankyrin G reduces the magnitude of VGSC currents (Lowe et al. (2008)), and this was attributed to a decrease in the density of VGSC expression. However, in the present invention, we found that activation of T1R2 / T1R3 does not reduce the number of VGSCs present, but rather inactivates VGSCs. In other words, reports of ankyrin G knockout concluded that the reduction in VGSC current was due to a mechanism that reduced the density of VGSC expression. However, we discovered that the control mechanism by T1R2 / T1R3 receptors controls VGSC current not only by the actual number of VGSCs on the cell membrane surface, but also by a mechanism that reduces the number of VGSCs that can be activated by inactivating VGSCs.In the present invention, it can be said that it was discovered that dephosphorylation of VGSC by CK2 inhibitors (such as TBB) not only affects the degree of expression of VGSC on the cell membrane, but also acts on the properties of VGSC functioning on the cell membrane, thereby inhibiting its function.
[0049] The binding site for ankyrin G in VGSCs has been identified, and the presence or degree of phosphorylation of this site by casein kinase 2 (CK2) is known to control the expression level of VGSCs in the cell membrane. Experiments using the CK2 inhibitor TBB revealed that TBB-mediated inhibition of CK2 suppresses VGSCs. Thus, CK2 inhibitors also inhibit VGSCs, leading to the discovery that they have an analgesic effect. Considering the aforementioned enhancement of VGSCs by paclitaxel (Taxol), a microtubule stabilizer that forms the cytoskeleton, and the fact that inhibition of CK2, which controls the binding strength between ankyrin G, which binds to VGSCs, and VGSCs, influences VGSC activity, it is clear that taste receptors control VGSCs through the cytoskeleton (mainly microtubule-ankyrin G). These findings also confirmed the mechanism by which T1R3 binding inhibitors enhance and inhibit VGSCs.
[0050] As described above, it was confirmed that compounds that bind to sweet and umami GPCR receptors (T1R3, T1R2, and T1R1), including T1R3 binding inhibitors, are all substances involved in the regulation (inhibition and enhancement) of VGSC activity via sweet and umami GPCR receptors. Table 2 shows these compounds sorted by their agonistic and antagonistic effects on the target T1Rs and VGSC currents.
[0051]
[0052] Among these compounds (Table 2), the present inventors confirmed that dicloprop (DichiorProp), a binding inhibitor of the T1R3 sweet receptor, and anti-T1R3 antibodies, in particular, can be expected to be effective in treating and preventing AD by preventing the binding of Aβ peptides to neurons in the brains of AD patients and preventing VGSC-mediated neuronal hyperexcitation, and can also be expected to be effective as therapeutic agents for neuropathic pain, leading to the completion of the present invention. Furthermore, artificial sweeteners such as aspartame, which bind to T1R2 or T1R2 / T1R3 and suppress VGSC currents, can also be expected to suppress neuronal hyperexcitation and therefore have similar therapeutic effects. Furthermore, since the primary binding site of Aβ1-42 peptide is on T1R3, but it also partially acts on T1R1, it was confirmed that glutamic acid, monosodium glutamate, and nucleic acid seasonings, which bind to T1R1, can also be used as therapeutic agents or for screening thereof, utilizing their inhibitory activity against the T1R1-mediated VGSC action of Aβ1-42.
[0053] <Effects of the Artificial Sweetener, Aspartame, on Cell Morphology> The effects of aspartame, an artificial sweetener that is an agonist of T1R2 / T1R3, on cell morphology were investigated (Figure 53-1). As shown in the example of MSG stimulation in Figure 33B, not only Aβ peptides but also taste substances control the polymerization state of cytoskeletal fibers. In this experimental example, undifferentiated SH-SY5Y cells were exposed to 120 μM aspartame, and changes in cell morphology were observed. As a result, it was observed that T1R2 / T1R3 stimulation by artificial sweeteners affected cell morphology and caused contraction. Considering this in parallel with the results of patch clamp experiments, it is thought that umami and sweet substances control cell morphology through T1R receptors.
[0054] <Effect of Aβ42 / Aβ40 Concentration Ratio on Cell Morphological Changes> Both Aβ1-42 and Aβ1-40 are present in cerebrospinal fluid (CSF) or blood, and the Aβ42 / Aβ40 concentration ratio is known to vary depending on whether or not cognitive impairment is present in Alzheimer's dementia. A correlation is observed between an Aβ1-42 ratio of 10% or less and the presence of cognitive impairment. In Alzheimer's dementia, where the Aβ42 / Aβ40 ratio indicates cognitive impairment (AD-D), cells shrink, neurite motility is impaired, and cells retract. On the other hand, when the Aβ42 / Aβ40 ratio and Aβ1-42 concentration were high, no shrinkage was observed, except for physiological cellular morphological changes. Instead, ruffling and wavy movements were observed around the cell periphery (Figure 55). β-alanine also caused ruffling-like changes in neurites (lamellipodia) (Figure 53-2). That is, in healthy individuals, the Aβ42 / Aβ40 ratio activates cells and prevents adverse effects such as cell shrinkage, maintaining intercellular junctions (capillaries, blood-brain barrier, renal glomerular membrane) and activating cell process movement, thereby maintaining or improving the plasticity of neural function. On the other hand, in individuals with cognitive impairment due to Alzheimer's disease, the Aβ42 / Aβ40 ratio conversely causes cells to shrink, resulting in weakened intercellular junctions and underlying changes in many diseases, including chronic nephritis. Similarly, in nerves, the shrinkage of cell bodies and neurites, as well as the reduction in neurite motility, reduces neural plasticity.
[0055] That is, the present invention includes the following aspects. [1] One aspect of the present invention relates to the use of a Type I taste receptor present on a cell surface (particularly the surface of a neuron, cardiac muscle cell, or skeletal muscle cell) as a target receptor for controlling the active current of a voltage-gated ion channel (e.g., a voltage-gated sodium channel (VGSC), a voltage-gated potassium channel (VGKC), or a voltage-gated calcium channel (VGCC)), and is described as a method invention as follows. Here, the target cells are human-derived cells or cells expressing human Type I taste receptors (e.g., primate-derived cells or humanized laboratory animal-derived cells), and are cells in which the active current of the voltage-gated ion channel on the cell membrane surface needs to be controlled. In addition to typical neurons and cardiomyocytes, all cells that fire VGSC-dependent action potentials are included in this study. However, skeletal muscle cells in particular have been shown to express more T1R3 RNA than neurons or cardiac muscle cells (normalized transcripts per million (nTPM), which averages RNA expression frequency across samples, is 1.1 for skeletal muscle cells, 0.9 for cardiac muscle, 0.9 for cerebellum, 0.7 for cerebral cortex, 0.4 for hippocampus, and 0.4 for kidney). Furthermore, the presence of Aβ peptides has been confirmed in skeletal muscle cells (Kuo et al. 2000). Furthermore, muscle weakness and disuse atrophy have been reported in diabetes (Perry et al. 2016). Therefore, it is likely that Type I taste receptors are present in skeletal muscle VGSCs (Nav 1.4) as well as neurons and cardiac muscle. For these reasons, we have listed them alongside neurons and cardiac muscle cells. Other cells that fire VGSC-dependent action potentials are thought to be candidates for application of the technology of the present invention, such as neurosecretory cells and β cells of the islets of Langerhans.
[0056] The present invention also includes newly added measurement methods (assays using cell morphology / motility, impedance assays, and assays using changes in intracellular calcium concentration as an index). Next, since species differences are important in research on many diseases such as Alzheimer's disease and chronic nephritis, and since the use of humanized mice (experimental animals) is important for this purpose, the present invention also includes the commercial use of mice with humanized T1R genes, and the commercial use (targeted drug discovery) of the Aβ peptide binding domain and the extracellular domain of T1R2. Specifically, since the T1R2 / T1R3 GPCR protein is an Aβ peptide binding protein, the T1R2 / T1R3 binding domain of Aβ peptide is also included. Drugs that can inhibit binding to GPCR proteins are highly effective in treating Aβ peptide-related diseases (such as Alzheimer's disease and chronic nephritis). Therefore, in drug discovery aimed at treating these diseases, T1R2 / T1R3 GPCR proteins, which contain Aβ peptide binding sites, are important drug discovery targets. Furthermore, the 229-258 (LB2) region of the VFD region amino acid sequence, to which Aβ25-35 binds, the 303-396 (LB1) region, to which Aβ1-40 binds, and the 400-570 region, which inhibits the VGSC current action of Aβ1-42, are important drug discovery targets. Therefore, in addition to T1R2 / T1R3 GPCR proteins, the T1R3 region represented by the above amino acid sequences is also included as a drug discovery target. Because Aβ40 mixed peptides have significantly different effects on enhancing VGSC currents and on cell morphology in human and mouse cells, future research should explore the role of T1R1, Unless the proteins produced by the T1R2 and T1R3 genes are human-derived, it is difficult to obtain research results that can be applied to human clinical trials or to develop therapeutic drugs that can be applied to clinical trials using mice. Therefore, it is necessary to replace the T1R GPCR gene from the host mouse with a human-derived gene. This includes the possibility of mice with humanized T1R genes being used in drug discovery research and development by commercial companies. When conducting drug discovery screening at the cellular level, we have shown that methods using changes in intracellular calcium concentration as an indicator and observing changes in impedance of cell sheets are effective as primary screening methods.Therefore, the present invention also includes embodiments of a screening method using the above method. Depending on the type of Aβ peptide, particularly the concentration ratio of Aβ42 / Aβ40 in patients with Alzheimer's disease versus that in healthy individuals, significant changes occur in cell morphology / dynamics, particularly in the morphology and motility of neurites when observed using nerves. This phenomenon can be easily measured under a microscope, and is therefore useful for screening drugs, such as β-alanine, that restore the activity of neurites that have become inactive due to the Aβ42 / Aβ40 ratio in patients with Alzheimer's disease, or for functional diagnosis using the patient's CSF or serum. Therefore, the present invention also includes embodiments of this measurement method.
[0057] [1-1] A method for controlling the activation current of a voltage-gated ion channel in a neuron, cardiac muscle cell, or skeletal muscle cell, comprising allowing a ligand that specifically binds to a specific Type I taste receptor and exerts an antagonistic or agonistic effect on the Type I taste receptor present on the cell surface. [1-2] The method according to [1-1], wherein the voltage-gated ion channel is a voltage-gated sodium channel (VGSC), a voltage-gated potassium channel (VGKC), or a voltage-gated calcium channel (VGCC). [1-3] The method according to [1-1] or [1-2], wherein the Type I taste receptor is a sweet receptor or an umami receptor, and is T1R1, T1R2, or T1R3, or a homodimer or heterodimer thereof. [1-4] The method according to [1-3], wherein the ligand specifically binds to T1R2 and / or T1R3 to inhibit the activation current of VGSC. [1-5] The method according to [1-4] above, wherein the ligand is a T1R3 ligand that specifically binds to T1R3 and exerts an antagonistic effect, thereby inhibiting the active current of VGSCs or inhibiting the active current of VGCCs, and is selected from the group consisting of an anti-human T1R3 antibody, lactizol, clofibrate, and dicloprop. The anti-human T1R3 antibody typically includes the following three types of antibodies: (1) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 229-258 aa region of human T1R3 protein, and that inhibits the binding of Aβ25-35 peptide to human T1R3 and inhibits the active current of VGSCs amplified by the Aβ25-35 peptide.(2) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 303-396 aa region of the human T1R3 protein, and that inhibits the binding of Aβ1-40 peptide to human T1R3 and suppresses the active current of VGSCs amplified by the Aβ1-40 peptide. (3) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 400-570 aa region of the human T1R3 protein, and that inhibits the binding of Aβ1-42 peptide to human T1R3 and suppresses the active current of VGSCs amplified by the Aβ1-42 peptide. [1-6] The method according to [1-4], wherein the ligand is a T1R2 or T1R2 / T1R3 ligand that specifically binds to T1R2 or T1R2 / T1R3 and exerts an antagonistic effect to inhibit the active current of VGSCs or that inhibits the active current of VGCCs, and is characterized in that the ligand is selected from artificial sweeteners such as saccharin, aspartame, and sucralose, and structural analogs such as gymnema tea extract. [1-7] The method according to [1-3], wherein the ligand specifically binds to T1R3, T1R2 / T1R3, or T1R1 / T1R3 and exerts an agonist-like effect to amplify the active current of VGSCs. [1-8] The method according to [1-7], wherein the ligand is a saccharide or a sweet amino acid. [1-9] The method according to [1-8] above, wherein the ligand is selected from the group consisting of glucose, sucrose, fructose, glutamine, serine, and mixtures thereof. [1-10] The method according to [1-3] above, wherein the ligand specifically binds to T1R1 to exert an agonist-like or antagonistic effect, thereby controlling the active current of VGSC and / or VGKC in cells.[1-11] The method according to [1-10] above, wherein the ligand is selected from the group consisting of glutamic acid (L-Glu), monosodium glutamate (MSG), inosine monophosphate, guanyl monophosphate, and mixtures thereof.
[0058] [2] Another aspect of the present invention is an invention relating to the "ligand (substance)" itself used in the above-mentioned "method" invention. The invention relating to the "ligand substance" is described as follows:
[0059] [2-1] A ligand substance for controlling the activation current of a voltage-gated ion channel in a neuron, cardiac muscle cell, or skeletal muscle cell, characterized in that the ligand substance is a Type I taste receptor ligand that specifically binds to a Type I taste receptor present on the cell surface and exerts an agonist- or antagonist-like effect. [2-2] The ligand substance according to [2-1], wherein the voltage-gated ion channel is a voltage-gated sodium channel (VGSC), a voltage-gated potassium channel (VGKC), or a voltage-gated calcium channel (VGCC), and the Type I taste receptor is a sweet receptor or an umami receptor, and is T1R1, T1R2, or T1R3, or a homodimer or heterodimer thereof. [2-3] The ligand substance according to [2-2], characterized in that the ligand inhibits the activation current of a VGSC by specifically binding to T1R2 and / or T1R3. [2-4] The ligand substance according to [2-3] above, wherein the ligand is a T1R3 ligand selected from an anti-human T1R3 antibody, lactisole, clofibrate, and dicloprop, which specifically binds to T1R3 and exerts an antagonistic effect, thereby inhibiting the active current of VGSCs. [2-5] The ligand substance according to [2-3] above, wherein the ligand is a T1R2 ligand or T1R2 / T1R3 ligand selected from saccharin, aspartame, sucralose, gymnema tea extract, and structural analogs thereof, which specifically binds to T1R2 or T1R2 / T1R3 and exerts an antagonistic effect, thereby inhibiting the active current of VGSCs. [2-6] The ligand substance according to [2-2] above, characterized in that the ligand specifically binds to T1R3, T1R2 / T1R3, or T1R1 / T1R3 to exert an agonist-like effect, thereby amplifying the active current of a VGSC or amplifying the active current of a VGCC. [2-7] The ligand substance according to [2-6] above, wherein the ligand is a sugar or a sweet amino acid. [2-8] The ligand substance according to [2-7] above, wherein the ligand is selected from glucose, sucrose, fructose, glutamine, serine, and mixtures thereof.[2-9] The ligand substance according to [2-2] above, wherein the ligand is a T1R1 ligand that specifically binds to T1R1 or T1R1 / T1R3 to exert an agonist-like action, thereby shifting the IV curve of a VGSC-activated current to the left or delaying inactivation, or suppressing a VGKC-activated current. [2-10] The ligand substance according to [2-9] above, wherein the T1R1 or T1R1 / T1R3 ligand is selected from glutamic acid (L-Glu), monosodium glutamate (MSG), inosine monophosphate (IMP), guanyl monophosphate (GMP), and mixtures thereof.
[0060] [3] Yet another aspect of the present invention relates to a pharmaceutical composition for preventing or treating various diseases caused by the amplification of VGSC active currents and / or the inhibitory effect of VGKC active currents resulting from the binding of sweet amino acids, which are T1R2 / T1R3 ligands (agonists), or umami substances, which are T1R1 / T1R3 ligands (agonists), to T1R2 / T1R3 or T1R1 / T1R3 present on cell surfaces (particularly the surfaces of neurons, cardiac myocytes, or skeletal muscle cells). In particular, the present invention targets neurological diseases associated with neuronal hyperactivity caused by the amplification of VGSC active currents resulting from the binding of sweet amino acids glutamine and serine, umami substances glutamic acid and its sodium salt (MSG), and nucleic acid seasonings IMP and GMP to T1R2 / T1R3 or T1R1 / T1R3.
[0061] [3-1] A pharmaceutical composition for preventing and / or treating a disease caused by amplification of VGSC current and / or inhibition of VGKC current, which is caused by binding of a sweet amino acid or an umami substance to T1R2 / T1R3 or T1R1 / T1R3 on the surface of neurons, cardiac myocytes, or skeletal muscle cells, the pharmaceutical composition comprising, as an active ingredient, a ligand that specifically binds to T1R2 or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect. [3-2] The pharmaceutical composition according to [3-1] above, wherein the disease is a neurological disease in which epileptiform neuronal hyperactivity is observed and / or neuropathic pain. [3-3] The pharmaceutical composition according to [3-2], wherein the neurological disease in which epileptiform neuronal hyperactivity is observed is selected from the group consisting of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies, focal cranial neurological symptoms of cerebrovascular disease, epilepsy, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, focal cranial neurological symptoms in areas damaged by traumatic brain injury, Huntington's disease, spinocerebellar degeneration, and multiple sclerosis. [3-4] The pharmaceutical composition according to [3-2], wherein the neuropathic pain is neuropathic pain associated with nerve overactivity due to amplification of VGSC currents, and is selected from the group consisting of peripheral neuropathy caused by the administration of anticancer drugs, failed-back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and diabetic polyneuropathy. [3-5] The pharmaceutical composition according to [3-1] or [3-2] above, wherein the ligand specifically binds to T1R3 and exerts an antagonistic effect, and is selected from the group consisting of an anti-human T1R3 antibody, cinacalcet, NPS-2143, lactisole, clofibrate, dicloprop, and structural analogs thereof. Anti-human T1R3 antibodies that serve as candidates for the pharmaceutical composition typically include the following three types of antibodies:(1) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 229-258 aa region of the human T1R3 protein, and that inhibits the binding of sweet amino acids or umami substances to human T1R3 and suppresses the active current of VGSCs amplified by sweet amino acids or umami substances. (2) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 303-396 aa region of the human T1R3 protein, and that inhibits the binding of sweet amino acids or umami substances to human T1R3 and suppresses the active current of VGSCs amplified by sweet amino acids or umami substances. (3) An anti-human T1R3 antibody, which is a monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 400-570 aa region of the human T1R3 protein, and which inhibits the binding of sweet amino acids or umami substances to human T1R3 and suppresses the active current of VGSCs amplified by sweet amino acids or umami substances. [3-6] The pharmaceutical composition according to [3-1] or [3-2] above, wherein the ligand specifically binds to T1R2 or T1R2 / T1R3 and exerts an antagonistic effect, and is selected from the group consisting of saccharin, aspartame, sucralose, gymnema tea extract, and structural analogs thereof.
[0062] [4] Yet another aspect of the present invention relates to a pharmaceutical composition for preventing or treating various diseases caused by the amplification of VGSC active current and / or the inhibitory effect of VGKC active current, which are generated by binding of Aβ peptides, which are ligands (agonists) of Type I taste receptors (the shortest Aβ peptide is Aβ25-35 peptide (SEQ ID NO: 1), and extensions of this amino acid sequence include Aβ1-38 (SEQ ID NO: 2), Aβ1-40 (SEQ ID NO: 3), and a typical Aβ1-42 (SEQ ID NO: 4). In other words, the Aβ peptide of the present invention can also be expressed as "Aβ peptides comprising the amino acid sequence set forth in SEQ ID NO: 1"), to Type I taste receptors (particularly, T1R2 / T1R3 or T1R3) present on the cell surface (particularly, on the surface of neurons, cardiac myocytes, or skeletal muscle cells). In particular, the present invention relates to a pharmaceutical composition for preventing or treating neurological disorders in which hyperactivity of neurons is observed, which is caused by the amplification of the active current of VGSCs, which occurs when the Aβ25-35 peptide, a ligand (agonist) of T1R2 / T1R3, binds to T1R2 / T1R3 present on the surface of neurons.
[0063] [4-1] A pharmaceutical composition for the treatment and / or prevention of a disease caused by neuronal hyperexcitation resulting from the binding of an Aβ peptide comprising the amino acid sequence shown in SEQ ID NO: 1 to a Type I taste receptor on the surface of a neuron, the pharmaceutical composition comprising, as an active ingredient, a ligand that specifically binds to T1R1, T1R2, or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect. [4-2] A pharmaceutical composition for the treatment and / or prevention of a disease caused by neuronal hyperexcitation mediated by T1R2 / T1R3 by an Aβ peptide selected from Aβ25-35 peptide, Aβ1-38 peptide, and Aβ1-40 peptide, the pharmaceutical composition comprising, as an active ingredient, a ligand that specifically binds to T1R2 or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect. [4-3] The pharmaceutical composition according to [4-1] or [4-2] above, wherein the disease is a neurological disease in which epileptiform neuronal hyperactivity is observed and / or neuropathic pain. [4-4] The pharmaceutical composition according to [4-3] above, wherein the neurological disease in which epileptiform neuronal hyperactivity is observed is a neurological disease selected from the group consisting of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies, focal cranial neurological symptoms of cerebrovascular disease, epilepsy, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, focal cranial neurological symptoms in a region damaged by traumatic brain injury, Huntington's disease, spinocerebellar degeneration, and multiple sclerosis. [4-5] The pharmaceutical composition according to [4-3] above, wherein the neuropathic pain is neuropathic pain associated with nerve overactivity due to amplification of VGSC currents, and is selected from the group consisting of peripheral neuropathy caused by anticancer drug administration, failed-back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and diabetic polyneuropathy. [4-6] The pharmaceutical composition according to [4-1] or [4-2] above, wherein the ligand specifically binds to T1R3 and exerts an antagonistic effect, and is selected from the group consisting of an anti-human T1R3 antibody, cinacalcet, NPS-2143, lactisole, clofibrate, dicloprop, and structural analogs thereof.Here, anti-human T1R3 antibodies that serve as candidates for pharmaceutical compositions typically include the following three types of antibodies: (1) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 229-258 aa region of the human T1R3 protein, and that inhibits the binding of the Aβ25-35 peptide to human T1R3 and suppresses the active current of VGSCs amplified by the Aβ25-35 peptide. (2) A monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 303-396 aa region of the human T1R3 protein, and that inhibits the binding of Aβ1-40 peptide to human T1R3 and suppresses the active current of VGSCs amplified by the Aβ1-40 peptide. (3) An anti-human T1R3 antibody, which is a monoclonal or polyclonal antibody that specifically binds to an epitope comprising at least a contiguous 3 to 5 amino acid sequence, preferably a 5 to 8 amino acid sequence, more preferably an 8 to 10 amino acid sequence, even more preferably an 11 to 13 amino acid sequence, and most preferably a 13 to 15 amino acid sequence, in the 400-570 aa region of the human T1R3 protein, and which inhibits the binding of the Aβ1-42 peptide to human T1R3 and suppresses the active current of VGSCs amplified by the Aβ1-42 peptide. [4-7] The pharmaceutical composition according to [4-1] or [4-2] above, wherein the ligand specifically binds to T1R2 or T1R2 / T1R3 and exerts an antagonistic effect, and is selected from the group consisting of saccharin, aspartame, sucralose, gymnema tea extract, and structural analogs thereof.
[0064] [5] Yet another aspect of the present invention relates to a method for screening for a substance capable of controlling the amplification or inhibition of the activation current of a voltage-gated ion channel induced via a Type I taste receptor on the surface of human neurons, cardiac muscle cells, skeletal muscle cells, etc. Here, neurons, cardiac muscle cells, skeletal muscle cells, etc. are cells that express a voltage-gated ion channel on their cell surface together with a Type I taste receptor, and typical voltage-gated ion channels are voltage-gated sodium channels (VGSCs), voltage-gated potassium channels (VGKCs), or voltage-gated calcium channels (VGCCs).
[0065] [5-1] A screening method for a substance capable of controlling the amplification or inhibition of the activation current of a voltage-dependent ion channel induced via a Type I taste receptor on the surface of a neuron, cardiomyocyte, or skeletal muscle cell, the method comprising the following steps (1) to (3): (1) a step of administering a fluorescently labeled known Type I taste receptor ligand to a culture medium of cultured human-derived cells expressing a voltage-dependent ion channel together with a Type I taste receptor on the cell surface, and culturing the cells; (2) a step of administering a test substance to the culture medium simultaneously with, before, or after step (1), and culturing the cells with or without administration; and (3) a step of selecting the test substance as a candidate substance capable of controlling the voltage-dependent ion channel current on the surface of a neuron, cardiomyocyte, or skeletal muscle cell, when it is observed or measured that the fluorescence intensity on the surface of the cultured cells when the test substance is administered is significantly amplified or decreased compared to when the test substance is not administered. [5-2] The method according to [5-1], wherein the control of the amplification or inhibition of the activation current of the voltage-dependent ion channel is the amplification of a VGSC current and / or the inhibition of a VGKC current, the Type I taste receptor is T1R1, T1R2, or T1R3, or a homodimer or heterodimer thereof, and the cultured human-derived cells used in step (1) are cultured human nerve cells, cultured human cardiomyocytes, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed. Here, the "human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed" are cells having endogenous Type I taste receptors, such as human HEK cells. The same applies hereinafter. [5-3] The method according to [5-1], wherein the Type I taste receptor is T1R2 / T1R3, the cultured human-derived cells used in the step (1) are cultured human neurons or human-derived cultured cells in which VGSCs are forcibly expressed, and the known Type I taste receptor ligand administered to the culture solution in the step (1) is Aβ25-35 peptide.[5-4] A method for screening for a substance capable of controlling the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are generated by binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors on the surface of human nerve cells, cardiac muscle cells, or skeletal muscle cells, comprising the following steps (1) to (4): (1) using the patch clamp method (membrane voltage clamp method), measuring the VGSC and / or VGKC current of cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells in which Type I taste receptors are expressed on the cell surface, and establishing a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the culture medium of the cells, measuring the VGSC and / or VGKC current of the cells using the same method as in step (1), and measuring the amount of amplification of the VGSC current and / or the amount of inhibition of the VGKC current caused by the binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor; (3) then administering a test substance to the culture medium of the cells, and measuring the VGSC and / or VGKC current of the cells using the same method as in step (1); (4) A step of evaluating the test substance as a substance capable of controlling the amplification of VGSC current and / or the inhibitory effect of VGKC current mediated by Type I taste receptors of the Aβ peptide, sweet amino acid, or umami substance in human nerve cells or cardiomyocytes, when the measured values of VGSC and / or VGKC current measured in step (3) show values that significantly inhibit either or both of the amplification amount of VGSC current and / or the inhibitory effect of VGKC current measured in step (2).[5-5] A screening method for a substance capable of controlling changes in the properties of action potentials (magnitude, width, and firing frequency of action potentials) that occur as a result of the amplification of VGSC current and / or the inhibition of VGKC current caused by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells, cardiac muscle cells, or skeletal muscle cells, the method comprising the following steps (1) to (4): (1) measuring and / or recording the waveform of spontaneous action potentials on the surface of cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells forcibly expressing VGSC and / or VGKC, which are cells that express Type I taste receptors on their cell surface and fire action potentials spontaneously or in response to external stimuli, using the patch clamp method (current clamp mode), the NanoTouch method, or the MEA method, and establishing a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the culture medium of the cells, and measuring and / or recording the waveform of action potentials induced by the binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor using a method similar to that of step (1); (3) then administering a test substance to the culture medium of step (2), and measuring and / or recording the waveform of action potentials induced by the administration of the test substance using a method similar to that of step (1); (4) when the measured value of the occurrence frequency of action potentials or the shape of the waveform measured in step (3) shows a significant change compared to the occurrence frequency of action potentials or the shape of the waveform measured in step (2), evaluating the test substance as a candidate substance capable of controlling the amplification of VGSC current and / or the suppression of VGKC current mediated by the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance in human neurons or cardiomyocytes.[5-6] A screening method for a substance capable of controlling cytoskeletal modification caused by binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human neurons, comprising the following steps (1) to (4): (1) culturing cultured human neurons or human-derived cultured cells expressing Type I taste receptors on their cell surface in a culture medium containing a fluorescent reagent, measuring the intracellular calcium concentration using an intracellular calcium measurement method with the fluorescent reagent, and establishing a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the cell culture medium, and measuring the intracellular calcium concentration increased by binding of the substance to the Type I taste receptor using a method similar to step (1); (3) subsequently administering a test substance to the culture medium from step (2), and measuring the intracellular calcium concentration using a method similar to step (1); (4) If the intracellular calcium concentration measured in step (3) is significantly lower than the calcium concentration measured in step (2), the test substance is evaluated as a substance that activates the Type I taste receptor in neurons and causes a change in the intracellular calcium concentration ([Ca2+]i), and the test substance is selected as a candidate substance that can control the modification of the cytoskeleton in human neurons via the Type I taste receptor by the Aβ peptide, sweet amino acid, or umami substance.[5-7] A method for screening for a substance capable of controlling the amplification of VGSC current and / or the inhibition of VGKC current, which are generated by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiomyocytes, the method comprising the following steps (1) to (4): (1) forming cultured human nerve cells, cultured human cardiomyocytes, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed, which are cells expressing Type I taste receptors on the cell surface, into a cell sheet, and measuring changes in the cytoskeleton and intercellular adhesion of the cultured cells as the amount of resistance on the cell sheet by an impedance method to establish a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the cell culture medium and measuring the changes in the cytoskeleton and intercellular adhesion caused by the binding of the substance to the Type I taste receptor as resistance on the cell sheet using a method similar to step (1); (3) then administering a test substance to the cell culture medium and measuring the resistance on the cell sheet using a method similar to step (1); (4) if it is confirmed that the change in resistance of the cell sheet is significantly greater when the test substance is administered than when it is not administered, selecting the test substance as a candidate substance capable of controlling the amplification of VGSC current and / or the suppression of VGKC current caused by structural changes in the cytoskeleton (microfilaments) and / or changes in intracellular calcium mediated by the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance. Other screening methods include the following.[5-8] A method for screening for compounds that modify / inhibit the action of Aβ peptides, sweet amino acids, or umami substances on VGSC and VGKC activity via T1Rs in CSF, comprising the steps of: (1) treating Type I taste receptors of human epithelial cells with Aβ peptides, sweet amino acids, or umami substances, and culturing the cells in a sheet form, and measuring the impedance (resistance) values at both ends of the cell sheet; (2) then measuring the impedance value when a test substance is applied to the cells; and (3) evaluating that the barrier function of the cell sheet has decreased when a decrease in impedance value is observed due to the action of the test substance, and selecting the test substance as a candidate compound that can control the amplification of VGSC current and / or the inhibition of VGKC current mediated by Type I taste receptors of the Aβ peptides, sweet amino acids, or umami substances. [5-9] A method for evaluating cell barrier function (degree of intercellular adhesion) mediated by T1Rs based on the difference in the ratio of Aβ42 / 40 contained in CSF or serum, comprising the steps of: (1) measuring the impedance (resistance) values at both ends of a cell sheet cultured in the form of a human vascular epithelial cell sheet; (2) then acting a test substance such as an Aβ peptide, a sweet amino acid, or an umami substance on the Type I taste receptors of the cells, and measuring the impedance value of the cell sheet at this time; and (3) evaluating whether the action of the test substance has caused a decrease in the impedance value, and evaluating whether there is a pathological effect on the barrier function of the cell sheet.
[0066] [6] Yet another aspect of the present invention relates to a method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification or inhibition of the activation current of voltage-dependent ion channels induced via Type I taste receptors on the surface of human neurons, cardiac myocytes, skeletal muscle cells, or the like.
[0067] [6-1] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are caused by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, the method comprising the following steps (1) to (4): (1) using the patch clamp method (membrane voltage clamp method) to measure the VGSC and / or VGKC current of cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed, which express Type I taste receptors on the cell surface, and establishing a control value; (2) administering Aβ peptide, sweet amino acid, or umami substance to a culture solution, and measuring the VGSC and / or VGKC current of the cells using the same method as in (1), and measuring the amount of amplification of the VGSC current and / or the amount of inhibition of the VGKC current from the control value; (3) Next, a step of administering a test substance to the culture medium of the cells and measuring the VGSC and / or VGKC current of the cells using the same method as in step (1); (4) When the measured values of the VGSC and / or VGKC current measured in step (3) show values that significantly inhibit either or both of the amplification amount of the VGSC current and / or the inhibition amount of the VGKC current measured in step (2), a step of evaluating the test substance as a substance that can control the amplification of the VGSC current and / or the inhibitory action of the VGKC current mediated by Type I taste receptors of Aβ peptides, sweet amino acids, or umami substances in human nerve cells or cardiomyocytes, and selecting it as a candidate compound for the active ingredient of the pharmaceutical composition.[6-2] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are generated by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, comprising the following steps (1) to (4): (1) measuring the action potential of cultured human nerve cells, cultured human cardiac muscle cells, or cultured human cells in which VGSC and / or VGKC are forcibly expressed, which are cells that express Type I taste receptors on their cell surface and can fire action potentials spontaneously or in response to external stimuli, using the patch clamp method (current-clamp mode), the NanoTouch method, or the MEA method, recording the magnitude, width, and firing frequency of the waveform, and establishing control values; (2) administering Aβ peptide, sweet amino acid, or umami substance to the culture medium of the cells, and measuring and / or recording the waveform width of the action potential induced by the binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor using the same method as in step (1); (3) then administering a test substance to the culture medium of step (2), and measuring and / or recording the waveform width of the action potential induced by the administration of the test substance using the same method as in step (1); (4) if the measured value of the occurrence frequency of the action potential or the shape of the waveform width measured in step (3) shows a significant change compared to the occurrence frequency of the action potential or the shape of the waveform width measured in step (2), evaluating the test substance as a substance capable of controlling the amplification of VGSC current and / or the inhibition of VGKC current mediated by the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance in human neurons or cardiomyocytes, and selecting it as a candidate compound for the active ingredient of the pharmaceutical composition.[6-3] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by cytoskeletal modification resulting from the binding of Aβ peptides, sweet amino acids, or umami substances to Type I taste receptors in human neurons, the method comprising the following steps (1) to (4): (1) culturing cultured human neurons or human-derived cultured cells (e.g., HEK cells) expressing Type I taste receptors on their cell surface in a culture medium containing a fluorescent reagent, measuring the intracellular calcium concentration with the fluorescent reagent by an intracellular calcium measurement method, and establishing a control value; (2) administering the Aβ peptides, sweet amino acids, or umami substances to the cell culture medium, and measuring the intracellular calcium concentration increased by the binding of the substances to the Type I taste receptors with the fluorescent reagent using a method similar to step (1); (3) then administering a test substance to the culture medium of step (2) and measuring the intracellular calcium concentration using a fluorescent reagent in the same manner as in step (1); (4) if the intracellular calcium concentration measured in step (3) is significantly lower than the calcium concentration measured in step (2), evaluating the test substance as a substance capable of activating Type I taste receptors in neurons and causing changes in intracellular calcium concentration ([Ca2+]i) and capable of regulating cytoskeletal modification mediated by the Aβ peptide, sweet amino acid, or umami substance in human neurons, and selecting the test substance as a candidate compound for the active ingredient of the pharmaceutical composition. Note that, because experiments measuring changes in intracellular calcium or experiments staining the cytoskeleton involve reactions prior to VGSC regulation, human-derived cultured cells (HEK cells) expressing Type I taste receptors on their cell surface but not VGSCs can be used.[6-4] A method for screening candidate compounds for active ingredients of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are produced by binding of Aβ peptides consisting of Aβ25-35, Aβ1-38, Aβ1-40, or Aβ1-42 to Type I taste receptors in human neurons or cardiomyocytes, the method comprising the following steps (1) to (3): (1) A step of expressing fluorescently labeled actin or tubulin in advance in cultured human neurons, cultured human cardiomyocytes, or human-derived cultured cells that express Type I taste receptors on the cell surface, and forcibly expressing VGSC and / or VGKC, and administering any Aβ peptide selected from Aβ25-35, Aβ1-38, Aβ1-40, and Aβ1-42 to the cell culture medium to confirm that the Aβ peptide binds to the Type I taste receptor, causing the cytoskeleton of the cells to polymerize and emit fibrous fluorescence; (2) In parallel with step (1), a step of administering the Aβ peptide to the cell culture medium to which a test substance has been administered in advance, and observing the degree of depolymerization of the fluorescently labeled fibrous cytoskeleton caused by the Aβ peptide; (3) When the degree of cytoskeletal depolymerization observed in step (2) is significantly reduced compared to the control value in step (1), the test substance is evaluated as a candidate compound having high inhibitory activity against the amplification of VGSC current and / or the suppression of VGKC current by the Aβ peptide, and selected as a candidate compound for the active ingredient of the pharmaceutical composition. Note that instead of expressing fluorescently labeled actin or tubulin, a method of staining actin with rhodamine phalloidin staining or the like, or a method of using an anti-tubulin antibody as a primary antibody and a fluorescently labeled secondary antibody can also be used.[6-5] A method for screening for a substance capable of controlling the amplification of VGSC current and / or the inhibition of VGKC current generated by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, the method comprising the following steps (1) to (4): (1) forming cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed, which are cells expressing Type I taste receptors on the cell surface, into a cell sheet, and measuring changes in the cytoskeleton and intercellular adhesion of the cultured cells as resistance values on the cell sheet by an impedance method to establish a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the cell culture medium, and measuring the changes in the cytoskeleton and intercellular adhesion caused by the binding of the substance to the Type I taste receptor as resistance values on the cell sheet using a method similar to step (1); (3) then administering a test substance to the cell culture medium, and measuring the resistance on the cell sheet using a method similar to step (1); (4) if it is confirmed that the change in resistance of the cell sheet is significantly greater when the test substance is administered than when it is not administered, selecting the test substance as a candidate substance capable of controlling the amplification of VGSC current and / or the suppression of VGKC current caused by structural changes in the cytoskeleton (microfibers) and / or changes in intracellular calcium that occur via the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance. As with the nanoTouch method, the impedance method completely covers the electrode surface in a sheet, allowing the impedance of the cell sheet to be measured by the change when a current is applied between the earth placed in the extracellular fluid and the cell-covered electrode (a conductive material such as conductive glass).When a constant current (I) is applied, V = IR (Ohm's law) dictates that as the impedance (resistance R) increases, the voltage (V) increases; when R decreases, I remains constant, and the output voltage V decreases.[6-6] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are caused by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, the method comprising the following steps (1) to (4): (1) using the patch clamp method (membrane voltage clamp method) to measure the VGSC and / or VGKC current of cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed, which express Type I taste receptors on the cell surface, and establishing a control value; (2) administering Aβ peptide, sweet amino acid, or umami substance to a culture solution, measuring the VGSC and / or VGKC current of the cells using the same method as in step (1), and measuring the amount of amplification of the VGSC current and / or the amount of inhibition of the VGKC current from the control value; (3) Next, a step of administering a test substance to the culture medium of the cells and measuring the VGSC and / or VGKC current of the cells using a method similar to step (1); (4) When the measured values of the VGSC and / or VGKC current measured in step (3) show values that significantly inhibit either or both of the amplification amount of the VGSC current and / or the inhibition amount of the VGKC current measured in step (2), a step of evaluating the test substance as a substance that can control the amplification of the VGSC current and / or the inhibitory action of the VGKC current mediated by Type I taste receptors of Aβ peptides, sweet amino acids, or umami substances in human nerve cells or cardiomyocytes, and selecting it as a candidate compound for the active ingredient of the pharmaceutical composition.[6-7] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are produced by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, comprising the following steps (1) to (4): (1) measuring and / or recording the waveform width of action potentials of cultured human nerve cells, cultured human cardiac muscle cells, or cultured human cells in which VGSC and / or VGKC are forcibly expressed, which are cells that express Type I taste receptors on their cell surface and are capable of firing action potentials spontaneously or in response to external stimuli, by the patch clamp method (current-clamp mode), the NanoTouch method, the MEA method, or a method using a fluorescent membrane potential-sensitive reagent or a fluorescent intracellular calcium-sensitive reagent, and establishing a control value; (2) administering Aβ peptide, sweet amino acid, or umami substance to the culture medium of the cells, and measuring and / or recording the waveform width of the action potential induced by the binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor using the same method as in step (1); (3) then administering a test substance to the culture medium of step (2), and measuring and / or recording the waveform width of the action potential induced by the administration of the test substance using the same method as in step (1); (4) if the measured value of the occurrence frequency of the action potential or the shape of the waveform width measured in step (3) shows a significant change compared to the occurrence frequency of the action potential or the shape of the waveform width measured in step (2), evaluating the test substance as a substance capable of controlling the amplification of VGSC current and / or the inhibition of VGKC current mediated by the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance in human neurons or cardiomyocytes, and selecting it as a candidate compound for the active ingredient of the pharmaceutical composition.[6-8] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current or the modification of the cytoskeleton, which is caused by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human neurons, the method comprising the following steps (1) to (4): (1) culturing cultured human neurons expressing Type I taste receptors on their cell surface, or human-derived cultured cells forcibly expressing VGSC, in a culture medium containing a fluorescent reagent, measuring the intracellular calcium concentration using an intracellular calcium measurement method, and establishing a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the cell culture medium, and measuring the intracellular calcium concentration increased by the binding of the substance to the Type I taste receptor using a fluorescent reagent, using a method similar to step (1); (3) then administering a test substance to the culture medium of step (2) and measuring the intracellular calcium concentration using a fluorescent reagent in the same manner as in step (1); (4) if the intracellular calcium concentration measured in step (3) is significantly lower than the calcium concentration measured in step (2), evaluating the test substance as a substance that can activate Type I taste receptors in neurons and cause a change in intracellular calcium concentration ([Ca2+]i) and that can control cytoskeleton modification or VGSC current amplification via Type I taste receptors by the Aβ peptide, sweet amino acid, or umami substance in human neurons, and selecting the test substance as a candidate compound for the active ingredient of the pharmaceutical composition. Here, when measuring intracellular calcium concentration, high-throughput screening can also be performed using a plate reader, so a procedure can be used in which a control well is exposed to only Aβ peptide, sweet amino acid, or umami substance, and the test substance is exposed to the control well in advance, or a solution mixed with Aβ peptide, sweet amino acid, or umami substance is simultaneously administered.[6-9] A method for screening candidate compounds for active ingredients of a pharmaceutical composition for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are produced by binding of Aβ peptides consisting of Aβ25-35, Aβ1-38, Aβ1-40, or Aβ1-42 to Type I taste receptors in human neurons or cardiomyocytes, the method comprising the following steps (1) to (3): (1) A step of expressing fluorescently labeled actin or tubulin in advance in cultured human neurons, cultured human cardiomyocytes, or human-derived cultured cells that express Type I taste receptors on the cell surface, and forcibly expressing VGSC and / or VGKC, and administering any Aβ peptide selected from Aβ25-35, Aβ1-38, Aβ1-40, and Aβ1-42 to the cell culture medium to confirm that the Aβ peptide binds to the Type I taste receptor, causing the cytoskeleton of the cells to polymerize and emit fibrous fluorescence; (2) In parallel with step (1), a step of administering the Aβ peptide to the cell culture medium to which a test substance has been administered in advance, and observing the degree of depolymerization of the fluorescently labeled fibrous cytoskeleton caused by the Aβ peptide; (3) When the degree of cytoskeletal depolymerization observed in step (2) is compared with the control value in step (1), and the degree of cytoskeletal depolymerization is significantly suppressed, the test substance is evaluated as a candidate compound having high inhibitory activity against the amplification of VGSC current and / or the suppression of VGKC current by the Aβ peptide, and selected as a candidate compound for the active ingredient of the pharmaceutical composition.[6-10] A method for screening candidate compounds for active ingredients of pharmaceutical compositions for preventing and / or treating diseases caused by the amplification of VGSC current and / or the inhibitory effect of VGKC current, which are generated by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors in human nerve cells or cardiac muscle cells, the method comprising the following steps (1) to (4): A method for screening a substance capable of regulating the above, the method comprising the following steps (1) to (4): (1) forming cultured human nerve cells, cultured human cardiac muscle cells, or human-derived cultured cells in which VGSC and / or VGKC are forcibly expressed, which are cells expressing Type I taste receptors on their cell surface, into a cell sheet, and measuring changes in the cytoskeleton and intercellular adhesion of the cultured cells as the amount of resistance on the cell sheet by an impedance method to establish a control value; (2) administering the Aβ peptide, sweet amino acid, or umami substance to the cell culture medium, and measuring the changes in the cytoskeleton and intercellular adhesion caused by the binding of the substance to the Type I taste receptor as resistance on the cell sheet using a method similar to step (1); (3) then administering a test substance to the cell culture medium, and measuring the resistance on the cell sheet using a method similar to step (1); (4) if it is confirmed that the change in resistance of the cell sheet is significantly greater when the test substance is administered than when it is not administered, evaluating the test substance as a candidate substance capable of controlling the amplification of VGSC current and / or the inhibition of VGKC current caused by structural changes in the cytoskeleton (microfilaments) and / or changes in intracellular calcium that occur via the Type I taste receptor of the Aβ peptide, sweet amino acid, or umami substance, and selecting it as a candidate compound for the active ingredient of the pharmaceutical composition. [6-11] A method for screening candidate compounds for the active ingredient of a pharmaceutical composition for preventing and / or treating a disease caused by amplification of VGSC currents resulting from binding of Aβ peptide to Type I taste receptors derived from human neurons or humanized laboratory animals, the method comprising a step of observing changes in the area or volume of cultured human neurons or humanized mouse neurons.[6-12] A method for screening an active ingredient of a pharmaceutical composition, in which a VGSC current is enhanced by applying an Aβ42 / 40 ratio (AD-D) observed in the cerebrospinal fluid of AD patients to a Type I taste receptor in a human neuron or a cell derived from a humanized laboratory animal, and if the increase in the VGSC current is then observed to be reduced by applying a test substance, the test substance is evaluated as a candidate compound for an active ingredient of a pharmaceutical composition for preventing and / or treating a disease caused by the amplification of the VGSC current caused by the binding of Aβ peptide.
[0068] In the present invention, we have discovered for the first time that Type I taste receptors (T1R1, T1R2, and T1R3) regulate the properties and magnitude of voltage-gated sodium channel currents (VGSCs) and voltage-gated potassium channel currents (VGKCs) through the cytoskeleton. While glutamate receptors (AMPA and NMDA) were previously thought to be essential players in the memory formation mechanism in the hippocampus, this discovery suggests that, in addition to glutamate receptor dynamics, voltage-gated ion channels may also play an important role in neuroplasticity and memory formation processes. This indicates that Type I taste receptors are effective targets for drug discovery in the treatment of memory disorders such as dementia. First, T1R1, which functions as a receptor for umami substances such as glutamate (and also partially acts on Aβ1-42), can be used to identify therapeutic candidates by exploring its agonists and amplifying allosteric control (positive allosteric modulators; PAMs). Next, T1R2 acts as a receptor for artificial sweeteners and inhibits voltage-dependent sodium channel currents via microfilaments, making it an effective drug discovery target for the development of analgesics and antiepileptic drugs. Furthermore, we identified T1R3 as a receptor for amyloid beta peptide (Aβ25-35), which is considered to be the most important clinical finding in Alzheimer's disease. Because Aβ25-35 amplifies VGSC currents and causes hyperactivity in nerves or myocardium, T1R3 antagonists and other inhibitors of Aβ25-35 binding to T1R3 are promising candidates for treating Alzheimer's disease. As described above, the present invention has discovered that Type I taste receptors (T1Rs) are receptors for amyloid β peptides (Aβ25-35 receptors are T1R3, and Aβ1-42 receptors are T1R1 and T1R3), and that Aβ peptides control VGSC and VGKC currents via T1Rs, at least in neurons. This has demonstrated that these receptors can serve as drug discovery targets for preventing or suppressing the binding / deposition of amyloid β peptides, which cause Alzheimer's disease, ALS, and functional decline in other tissues.Furthermore, the therapeutic agent for neuropathic pain provided by the present invention acts on VGSCs via sweet taste receptors and therefore is effective even under inflammatory acidic conditions, and is therefore expected to be particularly effective when used as a local anesthetic.
[0069] In addition, in the present invention, various anti-T1R3 antibodies were used to clarify which region of T1R3 or T1R2 / T1R3 acts to enhance VGSC current for the highly toxic amyloid β peptides Aβ25-35, as well as Aβ1-42 and Aβ1-40. Furthermore, the effects on VGSC current were compared using a mixture of cerebrospinal fluid Aβ1-42 / Aβ1-40 (Aβ42 / 40) adjusted to the concentration ratio of Alzheimer's disease (AD) patients (AD-D) and the concentration ratio of healthy individuals (NDC). As a result, no significant changes were observed with NDC, but VGSC current was significantly enhanced in AD-D. This suggests that the epileptiform symptoms observed in patients with Alzheimer's dementia may be due to neural hyperactivity resulting from the enhancement of VGSC current by Aβ42 / 40 (AD-D). This enhancement was reversed by β-alanine. Furthermore, we found that when AD-D was applied to mouse / rat neuron-like cells, its effect was reduced, in contrast to that in human cells. This finding points to a fundamental reason why research results using experimental mouse models in Alzheimer's disease drug discovery and research are not effective in human clinical trials. Similarly, we observed morphological changes in human neuron-like cells and confirmed that morphological changes induced by AD-D concentrations are significantly related to the onset of AD. We also found that these morphological changes were reversed by β-alanine. In other words, by observing the morphological and kinetic changes that cerebrospinal fluid or serum from AD patients induce in cultured human neuron-like cells, it is possible to determine the progression of the disease. This strongly suggests that β-alanine or its structural analogs may be a promising therapeutic agent for AD. Furthermore, electrophysiological techniques were able to demonstrate species differences in the effects of Aβ peptides on T1Rs.
[0070] Western blot showing silencing of endogenous T1R3 in HEK293 cells: The silencing effect of T1R3 protein expression was confirmed using a T1R3 antibody. Left lane: HEK293 control; right lane: HEK293 transfected with the silencing vector. Expression levels of endogenously expressed T1R1, T1R2, and T1R3 in HEK cells and SH-SY5Y cells were confirmed by quantitative PCR. Enhancement of VGSCs by glutamine: The effect of 500 μM glutamine on VGSC currents in SH-SY5Y cells was measured using the voltage clamp method. Left: Voltage clamp recordings before and after the application of 500 μM glutamine; transient enhancement of downward VGSC currents was confirmed. Right: IV plot analysis of the results from the left panel. Effect of Aβ25-35 on SH-SY5Y VGSC currents. The effect of 2 μM Aβ25-35 peptide on SH-SY5Y VGSC currents was measured using the voltage clamp technique. (A) Voltage clamp recordings before and after the application of 2 μM Aβ25-35 peptide. A transient downward VSC enhancement was observed after application. (B) IV plot analysis of the results shown on the left. Aβ25-35 peptide, similar to glutamine, increased the excitability of SH-SY5Y cells. Current-clamp recordings were performed using SH-SY5Y cells to confirm the effect of Aβ25-35 peptide on action potentials. Cells were stimulated using the following current pattern: a short stimulus (25 ms), followed by a 200 ms interval and a long stimulus (250 ms). The current intensity was increased in the order of 6, 8, 10, and 12 pA. The membrane potential was maintained at -80 mV during appropriate current injection. (A) Responses to each stimulus are shown at 125 mV intervals. (B) Four traces are overlaid. Effect of Aβ1-42 on HEK Nav1.5 VGSC currents. The effect of 74 nM Aβ1-42 peptide on HEK Nav1.5 VGSC currents was measured using voltage clamp. (A) Voltage clamp recordings before and after application of 74 nM Aβ1-42 peptide. The transient downward VGSC did not potentiate, as with Aβ25-35, but tended to decrease (n = 4). It also tended to shift the peak of the IV plot 5-10 mV hyperpolarizing. It delayed VGSC inactivation (Figure 37).(B) shows the results of (A) analyzed using an IV plot. Comparison of the effects of Aβ25-35 peptide on VGSCs in control HEK Nav1.5 cells and T1R3-silenced HEK Nav1.5 cells. (A) and (B) show voltage-clamp recordings of VGSCs from control HEK Nav1.5 cells before and after Aβ25-35 administration. 1 μM Aβ25-35 confirmed the potentiation of VGSCs. (C) and (D) show recordings of VGSCs from T1R3-silenced HEK Nav1.5 cells. Treatment with 2 μM Aβ25-35 peptide, twice the control dose, did not alter VGSCs. (E) shows that lactisole, which specifically binds to the T1R3 TM (TransMembrane) domain, inhibits the potentiation of VGSCs by Aβ25-35. The upper panel shows voltage-clamped VGSC currents. From left to right, the graphs show the control and the enhancement of VGSC currents by Aβ25-35. The subsequent administration of 1 mM lactisole inhibited the enhancement of VGSC currents by Aβ25-35. The bar graphs in the figure below show the changes caused by Aβ25-35 and lactisole, with the control peak current set at 100%. Symbols indicate each experiment, and the bar graphs represent the relative mean changes. HEK Nav1.5 cells cultured on glass coverslips were incubated in a culture medium containing a 1:1000 dilution of anti-T1R3 antibody (Abcepta, Inc.) for 10 to 30 minutes at room temperature. The coverslips were then transferred to HBPS solution, and the steady-state inactivation of VGSC (Nav1.5) currents, a process dependent on the membrane voltage, was measured using the voltage clamp technique. This was used as a control. Next, Aβ25-35 peptide was added to the recording solution, and the changes in VGSC currents were measured using the same experimental method as above. The Aβ25-35 peptide enhanced the maximum VGSC current in cells not pretreated with T1R3 antibody, but no enhancement was observed in cells pretreated with T1R3 antibody.The changes in the VGSC IV curve caused by the Aβ25-35 peptide were similar to those observed when T1R2 was stimulated by artificial sweeteners, resulting in a hyperpolarized shift in the steady-state inactivation curve. These findings suggest that the potentiation of VGSC currents by the Aβ25-35 peptide occurs via T1R3. This suggests that when the Aβ25-35 peptide is unable to act on T1R3 with a T1R3 antibody, it may act on T1R2. This suggests that T1R2 may act secondarily as a low-affinity binding site for the Aβ25-35 peptide. At present, it is possible that the Aβ25-35 peptide acts solely on T1R3, or, like sucrose and sucralose, on both T1R2 and T1R3. Concentration-dependent amplification of VGSC currents by the Aβ25-35 peptide, EC. 50The value was 86.8 nM. Using the perforated patch-clamp method, we observed the concentration-dependent V-cell current, membrane capacitance amplification, and desensitization process induced by the T1R3-mediated Aβ25-35 peptide. The upper half of the figure shows the change in membrane capacitance, and the lower half shows the magnitude of the V-cell current. Both the membrane capacitance and V-cell current increased with 120 nM Aβ25-35, but increasing the Aβ25-35 concentration to 240 nM reduced both the membrane capacitance and V-cell current, returning them to control levels (before Aβ25-35 treatment). As in Figure 10, we also reproduced the concentration-dependent V-cell current and membrane capacitance amplification induced by the T1R3-mediated Aβ25-35 peptide using the perforated patch-clamp method. (A) Increases in membrane capacitance and V-cell current (HEKNav1.5) after treatment with 12.5 nM Aβ are shown. Membrane capacitance was calculated by integrating the change in current waveform resulting from a 10 mV depolarization from the holding voltage while the membrane potential was fixed (top). The dotted area represents the control capacitance, and the white area above it represents the increase after Aβ treatment. VGSC current also increased with increasing capacitance. (B) The increase in membrane capacitance due to Aβ treatment was plotted against time. The waveform on the plot represents the membrane capacitance in an unactivated state of VGSC. (Left: control; right: after Aβ treatment). (C) Simultaneously with the capacitance measurement in (B), the change in the magnitude (increase) of VGSC current after Aβ treatment was measured and plotted against time. Comparison was made with the current density of VGSC induced by the treatment with Aβ25-35 peptide (including the experimental results in Figures 10 and 11). Bar graph: Current density (pA / pF) calculated by dividing the peak VGSC current value by the cell membrane capacitance measured in the control. From left to right, the bars represent control, low-concentration Aβ25-35, and high-concentration Aβ25-35. The following lines, "Inserted" and "Retrieved," show the current density of the intracellular vesicles, calculated by dividing the increase in VGSC current by the difference between the membrane capacitance measured under each experimental condition and that obtained under the control. In other words, this represents the increased membrane area resulting from the fusion of membrane components of intracellular vesicles bearing VGSCs on their surfaces to the plasma membrane.The current densities of vesicle-derived VGSCs inserted into the plasma membrane by low concentrations of Aβ25-35 and those of VGSCs endocytosed and internalized from the plasma membrane due to receptor desensitization by high concentrations of Aβ25-35 were nearly equivalent. This suggests that VGSCs from inserted vesicles may remain within the vesicle-derived membrane without diffusing to the surrounding plasma membrane during the short period of time observed in this experiment. The table on the right shows the individual experimental data used to generate the bar graph on the left. Effect of DichlorProp on VGSC currents: DichlorProp reduced the amplitude of VGSC currents. Membrane voltage-dependent VGSC activity was recorded by applying a prepulse of -120 mV followed by depolarizing stimuli from -80 mV to 50 mV in 10 mV intervals. The peak inward current decreased in a DichlorProp concentration-dependent manner. The curve on the left shows steady-state inactivation, plotting the current amplitude versus membrane potential for VGSCs activated by a test pulse of -20 mV followed by full pulses of -160 mV, -120 mV, and 0 mV. DichlorProp gradually shifts the current to the left. Effect of DichlorProp on the Slope and Vh of the Steady-State Inactivation Curve. Vh and slope were calculated using the Boltzmann equation (1 / (1+exp((V50-x) / slope)). The analysis software used was CurveExpert Professional (Hyams Development) (n=4). (A) Comparison of the slope of the curves for control, 300, and 500 μM DichlorProp. A t-test showed no significant difference among these three conditions. (B) Comparison of the effect on Vh. A statistically significant difference was confirmed from the measured value for 500 μM DichlorProp. It can be seen that the Vh value shifts to more negative potential values with high concentrations of DichlorProp. Effect of TBB on VGSC current (A) TBB reduced the amplitude of VGSC currents. Voltage-dependent VGSC activity was recorded after a prepulse of -120 mV followed by depolarizing stimuli from -80 mV to 50 mV in 10 mV increments. The peak inward current was reduced in a TBB concentration-dependent manner.The left panel shows the steady-state inactivation curve. The amplitude of the VGSC current activated by a -20 mV test pulse applied following all pulses from -170 mV to -120 mV to 0 mV is plotted against the membrane potential. TBB gradually shifts the current to the left. (B) Prepulse potentials are shown from top to bottom: -80 mV (top panel), -100 mV (middle panel), and -120 mV (bottom panel). The amplitude of the VGSC current induced by a -20 mV test pulse from the prepulse potential was recorded. The TBB concentration was increased from right to left. From left, the changes are shown for control and 10 μM TBB; the middle panel shows 20 μM TBB; and the right panel shows 30 μM TBB. At -80 mV (top panel), 10 μM TBB almost completely inhibited the VGSC current; at -100 mV (middle panel), the effect was approximately half; and at -120 mV (bottom panel), the effect was more than 80%. At 10 μM TBB, almost complete inhibition was observed except at -120 mV (bottom panel). (A) IC of the concentration-dependent inhibitory effect of TBB on the VGSC current. 50 VGSCs activated by a step from -80 mV to -20 mV with a prepulse were almost completely inhibited at 10 μM, while stimulation from -120 mV was only inhibited by approximately 50% at the TBB concentration used. Therefore, a Hill plot was used to calculate the TBB IC50 (15.8 μM) using measurements with a prepulse of -100 mV. The INa activated by a step from -100 mV to -20 mV was plotted against the TBB concentration. The vertical axis represents the INa control as 1, and the amplitude of INa after TBB treatment was averaged. (B) The state-state inactivation curve was calculated using the Boltzmann equation to calculate Vh before and after TBB administration, and the difference was plotted against the TBB concentration. This plot was further analyzed using the Hill equation to determine the IC. 50 The inhibitory effect of TBB was analyzed using different methods in (A) and (B), but the IC values were almost the same. 50Values were obtained. VGSC current recordings were performed using a pulse-and-ramp protocol. The membrane potential was clamped at -120 mV. A square-wave stimulus of -20 mV was applied to induce a transiently activating VGSC current component (A), followed by a ramp stimulus from -120 mV to +60 mV to induce a slowly inactivating VGSC current component (B). The amplitudes of both the transient component (A) and the slowly inactivating component (B) were suppressed (reduced) by the action of the CK2 inhibitor TBB. The effects of 10 mM MSG were observed. The VGSC currents induced by square-wave stimulation (A) and ramp-induced VGSC currents (B) were partially restored by TBB. (C) The MSG-induced potentiation of VGSC currents is plotted against time. This suggests that the potentiation of VGSC currents by MSG may have a mechanism of action independent of the inhibitory effect of TBB. VGSC currents induced by square-wave stimulation are indicated by ●, and VGSC currents induced by ramp stimulation are indicated by ▲. MSG-induced delay of VGSC inactivation in the presence of TBB: The SS curves in the left panel were obtained by stimulating VGSCs by step-shifting the VGSC membrane potential from different steady-state holding voltages to -20 mV. Inhibition of CK2 by TBB resulted in a significant hyperpolarized shift of the SS curve (left-pointing arrow). Subsequent application of MSG partially reversed the TBB-induced leftward shift and resulted in a rightward shift (right-pointing arrow). The right panel shows actual VGSC current traces measured using the SS curve. The effect of MSG on the VGSC current is confirmed to delay the inactivation process compared to TBB-treated VGSC currents. Comparing the current waveforms after MSG treatment with those of the control waveforms can be interpreted as an enhancement of the slow inactivation seen in the control waveforms. Paclitaxel (Taxol), like glutamine and Aβ25-35 peptide, also enhances VGSCs in HEK Nav1.5 cells. (A) VGSC currents under voltage clamp before (left control) and after (right) application of 2.4 μM Taxol. (B) IV plot of the VGSC peak current shown in (A). (C) The same experiment was performed using 1 μM Taxol. IV curves were generated when the prepulse was applied from -120 mV (●) and when the prepulse was applied from -80 mV (◯).In both cases, Taxol amplified the peak current amplitude. However, although Taxol slightly increased the measured repulse values at -70 mV and -80 mV, its overall effect on the SS curve was limited. Further investigation revealed that Taxol (which stabilizes microtubules) enhanced VGSCs in HEK Nav1.5 cells, similar to glutamine and Aβ25-35 peptide. Inhibitory effect of 5 μM NPS-2143 on HEK Nav1.5 VGSCs. (A) shows the process by which the actual VGSC current was inhibited by NPS-2143. (B) is an IT plot showing the decrease in current amplitude over time following the effect of NPS-2143. Stimulation pulses were applied every 8 seconds, starting from a prepulse of -120 mV and ending with -20 mV. Inhibitory effect of 5 μM cinacalcet on VGSC inward and potassium outward currents in SH-SY5Y cells. (A) shows the waveform before cinacalcet administration and after cinacalcet-induced inhibition. (B) is an IT plot showing the decrease in current amplitude over time due to cinacalcet action. Pre-pulses of -120 mV to -20 mV stimulation pulses were applied every 8 seconds. Cinacalcet inhibited both VGSC inward and potassium outward currents. Cinacalcet's VGSC inhibitory effect is mediated by T1R3. In HEK Nav1.5 cells in which T1R3 expression was silenced, the cinacalcet inhibitory effect was abolished. (A) shows VGSC current recordings before and after cinacalcet administration. In cells in which T1R3 expression was silenced, no change in VGSC current was observed due to cinacalcet action. Pre-pulse of -120 mV and test pulse of -20 mV. (B) is an IT plot showing the amplitude and time course of the VGSC current. 20 μM cinacalcet was applied twice at the arrowheads. The amplitude of VGSCs was measured with a -20mV test pulse when the pre-pulse was -80mV and -120mV, and the changes are shown below. The inhibitory effect of the CaSR agonist cinacalcet on VGSCs via T1R3 is inhibited by the state of cytoskeleton polymerization. (A) When actin polymerization is inhibited by cytochalasin D, the inhibitory effect of cinacalcet on VGSCs is lost.(B) IV curves and steady-state inactivation curves of VGSC currents in the presence of control, cytochalasin D, and high concentrations of cinacalcet. (B) When tubulin polymerization was inhibited with colchicine, unlike the actin polymerization inhibitor cytochalasin D, cinacalcet's T1R3-mediated inhibitory effect on VGSCs was observed, but colchicine had no effect. These results suggest that cinacalcet inhibits VGSCs by acting on actin via T1R3. (A) Inhibitory effect of the CaSR antagonist NPS-2143 on VGSCs: 5 μM NPS-2143 slowly inhibited VGSC currents, similar to cinacalcet. The vertical axis indicates the inhibitory process, with the magnitude of the control current set to 1. The horizontal axis indicates time (sec). (B) Inhibitory process of VGSC currents by NPS-2143. Dots indicate the peak VGSC current, and circles indicate the baseline level. The time course changes from left to right as in (A). Once NPS-2143's inhibition of VGSC current is nearly complete, the baseline (leak) current increases, but the baseline-leak current decreases when the CaR agonist cinacalcet is applied (B, top). (B, bottom) shows actual experimental values measured for peak current and baseline, plotted against each other. Cinacalcet's inhibitory effect on VGSCs under acidic conditions. (A) Cinacalcet inhibited VGSC-dependent action potentials in SH-SY5Y cells under acidic conditions at pH 6 (current-clamp). (B) Cinacalcet also inhibited HEK Nav1.5 VGSC currents using the voltage-clamp method, similar to the normal pH of 7.4. (B, top) Na. + Voltage clamp traces of Na current are shown. + Currents were activated by repeated voltage steps from -120 mV to -20 mV every 8 seconds. Application of 5 μM cinacalcet increased Na + The current was gradually suppressed, as shown in the IT relationship in (C). The initial low trace amplitude is the Na +The amplitude of the current corresponds to the magnitude of the current. The effect of saccharin on VGSC currents. (A) Saccharin concentration-dependently reduced the amplitude of VGSC currents. Voltage-dependent activation of VGSCs was recorded by applying a pre-pulse of -120 mV followed by depolarizing stimuli from -80 mV to 50 mV in 10 mV increments. (B) The plot shows a concentration-dependent decrease in the peak inward current. The curves on the left and right of the figure show steady-state inactivation curves, plotting the amplitude of VGSC currents activated by a test pulse of -20 mV applied following a full pulse from -120 mV to 0 mV versus membrane potential. Overexpression of T1R2 in HEK Nav1.5 cells and its effect on VGSC currents. IV curves were performed to examine the nature of activation. When a stimulation pulse was applied from the normal prepulse voltage of -120 mV, the peak current of VGSCs was small. However, when the membrane potential range of the steady-state inactivation curve measurement was extended to a negative range of -200 mV from the normal recording, the maximum peak current amplitude of VGSCs increased approximately fivefold. Therefore, when a stimulation pulse similar to that of the -120 mV experiment was applied with prepulse voltages set to -140 mV or -180 mV, the maximum peak current of VGSCs increased, similar to that obtained in the steady-state inactivation curve. These results suggest that overexpression of T1R2 may affect VGSC inactivation, similar to the effects of artificial sweeteners acting on T1R2. Effects of Gymnema Tea Extract (GTE) on VGSC Currents: (A) GTE reduced the amplitude of VGSC currents. Voltage-dependent activation of VGSCs was recorded by applying a prepulse of -120 mV followed by depolarizing stimuli from -80 mV to 50 mV in 10 mV increments. The peak current of the IV curve was reduced by 40-50% before and after GTE application. The curve on the left shows steady-state inactivation. The current amplitude of VGSCs activated by a test pulse of -20 mV applied following a full pulse from -120 mV to 0 mV is plotted against the membrane potential. GTE shifts the current to the left.(B) Steady-state inactivation curves were plotted for VGSC currents recorded from SH-SY5Y, Nav1.5-HEK, and NG108-15 cells. Vh (the membrane potential at which the magnitude of VGSC current is reduced by half) was calculated from these data using the Botzman equation. Vh was calculated for control and post-treatment with 10 μL of GTE. The difference in Vh (Vhdiff) and slope (K) (Kdiff) are summarized in Table (B). In all cells tested, Vh shifted toward hyperpolarization, and peak VGSC currents were reduced (inhibited) by approximately 60%. Changes in sodium current potentiation in SH-SY5Y cells pretreated with anti-T1R3 antibodies. Retinoic acid-differentiated SH-SY5Y cells were pretreated with anti-T1R3 antibodies. Similarly, a stimulation pulse was applied from a holding voltage of -120 mV to activate voltage-dependent VGSCs. An IV curve was generated as a control (Figure 8). Subsequent application of Aβ25-35 peptide resulted in a slight leftward shift in the IV curve, as in Figure 8, but no increase in VGSC currents, as observed in SH-SY5Y cells not treated with anti-T1R3 antibodies. This suggests that T1R3 GPCR is essential for the enhancement of VGSC currents by Aβ25-35 peptide. Binding of fluorescently labeled Aβ25-35 peptide (FL-Aβ25-35) to SH-SY5Y cells. The left panel shows the positive control results for SH-SY5Y cells treated with Aβ25-35 peptide. Under a fluorescence microscope, fluorescence derived from the Aβ25-35 peptide can be seen binding to the cells. On the right, cells were pre-treated with anti-T1R3 antibodies. FL-Aβ25-35 was applied for the same amount of time as the control, but almost no fluorescence derived from FL-Aβ25-35 was detected on the cell surface. The effect of Aβ25-35 on VGSC current enhancement in the presence of latrunculin A, which inhibits actin polymerization. (A) Effect of latrunculin A on VGSC current. The magnitude of VGSC current before and after the application of 12.6 μM latrunculin A is plotted against the stimulation pulse potential (● before latrunculin A application, □ after application).(B) The effect of latrunculin A was measured by applying a stimulation pulse from a holding voltage of -80, -100, or -120 mV to -20 mV. The inhibition by latrunculin A was membrane potential-dependent, with the inhibitory effect at -80 mV being significantly greater than that at -120 mV. (C) To examine whether actin polymerization is involved in the mechanism of action of Aβ25-35, the effect of 12.5 nM Aβ25-35 was observed in the presence of latrunculin A, and the magnitude of the VGSC current was plotted against the membrane potential (□ before Aβ25-35 treatment, ◇ after treatment). Aβ25-35 was confirmed to amplify the VGSC. The degree of amplification was more pronounced in the presence of latrunculin A than in its absence. (D) Time series of the amplification of the VGSC current by Aβ25-35 in the presence of latrunculin A. In the presence of colchicine, Aβ25-35 did not potentiate the VGSC current. (A) As in the SS inactivation protocol, VGSC currents were stimulated by varying the pre-pulse voltage of a -20 mV stimulation pulse. Control traces are shown on the left, followed by Aβ25-35 in the presence of colchicine, and on the right, followed by Aβ25-35 in the presence of colchicine. (B) VGSC current amplitudes are plotted against the stimulation pulse voltage for control, colchicine, and Aβ25-35. The enhancement by Aβ25-35 was inhibited in the presence of colchicine. (C) The waveform of the VGSC current was unchanged by Aβ25-35 in the presence of colchicine. (D) The peak current during the measurement shown in (C) is plotted against time, demonstrating the inhibition of Aβ25-35. (E) An example of the increase in VGSC currents by colchicine in cells different from those used in (A)–(D) above. The action of Aβ25-35 peptide caused the disappearance of the microtubule filament-like structures observed before the action (as indicated by GFP-Tublin labeling). The action of MSG, an agonist of the umami taste receptor, also caused the disappearance of the microtubule filament-like structures (as indicated by GFP-Tublin labeling), similar to the action of Aβ25-35 peptide.Changes / disappearance of microfilament filament structure (as determined by GFP-Actin labeling) by the Aβ1-42 peptide, cinecalcet. Delayed inactivation of VGSC currents induced by the T1R1 agonist, glutamate (MSG), in HEK NaV1.5 cells. MSG significantly delayed the inactivation of transient VGSC currents. As a result, the transient VGSC current component was reduced, but at the same time, it enhanced the amplitude of the small, sustained VGSC current observed following the transient VGSC. Transient activating currents were examined using square-wave stimulation (top left) and sustained currents using ramp waveforms (top right). The time series (current amplitude vs. time) plots of the measurements obtained using square-wave stimulation (top left) are shown below. Effects of the T1R1 agonists, glutamate (MSG) and Aβ1-42, on voltage-gated potassium channels. (A) Voltage-clamp experiments using SH-SY5Y cells confirmed that MSG treatment delayed the inactivation of VGSC currents and reduced voltage-dependent potassium channel currents. The upper left panel shows voltage-clamp results before MSG administration, while the right panel shows results after. The lower right panel shows the upward outward potassium current and an IV curve below the current trace. In the lower right panel of (A), a ramp pulse followed by a voltage hold at 40 mV slowly inhibits / decreases the magnitude of the potassium current. (B) Using HEK cells expressing Kv1.2, we confirmed the effect of Aβ1-42 on potassium channels, which delayed VGSC inactivation similar to that of MSG, using the above ramp waveform. Aβ1-42 reduced Kv1.2 potassium, similar to the effect of MSG in SH-SY5Y cell recordings. The upper panel of (B) shows the actual experimental trace, and the lower panel shows a time series plot of the Aβ1-42-induced inhibition of potassium channel currents. Inhibitory effects of IMP and Aβ1-42 on VGSC current and delayed inactivation of VGSC current; (A) The upper panel shows the decrease in VGSC current observed in the control and after the action of 1 mM IMP. (B) Steady-state inactivation curve and IV plot of the experimental results (A). IMP reduces VGSC current, but transient enhancement occurs within approximately 5 minutes after the action.(C) The effect of IMP on VGSC currents was assessed using a voltage-clamp experiment with a ramp waveform (a downward arrow indicates an increase in VGSC current, followed by a decrease in VGSC current, indicated by an upward arrow). (D) and (E) show the effect of Aβ1-42 analyzed using the same voltage-clamp experiment as in (A) and (B). Increasing concentrations of Aβ1-42 (12.5 nM and 25 nM) resulted in a concentration-dependent decrease in VGSC currents, similar to MSG and IMP. Furthermore, as with IMP, a delay in VGSC inactivation was observed. The effect of GMP on inward VGSC currents and outward potassium currents was investigated using SH-SY5Y cells. (A) Total currents observed by voltage-clamp measurement before (left) and after (middle) administration of 2 mM GMP, and after further administration of 5 mM MSG, are shown. (B) IV curves of the inward VGSC currents were generated, confirming that GMP administration enhanced VGSC currents. Here, we plotted not only VGSC currents but also voltage-dependent potassium currents. Steady-state inactivation curves were also included in the same plot. Closed symbols indicate changes from control, while open symbols indicate changes after GMP administration. VGSC currents showed a slight increase and a leftward shift in the I-V curve (downward (inward) arrow at -20 mV), and the peak of the upward (outward) potassium current decreased (downward arrow at +50 mV). No changes were observed in the steady-state inactivation curve. The enhancement of VGSC currents by GMP alone was smaller than that by IMP, and this effect varied depending on the recording cell. The difference between the effects of GMP and IMP on VGSC currents is that GMP's effect is sustained. Furthermore, unlike MSG, GMP has little effect on the inactivation process. As shown in (A), no changes in the inactivation process were observed before and after GMP administration, as seen with MSG. Therefore, we performed I-V plots to examine the effects of MSG administration on VGSC currents after GMP administration. In the presence of GMP, MSG was confirmed to cause a leftward shift of approximately 10 mV (leftward arrow) in the IV curve compared to the control (C).Effect of MSG on the kinetics of VGSC current inactivation in the presence of an artificial sweetener (saccharin): Voltage-clamp experiments were performed on HEK Nav1.5 cells, which had saccharin-induced T1R2 activation, using square-wave stimulation (left) and ramp waveforms (right) to detect the transient activation of VGSC currents. The top panel shows waveforms before administration (control), the middle panel shows waveforms after administration (30 seconds after administration), and the bottom panel shows waveforms after administration (10 minutes after administration). The inactivation process of the transient VGSC current activated by square-wave stimulation was significantly delayed after MSG administration. The degree of delay weakened over time, but the effect persisted even after 10 minutes (bottom panel). The bottom panel shows the voltage waveforms used for stimulation. Effect of MSG2.5 on VGSC currents in SH-SY5Y and HEK Nav1.5 cells. The effects of MSG2.5 on VGSCs were investigated using voltage-clamp techniques in (A) SH-SY5Y cells and (B) Nav1.5 HEK cells. MSG2.5 amplified the peak VGSC current, but, unlike MSG alone, had limited effect on the inactivation process. In the upper panels of (A) and (B), the left side shows the VGSC current measured by voltage-clamp techniques before and after MSG2.5 treatment. The I-V relationship of the peak voltage amplitude versus membrane potential is shown on the right. In the lower panel of (C), we analyzed how MSG2.5 altered the sustained VGSC current component 540 ms after stimulation onset, rather than the transient peak current, in an experiment using Nav1.5 HEK cells. The I-V relationship is shown in the center of (C). An experiment using a ramp waveform instead of the square-wave stimulation shown on the left of (C) is shown on the right of (C). The peak shifted temporarily toward hyperpolarization after MSG2.5 treatment (1 minute 12 seconds after treatment) compared to before treatment, but returned to nearly the same waveform after 4 minutes. The effect of MSG2.5 on VGSC currents in HEK Nav1.5 cells with silenced T1R1 expression. VGSC currents were recorded using voltage clamp. (A) In cells with silenced T1R1 expression, the change in VGSC currents induced by 5 mM MSG2.5 was suppressed. (C) The same cells as in (A) were subjected to ramp-wave stimulation every 8 seconds before and after MSG2.5 treatment to observe and analyze the sustained effect of MSG2.5 on VGSC currents.Similar to the results obtained with square-wave stimulation, no effect of MSG2.5 was observed. (B) On the other hand, in cells with silenced T1R3 expression, the effect of MSG2.5 on VGSC currents was observed, similar to that observed in cells without silencing. This confirms that T1R1 expression is essential for the effect of MSG2.5 on VGSC currents, and that the presence or absence of T1R3 is not involved in the effect of MG2.5 on VGSC currents. Mechanisms of pain and epileptiform symptoms due to neuronal hyperactivity: In addition to the aforementioned amyloid beta peptide and sweet amino acids such as glutamine (L-Gln), we also describe the mechanism of neuropathic pain induced by chemotherapy. Chemotherapy drugs such as paclitaxel increase VGSC currents by polymerizing microtubules, leading to neuronal hyperactivity. In addition to paclitaxel, which stabilizes microtubules, colchicine, which inhibits microtubule polymerization, was also observed to increase VGSC currents. Under these conditions, the VGSC current per neuron increases, the action potential threshold decreases, and action potentials become more readily generated. Furthermore, even stimuli that elicit a single action potential generate multiple burst-like action potentials. Using the nanocharge method, we measured the VGSC enhancement effect of Aβ25-35 peptide via T1R3: Aβ25-35 peptide was added to differentiated SH-SY5Y cell culture medium, and the change in intracellular potentials was measured from before addition. While the rate of action potential generation was low in the control group (top panel), the frequency of spontaneous action potentials increased after Aβ25-35 peptide treatment (bottom panel). Changes in VGSC currents following treatment with Aβ1-38 and Aβ1-40 in HEK Nav1.5 cardiac myocytes: (A) Aβ1-38 (B) Aβ1-40. The bottom panels of both (A) and (B) show current traces obtained using the steady-state inactivation protocol under voltage clamp conditions: control (left) and after 12.5 nM Aβ peptide treatment (right).The upper panel shows the analyzed IV curve and steady-state inactivation protocol curve. Here, ● indicates the control, and ◯ indicates the Aβ peptide treatment. The IV curves are measured with prepulses of -80 mV and -120 mV. Aβ1-38 shifted the steady-state inactivation curve to the right, enhancing the small current from a prepulse of -80 mV. Meanwhile, it reduced the current from -120 mV. Conversely, Aβ1-40 shifted the steady-state inactivation curve to the left, resulting in a decrease in the VGSC current at both prepulses. Effects of Aβ1-40 and Aβ1-42 on intracellular calcium. The changes in intracellular calcium concentration induced by administration of Aβ1-40 and Aβ1-42 peptides in HEK cells endogenously expressing T1R GPCRs were measured using a fluorescent dye (Cal-520, AAT Bioquest) under a fluorescent microscope. (A) and (B) show the dynamics of intracellular calcium in response to Aβ1-40 and Aβ1-42, respectively. Aβ1-40 increased intracellular calcium. In contrast, Aβ1-42 responded biphasically to intracellular calcium, initially decreasing slightly before increasing it. Previously, studies of taste responses to T1R GPCRs using changes in intracellular calcium as an indicator typically involved overexpressing the T1R GPCR gene and calcium-responsive G16 or gustducin / G16. However, the findings of this study demonstrate that measurement and screening using intracellular calcium responses as an indicator is possible using only endogenously expressed T1R GPCRs and the G proteins coupled to the receptors in HEK cells. (A) shows the effect of Aβ1-40 peptide as a ligand using HEK cells stably expressing Nav1.5. (B) shows the inhibitory effect of an anti-T1R3(303-396) antibody against Aβ1-40 peptide, which targets the T1R3 ligand binding site 2 (303-396aa) identified by patch clamp experiments. (C) shows the inhibitory effect of the antibody on Aβ1-40 peptide on the same scale to compare it with the effect of Aβ1-40 peptide alone. The vertical axis represents impedance (resistance, kilohms), and the horizontal axis represents time (seconds).Cav1.2 activity was measured by measuring changes in intracellular calcium concentration. (A) shows actual experimental results. The vertical axis, RLU (Relative Light Unit), is averaged with the strongest response set at 1. The horizontal axis represents time (in seconds). The cell membrane was depolarized with 77.5 mM KCl, activating Cav1.2 channels. The extracellular calcium concentration was then increased to 5 mM, increasing the calcium influx into the cells through Cav1.2 channels and making it easier to measure the increase in intracellular calcium. Cav1.2 channels were activated by increasing the extracellular KCl concentration, followed by the application of Aβ1-42. (B) A hyperbolic decay equation was fitted to the response unaffected by Aβ1-42, demonstrating the activation of Cav1.2 channels specifically induced by Aβ1-42. Whole-cell currents from Jurkat cells are shown in (A) and (B). (A) shows the control, and (B) shows the results after Aβ1-42 stimulation. The downward signals indicated by arrows in (A-1) and (B-1) are VGSC currents. The time axis is enlarged in (A-2) and (B-2) to easily observe the changes induced by Aβ1-42. The membrane potential change measured by voltage clamp is shown above the current response. The membrane potential was held at -120 mV and varied in 10 mV steps from -50 mV to +50 mV. (C) shows the VGSC inward (downward) current and the outward (upward) current measured during the last 10 ms of the voltage pulse. These data are summarized in an XY plot. The horizontal axis represents the stimulation voltage, and the vertical axis represents the current magnitude. Aβ25-35 concentration-dependently enhances Nav1.5 currents. EC by changing the solvent for Aβ25-35 from ddH2O to 10 mM NaOH to keep more Aβ25-35 in the monomeric state. 50The calculated value was approximately 10 times lower (7.9 nM). The upper panel shows a bright-field image, and the lower panel shows a fluorescent image of cell-bound Aβ1-40. In (A), the binding of fluorescently labeled Aβ1-40 peptide to the cell surface can be confirmed as a fluorescent image. In (B), when cells treated with fluorescent Aβ1-40 were treated with anti-T1R3 (303-396) antibody, the binding of fluorescent Aβ1-40 almost disappeared. To avoid the effects of fluorescent bleaching, we observed a region that had not previously been exposed to fluorescent light. (A) Nav1.6 VGSC currents were recorded using the patch clamp technique in voltage-clamp mode. ● indicates the control, △ indicates the VGSC current after treatment with Aβ1-42, and ■ indicates the VGSC current after treatment with T1R3 antibody. At each step, the VGSC current was amplified. (B) A similar experiment was performed with Thaumatin instead of antibody. Unlike the T1R3 antibody, no further amplification of VGSC current was observed after Aβ1-42 treatment. (C) On the other hand, thaumatin amplified VGSC current, similar to Aβ1-42. Even with increasing concentrations, no further amplification of VGSC current was observed. Voltage-clamp measurements of Nav1.5 VGSC current were performed, and an IV plot was created. (A) ● indicates the control before Aβ1-42 treatment, △ indicates the VGSC current enhanced by 12.5 nM Aβ1-42, and ■ indicates the VGSC current attenuated by anti-T1R3 (400-570) antibody (Epitope 400-570). (B) Suppression of T1R2 expression by expression of an miRNA vector abolished the effect of Aβ1-40 on VGSC current. ● indicates the state before Aβ1-42 treatment, and △ indicates the state after treatment. (53-1) To investigate the effect of aspartame, an artificial sweetener that acts as a T1R2 / T1R3 agonist, on cell morphology, undifferentiated SH-SY5Y cells were exposed to 120 μM aspartame and observed for changes in cell morphology. The results confirmed that T1R2 / T1R3 stimulation by artificial sweeteners affected cell morphology and caused contraction. (53-2) The effect of β-alanine on cell morphology was investigated using SH-SY5Y cells differentiated into neuronal-like cells. SH-SY5Y cells were differentiated in the presence of 1% FBS and retinoid acid.(A) shows SH-SY5Y cultured cells observed under an optical microscope. The morphological changes of lamellipodia in the area circled in white were observed over time. (B) shows the changes observed after β-alanine treatment at 5-minute intervals. The branching structure in the upper left circle transformed into a thin sheet-like structure over time. The neurite terminal structure in the right circle was initially fan-shaped, then contracted once, and then expanded again. The effect of Aβ1-40 on the cell morphology of HEK cells (A1) and HUEhT-1 cells (A2) was observed. The left column shows the control, and the right column shows the cell morphology after Aβ1-40 treatment compared to the control in the same field of view. In both (A1) and (A2), individual cells are clearly contracted. In (B1) and (B2), the same cells as in (A) were treated with a mixture of Aβ1-42 and Aβ1-40, the Aβ42 / 40 ratio observed in AD dementia (AD-D). As in (A), cell shrinkage was observed, but the effect was weaker than that observed in HUEhT-1 cells treated with Aβ1-40 alone. In this figure, Aβ42 / 40 was treated at a ratio measured as the Aβ42 / 40 ratio in healthy controls (Aβ ND), and changes in cell morphology were observed. The effect of this mixture was less pronounced in the cell body than in patients with cognitive symptoms, but ruffling at the cell periphery was observed. In this figure, the effects of AβAD and ND on cell morphology were observed using a mouse-derived brain microvascular endothelial cell line (βEnd.3). Unlike human cells, most cells showed no morphological changes, with the exception of a few subpopulations. Aβ1-40 is formed when the terminal Ile-Ala (Isoleucyl-alanine) is cleaved from Aβ1-42. Isoleucyl-alanine has a structural formula similar to β-alanine. (A) Diagram showing that Aβ1-42 is formed when Ile-Ala (Isoleucyl-alanine) is added to the end of Aβ1-40. (B) Structural analogs containing isoleucyl-alanine and β-alanine are shown. The structural formulas of alanine with an amino group on the α carbon, β-alanine with an amino group on the β carbon, GABA with an amino group on the γ carbon, and carnosine, which is composed of histidine and β-alanine, are shown.We used whole-cell patch clamp recordings of VGSC currents from human-derived cells (HEK, SH-SY5Y) expressing human Nav1.5 or mouse / rat hybridoma cells NG108-15 differentiated into neuronal cells by treatment with forskolin and low FBS. We also investigated the effects of Aβ peptides (Aβ40 and Aβ42 mixtures) on the VGSC currents. Two mixtures were used: one with the Aβ42 / 40 ratio observed in the CSF of healthy individuals (NDC) and the other with the Aβ42 / 40 ratio observed in the CSF of AD patients exhibiting cognitive impairment (AD-D). (A-1) Treatment with Aβ42 / 40 at the AD-D ratio enhanced VGSC currents compared to baseline (n=6). This enhancement was greater than that observed when other Aβ peptides were treated alone. This result is qualitatively similar to the experiment shown in Figure 31, in which Aβ25-35 was administered after treatment with the actin-depolymerizing agent latrunculin A. In the figure, ● indicates the control, and ▲ indicates the treatment after the Aβ peptide mixture. VGSC currents were recorded using the voltage-clamp technique. The membrane potential was fixed at -120 mV, and 80-ms stimulation pulses were applied. Pulses were increased in 10 mV increments from -80 mV to 50 mV. The maximum VGSC currents from control recordings were averaged, and the effects of Aβ peptides were compared across multiple cells. In the IV plots, the mean values are indicated by symbols, and the error bars represent standard error. (A-2) Cell morphology was observed, suggesting that β-alanine activated lamellipodia, causing ruffling, potentially enhancing cell motility and synaptic plasticity. The VGSC currents enhanced by the Aβ42 / 40 AD-D ratio were reduced by the application of β-alanine, restoring them to nearly control levels (n=2). Here, the bar graphs are set to 1, and the average increase and recovery are shown, with the horizontal lines representing actual experimental measurements. (B) A peptide mixture with an Aβ41 / 40 ratio similar to that observed in healthy subjects was applied. Unlike AD-D, almost no change in VGSC current was observed (n=5).(C) When Aβ42 / 40 from AD-D, which significantly enhanced VGSC currents in human cells (human T1R2 / T1R3), was applied to VGSC currents expressed in mouse / rat hybridoma cells NG108-15, unlike human cells expressing human T1R2 / T1R3, VGSC currents were not increased but rather decreased in mouse / rat T1R2 / T1R3 (n=3). The position of the peptide used to generate the anti-T1R3 antibody is shown on the crystal structure by Nuemket et al. (2017). (A) shows the crystal structure of the T1R2 / T1R3 heterodimer (PDB, 5X2M, Crystal structure of the medaka fish taste receptor T1r2a-T1r3 ligand binding domains in complex with L-glutamine). (B) shows the crystal structure of T1R3 alone, with the positions of the peptide sequences used as antigens indicated by white bars. It can be seen that 229-258 corresponds to LB2, 303-396 to LB1, and 400-570 corresponds to the amino acid sequence between LB1 and LB2, including the CRD.
[0071] 1. Definition of Terms (1) In the present invention, it was discovered for the first time that sweet taste G protein-coupled receptors (GPCRs) (T1R2 / T1R3) control VGSC. In addition, since T1R2 / T1R3 are expressed in many tissues including nervous tissue, it is believed that they play a role in controlling VGSC in all excitable cells such as nerves and muscles. In the present invention, the term "sodium channel" or "Na + When we refer to "channels," we mean "voltage-gated sodium channels (VGSCs)."
[0072] G proteins are known to regulate voltage-gated sodium channels (VGSCs). Their actions affect the threshold for action potentials, affecting the likelihood of action potential initiation. Additionally, they also affect the likelihood and duration of recurrent action potentials, particularly in neurons. This is recognized as a key regulator of how multiple synaptic inputs are integrated, resulting in action potential generation and the degree of dendritic membrane depolarization, which affects the degree of neurotransmitter release (Gonzalez-Burgos and Barrionuevo, (2001); Schwindt and Crill, (1995); Williams, (1999)).
[0073] Many GPCRs have been reported to phosphorylate VGSCs and modify their activity through the action of serine / threonine kinases (PKA, PKC). PKA activation has been widely reported to inhibit VGSCs, including muscarinic acetylcholine receptors in hippocampal pyramidal neurons (Cantrell et al., 1996), 5-HT2a / c receptors in cortical pyramidal neurons (Carr et al., 2002), and D1-class dopamine receptors in hippocampal pyramidal neurons and striatal medium spiny neurons (Cantrell et al., 1997; Surmeier et al., 1992). PKC activation has also been reported to inhibit VGSCs through D2 dopamine receptor activation in striatal medium spiny neurons and cholinergic interneurons (Carr et al., 2003).
[0074] (2) Substances acting on T1Rs (T1R1, T1R2, and T1R3) and their control of VGSC currents. The effects of compounds acting on T1R3 (T1R3 / T1R3) are summarized in Table 3, compounds acting on T1R2 (T1R2 / T1R2 or T1R2 / T1R3) in Table 4, and compounds acting on T1R1 (T1R1 / T1R1 or T1R1 / T1R3) in Table 5. The sweet-tasting amino acids in Table 3, such as glutamine and serine, are also present in CSF and, like Aβ25-35, have the effect of enhancing VGSCs, causing neuronal hyperexcitation and are highly likely to be amino acids that cause epileptiform neurological disorders and / or neuropathic pain. Furthermore, since glutamic acid (MSG) and inosinic acid (IMP), which act as umami substances on T1R1 (Table 5) and delay the inactivation of VGSCs, are both compounds present in CSF (Barnett, et al., (2020)), they may be one of the causes of epilepsy-like neurological disorders and / or neuropathic pain by enhancing VGSCs via T1R1, either alone or in concert. (Hereinafter, amino acids that serve as umami seasonings, such as glutamic acid (MSG), and nucleic acids such as inosinic acid (IMP), may also be referred to as "umami substances.")
[0075]
[0076]
[0077]
[0078] 2. Diseases Treated by the Present Invention / Control of VGSC Currents via T1Rs (1) Central Nervous System Neurological Disorders (1-1) Pain and Epileptiform Hyperactivity Caused by Excessive VGSC Activity One of the primary target diseases of the present invention is a disease in which pain and epileptiform hyperactivity caused by excessive VGSC activity are thought to be the root cause of clinical symptoms, ultimately resulting in neuronal death. Activation of sodium channels transiently allows large amounts of sodium cations to enter cells, playing an important role in the generation of action potentials. The inactivation of sodium channels within a few milliseconds after activation, followed by activation of potassium channels, relieves the accumulation of cations in cells caused by sodium (cation) influx and restores the intracellular potential to the resting membrane potential. This interplay between sodium and potassium channels is important for the rapid completion of spike-like action potentials, which is essential for the efficient and safe transmission of electrical signals from the periphery to the central nervous system or from the central nervous system to the periphery. Delayed inactivation of the sodium channel VGSC delays the recovery of the membrane potential from a depolarized state due to an action potential, causing hyperactivity of the nerve, which can lead to arrhythmias or epileptic convulsions in the nerves, and ultimately to neuronal cell death.
[0079] (1-2) Consideration of the mechanism of action of Aβ peptide (Aβ25-35) involved in the development of Alzheimer's disease (AD) and therapeutic drugs for AD disease. While it is not intended to limit the mechanism of neuronal hyperactivity (epileptic seizures) observed in Alzheimer's disease to this mechanism alone, the following considerations, including the results of the examples of the present invention, can explain the mechanism. Specifically, amyloid β peptide (Aβ25-35) binds to T1R3 and recruits VGSCs derived from intracellular endosomes to the cell membrane, thereby enhancing neuronal activity. This is thought to be the mechanism behind the epileptiform neuronal hyperactivity reported in Alzheimer's disease. Because the above-mentioned VGSC enhancement does not occur in cells in which T1R3 is silenced, these cells are targets for drug discovery to treat neuronal hyperactivity using drugs that inhibit the binding of amyloid β peptide (Aβ25-35) to T1R3 or antibodies against T1R3. In overactive neurons, VGSC activity can be suppressed via T1R2 / T1R3 by using substances (drugs) that depolymerize the cytoskeleton (microfilaments), such as dicloprop or artificial sweeteners (aspartame). These "Group 3" T1R2 / T1R3 antagonists (or T1R2 agonists), such as dicloprop and artificial sweeteners (aspartame), inhibit the binding of amyloid beta peptide (Aβ25-35) to T1R3, strongly suggesting their potential as therapeutic agents for diseases such as Alzheimer's disease (AD), which are believed to be caused by amyloid beta peptide (Aβ25-35). Furthermore, when anti-T1R3 antibodies are used in competition with fluorescent Aβ25-35 peptide to observe binding to T1R3 on the cell surface, binding of Aβ25-35 peptide to T1R3 is completely blocked. Therefore, anti-T1R3 antibodies may be the most effective therapeutic agents for AD. Furthermore, as a symptomatic treatment to suppress VGSC overactivity, suppression of VGSCs by aspartame, gymnema tea extract (gymnetic acid), calcium-sensing receptor (CaSR) agonists (such as cinacalcet), and CaSR antagonists (such as NPS-2143) is effective.
[0080] (1-3) Neurological diseases in which epileptiform neuronal hyperactivity similar to AD is observed. There are also many neurological diseases in which epileptiform neuronal hyperactivity similar to Alzheimer's disease is often observed, and it is assumed that all of these diseases develop through the same mechanism as Alzheimer's disease. Examples of diseases that may develop through such a mechanism include: ・Alzheimer's disease: Memory impairment ・Dementia with Lewy bodies: Dementia, hallucinations ・Cerebrovascular disease: Localized cranial neurological symptoms appear in the area damaged by cerebral infarction (hemorrhage) ・Epilepsy: Partial seizures, complex seizures. However, symptoms vary depending on the type of seizure. ・Parkinson's disease: Brachykinesia is a necessary condition. In addition, muscle rigidity or resting tremor is present. Other symptoms include postural reflex disorders, and non-motor symptoms include constipation, REM sleep disorders, and decreased sense of smell. Progressive supranuclear palsy Parkinsonism (bradykinesia, muscle rigidity, gait disturbance), swallowing disturbance, unsteadiness when walking, oculomotor disorders (up and down eye movement disorders). Multiple system atrophy Parkinsonism (bradykinesia, muscle rigidity, gait disturbance), swallowing disturbance, unsteadiness when walking (cerebellar symptoms), falls, orthostatic hypotension, bladder and rectum disorders (autonomic nervous system disorder). Amyotrophic lateral sclerosis (ALS) Progressive muscle weakness in the limbs, atrophy, swallowing disturbance, tongue atrophy. Traumatic brain injury Symptoms also vary depending on the area affected by the trauma. Localized cranial nerve symptoms appear in the area damaged by trauma. Huntington's disease: Involuntary movements, primarily chorea, and psychiatric symptoms, as well as dementia. Spinocerebellar degeneration: Unsteadiness, difficulty walking, difficulty using the hands, and reduced smoothness of movement. Multiple sclerosis: Characterized by demyelination, with repeated relapses and remissions of neurological symptoms such as motor paralysis, visual impairment, and sensory impairment.
[0081] (1-4) Pathological Conditions Induced by Delayed VGSC Inactivation Delayed VGSC inactivation by MSG induces the pathological conditions shown above (Table 4). While MSG-induced neuronal hyperactivity was previously thought to be solely attributable to glutamate receptors, the delayed inactivation of VGSC currents via T1R1 and T1R1 / T1R3 induces neuronal hyperexcitability. Therefore, T1R1 and T1R1 / T1R3 inhibitors (which prevent MSG from binding to the T1R1 receptor) are highly effective drug discovery targets for the treatment of the above-mentioned diseases. It is easy to imagine that the simultaneous enhancement of VGSC currents via T1R2 / T1R3 by sweet amino acids such as glutamine and serine, and amyloid beta peptide (Aβ25-35), and the delayed inactivation of VGSCs by MSG, would lead to neuronal hyperexcitability and neuronal cell death. This phenomenon is thought to occur particularly when nerves, astrocytes, etc. undergo necrotic cell death due to mechanical stress, such as in stroke or spinal cord injury, and when intracellular amino acids are released in large quantities outside the cell.
[0082] (1-5) Physiological Roles of Aβ25-35 and Aβ1-42 Aβ peptides are also found in CSF (Lehmann et al. (2020)) and are known to be released from synapses (Groemer et al. (2011)). We consider the physiological role of Aβ peptides in long-term potentiation (LTP) in synaptic cells. Tetanic stimulation, which induces synaptic plasticity in neurons, induces long-term potentiation (LTP). During this process, Aβ peptides are thought to be released from presynaptic terminals simultaneously with the release of the neurotransmitter glutamate into the synaptic cleft. The conventional theory is that massive release of glutamate activates NMDA-type glutamate receptors, and calcium influx from postsynaptic terminals inserts AMPA-type glutamate receptors present in intracellular endosomes onto the cell surface (synaptic cleft), increasing the number of glutamate receptors and resulting in a sustained increase in synaptic signal transmission efficiency. In the present invention, we discovered that VGSCs are inserted into the cell membrane via T1R3 receptors by Aβ25-35, similar to the mechanism by which AMPA-type glutamate is inserted from intracellular endosomes into the cell membrane (postsynaptic membrane) in LTP (Park et al. (2004)). In addition, we found that glutamate itself, via the T1R1 receptor, delays VGSC inactivation, increases sustained VGSC inward currents, and facilitates the generation of burst-like activity in cells. Furthermore, we found that glutamate inhibits voltage-dependent potassium channel currents such as Kv1.2 through the T1R1 receptor. This means that glutamate increases sustained VGSC inward currents and simultaneously decreases outward potassium channel currents via T1R1, creating a state in which cells are prone to hyperexcitability.They also found that Aβ1-42 exerts the same effect on VGSC and VGKC as glutamate via the T1R1 / T1R3 receptor at nanomolar concentrations. This discovery indicates that Aβ peptides are not only responsible for cell death and disease symptoms in Alzheimer's disease, but also in diseases such as amyloidosis, in which Aβ peptides are involved, and also play an important role in physiological functions such as neuroplasticity. The search for amplifying allosteric control of T1R1 (positive allosteric modulators; PAMs) is considered to be an important drug discovery target for improving symptoms such as memory decline.
[0083] (2) Neuropathic Pain (2-1) Mechanism of Action of Neuropathic Pain and Scope of the Therapeutic Agents of the Present Invention Inferred from the Mechanism of Action The present invention also targets the effective treatment of neuropathic pain associated with nerve overactivity due to the amplification of VGSC currents. A typical mechanism of action of such neuropathic pain is shown in Figure 42. The neuropathic pain targeted by the present invention is typically neuropathic pain caused by the administration of anticancer drugs (e.g., taxol), but also chronic neuropathic pain syndromes caused by diseases such as failed-back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and diabetic polyneuropathy. Other neuropathies that are thought to be caused by similar mechanisms include the following: - Cancer neuropathy (paraneoplastic peripheral neuropathy): effects on nerves other than those caused by direct compression of cancer - Peripheral neuropathy (neuropathy) caused by anticancer drug treatment: numbness, pain, and numbness in the hands and feet caused by paclitaxel, etc. Furthermore, in neurological diseases in which epileptiform neural hyperactivity is observed, such as AD, as exemplified in (1) above, VGSC action potentials in all nerve cells, including not only the central nervous system (CNS) but also the peripheral nervous system (PNS), rapidly increase and remain excited, simultaneously causing neuropathic pain. In other words, it is also effective as a preventive and therapeutic agent for neuropathic pain caused by the diseases exemplified in (1).
[0084] One possible mechanism underlying the development of "neuropathic pain" is the enhancement of VGSC currents on the cell membrane and the resulting pain due to nerve overactivity. Potential causative substances include chemotherapeutic agents used in chemotherapy, as well as amyloid beta peptides, sweet amino acids such as glutamine (L-Gln), and umami substances such as glutamic acid and inosinic acid. One possible mechanism of action for the development of such neuropathic pain is illustrated in Figure 42. While not intended to be limiting, this mechanism of action can be used to explain the results of the examples of the present invention. Specifically, chemotherapy drugs such as paclitaxel increase VGSC currents by polymerizing microtubules, leading to nerve overactivity. In addition to paclitaxel, which stabilizes microtubules, colchicine, which inhibits microtubule polymerization, was also observed to increase VGSC currents. In this state, the VGSC current per neuron increases, the action potential threshold decreases, and action potentials become more likely to occur. Furthermore, a stimulus that would normally elicit a single action potential generates multiple, sustained burst-like action potentials. As shown in Figure 42, the mechanism by which amyloid beta peptide (Aβ25-35) and sweet amino acids such as glutamine (L-Gln) enhance VGSC currents in the CSF and induce neuronal hyperactivity is thought to share a commonality with the mechanism underlying chemotherapy-induced neuropathic pain.
[0085] (3) Other Diseases Involving Amyloid β Peptide (3-1) Cardiac Disease Involving Abnormal VGSC (or VGKC) Currents via T1Rs Caused by Amyloid β Peptide Heart failure, like Alzheimer's disease, is a serious modern disease that not only affects quality of life but also threatens life. Troncone et al. (2016) reported that cardiac function was examined using echocardiography and found that patients with Alzheimer's disease exhibited memory impairment as well as cardiac diastolic dysfunction. The expression levels of Aβ1-40 and Aβ1-42 in the myocardium were elevated in patients with Alzheimer's disease compared with healthy controls. Because Type I taste receptors (T1R1, T1R2, and especially T1R3) are receptors for amyloid β peptide, they are thought to play an important role in the pathogenesis of the various neuronal diseases mentioned above. In neurons, amyloid beta peptides induce overactivity by inserting ion channels such as VGSC and VGKC from intracellular pools onto the cell membrane, leading to epileptiform hyperactivity and ultimately to neuronal cell death (Alzheimer's disease, ALS). The amyloid beta 25-35 peptide acts on T1R3, increasing ion channels such as VGSC on the cell membrane and causing overactivity. The amyloid beta 1-42 peptide acts on T1R1 and T1R1 / T1R3 umami taste receptors, delaying VGSC inactivation and inducing sustained VGSC components, contributing to the generation of action potentials such as bursts. However, elevated amyloid beta 1-42 peptides, like MSG (glutamic acid), are thought to decrease VGSC and inactivate neuronal activity. This same phenomenon is thought to apply to cardiomyocytes, which express a large amount of T1R3. (2011) reported that the Cav1.2 current, which corresponds to the VGCC (voltage-gated calcium channel) expressed in cardiac muscle, similar to the VGSC of the present invention, is amplified by the action of amyloid β25-35 peptide. This phenomenon can also be explained by considering that the T1R3 identified in the present invention functions as a receptor for amyloid β25-35 peptide.
[0086] Troncone et al. (2016) reported that amyloid beta (1-40) peptide is present in the myocardium of patients with Alzheimer's disease and diastolic dysfunction. Shibata et al. (2006) reported that NaV1.5, CaV1.2a, and KV1.5 colocalize in caveolae within the recycling endosome (cardiomyocyte cellular reservoir) of cardiomyocytes. Palygin et al. (2008) reported that the α subunit of G protein (Gs alpha) translocates to the plasma membrane upon binding to caveolin 3, a membrane protein localized in the recycling endosome. These findings suggest that amyloid beta (1-40) peptide may induce myocardial hyperactivity and lead to tachyarrhythmias. The action of Aβ1-40 peptide or its deposition has been observed in many diseases, suggesting a correlation with these diseases. Therefore, further research into how Aβ1-40 peptide acts as a ligand for T1R GPCRs and regulates the polymerization state of the cytoskeleton, and how this is involved in the pathogenesis of these diseases downstream, is likely to lead to the establishment of treatments for many diseases and even to valuable discoveries as targets for drug discovery.
[0087] (3-2) Other Cardiac Diseases Possibly Involved in Amyloid β Peptide Troncone et al. (2016) reported that the simultaneous observation of amyloid β peptide deposition in the myocardium and cardiac dysfunction in patients with Alzheimer's disease suggests that Alzheimer's disease may be a systemic or metastatic disease causing multiple organ failure, including cardiac disease. Furthermore, numerous studies have examined the correlation between amyloid β peptide and cardiac disease. Because the amyloid β peptide (Aβ1-42) localized in cranial nerves and the platelet-derived amyloid β peptide (Aβ1-40) localized in non-neuronal tissues such as the heart are different in size, it has been suggested that the development of cardiac disease due to amyloid β peptide may not be limited to patients with Alzheimer's disease (Troncone et al., 2016). If this is the case, the myocardial deposition of amyloid β peptide and cardiac dysfunction may be due to platelet-derived Aβ1-40, rather than the Aβ1-42 found in cranial nerves. In fact, the effect of Aβ1-40 on VGSC differs from that of Aβ1-42; in Nav1.5 expressed in cardiac muscle, it suppresses VGSC by shifting the S-S curve toward hyperpolarization. This effect differs from the experimental results of Aβ1-42 acting on the T1R1 / T1R3 umami receptor, and is similar to the effect of the artificial sweetener dichloroprop, which acts on the T1R2 / T1R3 sweet receptor. Because cardiac contraction is functionally a syncytium, if the generation of action potentials in some cardiac myocytes is suppressed by Aβ1-40, it is thought that the periodic transmission of action potentials is prevented, thereby inducing arrhythmias, etc.
[0088] Inyushin et al. (2020) pointed out that platelet-derived amyloid beta peptides are involved in Aβ deposition in the brain, cancer, glaucoma, and skin, as well as in preeclampsia, Alzheimer's disease, and late-stage Parkinson's disease. In particular, in glaucoma, amyloid beta peptides have been shown to deposit in the retinal ganglion cell layer, which is undergoing cell death, and to cause changes in the surrounding microvasculature. The therapeutic effect of anti-amyloid beta antibodies has been confirmed in glaucoma. Given that T1R and T3R are common GPCP-type receptors expressed in all tissues (The Human Protein Atlas (https: / / ww.proteinatlas.org / )), it is possible that amyloid beta peptide deposition on T1R or T3R may be involved in retinal ganglion cell cell death. According to Stamatelopoulos et al. (2017), amyloid beta 1-40 (Aβ40) accumulates primarily in cerebrovascular (but not neuronal) tissues, inducing cerebral amyloid angiopathy. Aβ40 also exists in the myocardial tissue of patients with Alzheimer's disease and heart failure, where it promotes atherosclerosis through plaque formation and has deleterious effects on the cardiovascular system. The amount of circulating Aβ1-40 in the blood is related to the presence and severity of atherosclerosis and to cardiovascular mortality in patients with coronary artery disease. Plasma-derived circulating Aβ1-40 levels are elevated in patients with heart failure compared with control participants and are positively correlated with renal dysfunction, diabetes, and coronary artery disease, which are risk factors for heart failure, suggesting that Aβ1-40 is an important predictor of heart failure mortality. Similarly, Bayes-Genis et al. (2017) reported that circulating Aβ1-40 levels are elevated in all outpatients with heart failure and are a predictor of the cause of heart failure. A noteworthy point in this paper is that, unlike Aβ1-42, blood Aβ1-40 levels are reported to be unrelated to cognitive decline. These findings suggest that Aβ1-40 may also bind to T1Rs in the cardiovascular system, potentially triggering heart failure.
[0089] A history of atherosclerosis, as well as hypertension, has been reported to promote electrophysiological remodeling and arrhythmia development after acute myocardial infarction (Guvenc et al. (2010) , De Jesus et al. (2015)). Therefore, it is highly likely that type I taste receptors (T1Rs), which are thought to be receptors for Aβ peptides, are involved in promoting arrhythmia development by affecting the polymerization state of myocardial cytoskeletal fibers and affecting ion channel function. Taxol, used in the present invention to enhance VGSCs, has been reported to not only stabilize microtubules but also increase the proportion of detyrosylated microtubules along with cytoskeletal density, resulting in increased cytoskeletal rigidity (Kerr et al., 2015). Clinical studies have also demonstrated the relationship between myocardial function and the cytoskeleton. Increased cytoskeletal stiffness due to microtubule detyrosination also occurs in myocardium. It has been reported that detyrosination of many microtubules (polymerized tubulin) increases muscle mechanical resistance (stiffness) and reduces muscle contractility, including cardiac muscle (Chen et al., 2018). Furthermore, proteomic analysis by Chen et al. demonstrated that the thickened microtubule network characteristic of heart failure, observed in the left ventricle of patients with heart failure, is consistently highly detyrosinated, which correlates with increased cardiomyocyte stiffness and impaired contractility. Based on these findings, it is entirely possible that amyloid beta peptides may act on the cardiomyocyte cytoskeleton via type I taste receptors (T1Rs), triggering cardiac dysfunction.
[0090] (3-3) Other Diseases Possibly Associated with Aβ1-40 Peptide Given the positive correlation between blood Aβ1-40 concentrations and renal dysfunction and diabetes, it is possible that Type I taste receptors, like those in the heart, act as receptors for Aβ1-40 peptide and may be one of the factors causing cellular dysfunction in the kidneys and pancreas. For example, in kidney disorders such as nephrotic syndrome and renal failure, amyloid β25-35 and amyloid β1-42 depolymerize microtubules and microfilements in neurons (Pianu et al. (2014)). Similarly, it is possible that Aβ1-40 depolymerizes microtubules and microfilements in certain kidney cells. The kidneys are important organs that filter waste products from the blood and excrete them as urine. When kidney function declines, waste products accumulate in the blood, disrupting the function of various organs. Considering that podocytes, which play an important role in renal function, exhibit impaired cytoskeletal structure and impaired glomerular filtering function, leading to nephrotic syndrome, characterized by symptoms such as proteinuria, it is possible that chronic stimulation of Type I taste receptors on podocytes by amyloid β1-40 peptides could result in depolymerization of the podocyte cytoskeleton (particularly microfilaments), leading to a decline in renal function (Schell et al. (2014)), potentially causing renal dysfunction. This suggests that cytoskeletal polymerization / depolymerization may affect cell morphology.
[0091] In diseases that may be caused by Aβ1-40, Type I taste receptors act as amyloid β peptide receptors, causing functional disorders in various organs and the onset of various diseases due to effects on the function of ion channels (particularly VGSC and VGKC) or on cytoskeletal structures (promoting or inhibiting polymerization and depolymerization). In particular, when structural effects on microtubules and microfilaments are thought to be the cause of the disease, methods for measuring the polymerization state of microtubules and microfilaments using markers such as GFP are effective testing methods for diagnosis and drug discovery screening.
[0092] (4) Administration Method and Dosage of the Therapeutic Pharmaceutical Composition of the Present Invention Pharmaceutical compositions containing, as active ingredients, substances acting on type I taste receptors (T1Rs), particularly substances stimulating T1R2 / T1R3, provided by the present invention, can suppress the excessive activity of VGSCs, which cause epileptiform hyperactivity in CSF and inflammatory pain in neurons, as well as Alzheimer's disease (AD). These compositions can be used as pharmaceutical compositions for the prevention or treatment of Alzheimer's disease (AD). These compositions may be used in combination with existing therapeutic agents for Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and other conditions. Furthermore, the T1R2 / T1R3-stimulating substances of the present invention can be used as active ingredients in pharmaceutical compositions for the prevention or treatment of neuropathic pain. These compositions can also be used in combination with existing analgesics, such as opioid preparations, or vasoconstrictors, such as epinephrine, which are used to localize the drug and reduce side effects on other organs. The pharmaceutical composition of the present invention may be administered orally, nasally, rectally, or parenterally. For oral administration, the dosage form may be powder, granules, capsules, pills, tablets, elixirs, suspensions, emulsions, and syrups, and may be appropriately selected from these. These preparations may be modified to provide sustained release, stability, easy disintegration, difficult disintegration, enteric coating, or easy absorption. For intravenous, intramuscular, or subcutaneous administration, the dosage form may be injections or infusions (including dry products prepared immediately before use), and may be appropriately selected. Pharmaceutically acceptable carriers and additives may be incorporated into the pharmaceutical composition of the present invention depending on the dosage form (oral administration or various parenteral administration dosage forms). Pharmaceutically acceptable carriers and additives include solvents, excipients, coating agents, bases, binders, lubricants, disintegrants, solubilizing agents, suspending agents, thickening agents, emulsifying agents, stabilizers, buffers, isotonicity agents, soothing agents, preservatives, flavoring agents, fragrances, and coloring agents.
[0093] When the pharmaceutical composition of the present invention is used as a preventive or therapeutic agent for diseases caused by VGSC activation due to the binding of Aβ peptides (such as Aβ25-35 peptide) or sweet amino acids and umami substances in CSF to T1Rs (e.g., a preventive or therapeutic agent for Alzheimer's disease, epilepsy, ALS, and neuropathic pain), the oral dose, calculated as the amount of the compound of the present invention, is preferably in the range of 0.03 to 300 mg / kg body weight, more preferably 0.1 to 50 mg / kg body weight. When administered intravenously, the dose may be such that the effective blood concentration of the compound of the present invention is in the range of 0.2 to 50 μg / mL, more preferably 0.5 to 20 μg / mL. The same applies when used as a pharmaceutical composition for the prevention or treatment of neuropathic pain. Note that these doses may vary depending on the age, sex, body weight, the nature and severity of the condition, and the route of administration.
[0094] Among the compounds belonging to "Group 3" that can typically stimulate T1R2 / T1R3 and inhibit VGSC activity, the artificial sweeteners aspartame, dicloprop, and cinacalcet are exemplified below in detail with respect to dosage, usage, etc.; however, the compounds that serve as active ingredients in the pharmaceutical composition of the present invention are not limited to these compounds and their specific numerical ranges.
[0095] For example, in the case of the artificial sweetener aspartame, IC 50 Aspartame inhibits VGSCs at a concentration of 15-17 μM. Because aspartame is completely digested in the small intestine, parenteral administration, such as intravenous injection, is preferred rather than oral administration. The purpose of administration is not to completely suppress VGSCs, but to reduce their firing frequency and prevent bursts. Therefore, a concentration of 4.5-10 mg / kg is preferred for intravenous administration. Since Nav1.5, expressed in the myocardium, requires a concentration more than twice that of Nav1.5 at -100 mV, near the resting membrane potential of the myocardium, the effect of aspartame on myocardial activity is thought to be low. Because the effects of aspartame tend to be weakened in the presence of Aβ peptides, it is thought to be more effective as a pharmaceutical composition for preventing and treating pain caused by inflammation, injury, etc., than as a pharmaceutical composition for treating AD.
[0096] Dichlorprop acts on VGSCs (Nav1.7, Nav1.6) expressed in nerve cells (SH-SY5Y) at lower concentrations than aspartame, and increases the membrane potential before the appearance of an action potential to the same extent. In particular, in nerve activity that shows burst-like activity (pain, epileptiform seizures, AD, etc.), the membrane potential shifts in the depolarization direction, so it is effective at lower concentrations (IC 50 It is effective at concentrations between 9 μM and 17.3 μM. It is believed that oral administration at a dose of 2-10 mg / kg is as effective as parenteral administration. Although administration at even higher concentrations is considered possible as needed, the upper limit of the dose concentration is that it does not suppress Nav1.5, a myocardial VGSC, at the resting membrane potential of the myocardium.
[0097] In the case of cinacalcet, 5 μM completely inhibits VGSC activity, and significant side effects are expected when administered systemically. Therefore, its role as a pharmaceutical composition for local anesthetics is recommended. It is administered by local injection as a local anesthetic. The preferred administration concentration is 1-2 mg / kg (containing 1:100,000 epinephrine). When the area requiring pain relief is inflamed or acidic (such as terminal cancer pain or acute periodontitis (dental treatment)), conventional local anesthetics (e.g., lidocaine) are pH-dependent and therefore ineffective. In such cases, adding epinephrine, like conventional local anesthetics, suppresses systemic side effects by constricting local blood vessels, thereby functioning as an effective analgesic when administered safely.
[0098] 3. Screening Method (1) Type I Taste Receptors (T1Rs) as Drug Discovery Targets for Diseases Associated with Increased Aβ Peptides and Sweet Amino Acids (e.g., Serine, Glutamine) and Umami Substances (e.g., Glutamate, Inosinate) in CSF. In the present invention, we have confirmed that, among Aβ peptides, Aβ25-35 peptide enhances VGSC via T1R3, and nanomolar concentrations of Aβ1-42 peptide delay the inactivation of VGSC via T1R1 in addition to T1R3, inhibit voltage-dependent potassium channels (e.g., Kv1.2), and enhance neuronal (cardiac) hyperactivity. On the other hand, glutamate, which is known to act as an "excitatory neurotransmitter" as a glutamate receptor agonist, delays the inactivation of VGSC via T1R1, inhibits voltage-dependent potassium channels (e.g., Kv1.2), and enhances neuronal (cardiac) hyperactivity (data not shown). As described below, given that enhanced VGSCs cause neuronal cell death and are a contributing factor to AD and other conditions, drug discovery targets include not only the Aβ25-35 peptide or Aβ1-42 peptide, which exhibit agonistic effects on T1R3 or T1R1, but also sweet amino acids such as glutamine and serine present in cerebrospinal fluid (CSF), as well as umami substances such as glutamic acid, aspartic acid, and inosinic acid, which are also present in CSF. In particular, substances that inhibit the binding of glutamine (L-Gln), a sweet amino acid whose level is elevated in CSF in Alzheimer's disease, epilepsy, and ALS, or substances that inhibit the function of such conjugates, are highly likely to be therapeutic agents for AD and neuropathic pain. Here, a substance that inhibits the function of a T1Rs binding compound refers to a substance that inhibits the binding of Aβ peptide to T1Rs itself, and a substance that does not inhibit the binding of a target substance to T1Rs itself, but inhibits signal transduction that occurs after the target substance binds to T1Rs. The present invention provides a method for efficiently screening such "T1Rs" inhibitors.
[0099] (2) In vitro screening method for substances that inhibit the binding of Aβ peptides or sweet amino acids or umami substances in CSF to T1Rs, or substances that inhibit the function of their bound products: A mechanism is assumed in which Aβ peptides or sweet amino acids or umami substances in CSF bind to T1Rs on the surface of target cells, thereby enhancing the VGCS or VGKS current of the target cells, resulting in cell death. This relates to a screening method that is effective for searching for substances that inhibit the binding of Aβ peptides or sweet amino acids or umami substances in CSF to T1Rs, or substances that inhibit the function of their bound products. The effect on the VGSC current that occurs as a result of the binding of Aβ peptides or sweet amino acids or umami substances in CSF to Type I taste receptors (T1Rs), including T1R3, is thought to occur via multiple steps. i) First, Aβ peptides or sweet amino acids or umami substances in CSF bind to Type I taste receptors (T1R1 / T1R3, T1R2 / T1R3 GPCRs), ii) G protein activation occurs as a result of Type I taste receptor activation by Aβ peptides or sweet amino acids or umami substances in CSF, iii) the resulting polymerization or depolymerization of microfilaments and microtubules, and iv) at the end of this cascade, there is a regulatory effect of enhancing or suppressing VGSC or VGKC currents. Furthermore, activation of adenylate cyclase and phospholipase C via G protein β and γ subunits caused by activation of T1Rs GPCRs activates IP3 channels and ryanodine receptor channels, releasing calcium from the ER and increasing intracellular calcium concentrations. Based on the above, the following multiple sites of action are thought to be drug discovery targets for suppressing or inhibiting the action of Aβ peptides or sweet amino acids or umami substances in CSF on cellular VGSC or VGKC currents, or for increasing or changing the dynamics of intracellular calcium that occurs as a result of calcium efflux from intracellular calcium stores such as the ER, rather than calcium that flows in from outside the cell through calcium channels.(1) A method to prevent the binding of Aβ peptides or sweet amino acids or umami substances in CSF to Type I taste receptors such as T1R3: For example, this would involve searching for anti-T1R3 antibodies or compounds with equivalent effects. (2) Search for compounds that suppress the activation of Type I taste receptors that occurs as a result of the binding of Aβ peptides or sweet amino acids or umami substances in CSF to Type I taste receptors: For example, in the case of T1R3, search for compounds such as lactisole and dichlorprop that specifically bind to T1R3 and prevent the conformational change in T1R3 that occurs upon the binding of Aβ peptides or sweet amino acids or umami substances in CSF, thereby preventing the activation of G proteins downstream of signal transduction from T1R3. (3) In the case of sweet taste receptors (T1R2 / T1R3), one possible approach would be to search for compounds that have an inhibitory effect on VGSC currents by activating T1R2 / T1R3, such as artificial sweeteners (saccharin, aspartame, gymnema tea extract, sucralose, etc.), which are T1R2 agonists that form heterodimers with T1R3, and that, through their ability to inhibit VGSC currents, suppress the amplification of VGSC currents induced by the binding of Aβ peptides (particularly Aβ25-35) or sweet amino acids in CSF (such as glutamine) to T1R3. The approaches (2) and (3) above can also be applied to the search for substances that use changes in intracellular calcium concentration as an output.
[0100] The method of measuring the effects of Aβ peptides or sweet amino acids or umami substances in CSF using the membrane voltage clamp method (patch clamp method) shown in (2-3) below is the most accurate and useful, but because voltage clamp measurement requires tedious, skilled manipulation under a high-magnification microscope, the fluorescent labeling observation methods described in (2-1) and (2-2) below are effective for simplicity and improved screening efficiency. For example, by applying the drug discovery screening method described in (1) above to (2-1), changes in the cytoskeleton caused by the binding of fluorescently labeled Aβ peptides or sweet amino acids or umami substances in CSF to T1R3 can be observed using a fluorescent microscope. Therefore, by confirming the presence or absence of such changes, substances that prevent the changes caused by the binding of Aβ peptides or sweet amino acids or umami substances in CSF can be searched for. Furthermore, when screening from the viewpoints of (2) and (3) above, the polymerization state of microfilaments and microtubules visualized by fluorescently labeled actin and tubulin using the method of (2-2) can be measured to observe the polymerization state of the cytoskeleton caused by the binding of Aβ peptides or sweet amino acids or umami substances in CSF to Type I taste receptors, including T1R3, and screening for substances that can inhibit changes in VGSC or VGKC currents caused by the binding of Aβ peptides to Type I taste receptors can also be performed by monitoring intracellular calcium concentrations.
[0101] (2-1) Method for observing fluorescent labels on the surface of target cells As a typical example, a method for screening for a substance that inhibits the binding of Aβ peptide (Aβ25-35) to T1R3 will be described below. Naturally, the combination of target Aβ peptide, T1Rs, and cells is not limited to the above combination. As described above, an anti-T1R3 antibody is incubated with a fluorescently labeled Aβ peptide (Aβ25-35) in cultured neurons (SH-SY5Y cells differentiated with RA) or Nav1.5 or other NaV receptors. +When added to HEK cells or other cells in which the channel is forcibly expressed, it can completely block the binding of fluorescent Aβ peptide to T1R3 on the cell surface. By observing the fluorescent label on the cell surface, the degree of competitive inhibition of binding with T1R3 can be visually evaluated. That is, following this method, cells expressing large amounts of T1R3, such as cultured neurons (e.g., SH-SY5Y cells differentiated with RA), are used, and a test substance is administered to the cell culture medium together with the fluorescent Aβ peptide. Whether or not binding of the fluorescent Aβ peptide to the cell surface is inhibited can be determined by observing the fluorescence on the cell surface. By applying this method, it is possible to screen for drugs effective as AD therapeutic agents from test substances. If an anti-T1R3 antibody is used as the test substance, it is possible to screen for neutralizing antibodies with higher efficacy among anti-T1R3 antibodies. Specifically, a fluorescently labeled Aβ peptide (Aβ25-35 or Aβ1-42) is administered to cultured neurons expressing a large amount of T1R3 (or T1R3) or to cultured human cells forcibly expressing a sodium channel such as Nav1.5, and fluorescence emission from the cell surface is confirmed by imaging. Next, it is confirmed whether or not the amount of fluorescence on the cell surface is reduced by administering the test substance, thereby enabling the presence or absence and strength of the T1R3 binding inhibitory activity of the test substance against the Aβ peptide to be determined.
[0102] (2-2) Other Methods for Observing Fluorescent Labeling: In the present invention, we have shown that T1R GPCRs expressed on the cell membrane alter the function of effectors such as VGSCs through changes in the polymerization state of cytoskeleton components such as actin and tubulin in response to agonists. This property can be utilized. By expressing fluorescently labeled actin or tubulin in cells that endogenously express T1R GPCRs, such as HEK cells, and observing changes to the cytoskeleton using a fluorescence microscope, it is possible to screen for inhibitors of the action of Aβ peptides, sweet amino acids in CSF, or umami substances. Similarly, drug discovery screening can be performed targeting T1R GPCRs with pharmacological effects such as analgesia and antiepileptic effects. Furthermore, this method is as effective as the impedance method (2-6) below, even when the final effector of Aβ peptides, sweet amino acids, or umami substances in CSF is not an ion channel. Control experiments to distinguish between direct effects on the cytoskeleton or effects via other GPCRs can be performed using a GFP-tagged T1R GPCR silencing vector and RFP-tagged actin or tubulin.
[0103] (2-3) Patch clamp technique: The patch clamp technique records intracellular potentials and can simultaneously record intracellular potentials and inject current to stimulate cells. Patch clamp recording modes include voltage-clamp and current-clamp. Voltage-clamp mode records ion channel currents such as VGSCs. Current-clamp mode records changes in intracellular potentials. This allows recording of action potentials, which are changes in cell membrane potential, and the amplitude, magnitude, and frequency of action potentials. Furthermore, in patch clamp experiments, control recordings and responses after the application of a reagent are made from the same cell, and the results after and before the application are compared to determine whether or not the reagent has had an effect. Single-cell electrophysiological observations (patch clamp) are unique compared to other experimental methods in that they allow recording of a control from the same cell and observing changes after the application of a reagent over time. Experimental results obtained using patch clamp allow direct measurement of changes in the reagent over time, making it the most accurate experimental method. The delayed inactivation of VGSCs mediated by T1R1 by monosodium glutamate (MSG) may be useful for antiarrhythmic drug screening. The increase in persistent sodium currents caused by delayed inactivation plays an important pathophysiological role in cardiac diseases, including rhythm disorders (Horvath et al., (2020)). As described in this study, Nav1.5, the main VGSC in cardiac muscle, generates persistent sodium currents by delaying its inactivation with MSG.
[0104] In conventional drug discovery screening, persistent sodium currents are pharmacologically induced using Nav1.5 mutants, veratridine, sea anemone toxin (ATX-II), etc., and their efficacy is then confirmed. However, in the present invention, we have found that umami stimulation delays the inactivation of Nav1.5. This makes it possible to conduct safety pharmacological testing of Nav1.5 without inactivation, using only umami stimulation, without the need for such special mutants or expensive drugs. Specifically, MSG is administered to the culture medium of cultured cardiomyocytes to delay the inactivation of VGSC currents via the umami receptor (T1R1), thereby generating persistent sodium currents (VGSCs) in the cultured cardiomyocytes. Drug discovery screening can then be performed using changes in VGSC currents as an indicator.
[0105] The effects of Aβ peptides or umami substances on the persistent potassium current (VGKC) in cardiomyocytes can be similarly investigated using SH-SY5Y cells expressing VGKC (e.g., Kv1.2, Kv3.2, Kv3.3) or human cultured cells expressing VGKC such as Kv1.2, using HEK cells endogenously expressing T1R GPCR as host cells. Indeed, as shown in the experimental example in Figure 36B, Aβ peptides were applied to VGKC-expressing human cultured cells, and VGKC currents were recorded using the voltage clamp method with ramp or square voltage waveforms, allowing the change (inhibition) of VGKC currents by Aβ peptides to be measured. The inhibitory effect on VGKC was also similarly measured using the umami substance monosodium glutamate (MSG) (Figure 36A).
[0106] The patch clamp method was used to demonstrate that the regulatory effect of the Aβ peptides (Aβ25-35, Aβ1-38, Aβ1-40, Aβ1-42) on VGSC currents is lost when T1R3 is silenced.
[0107] (2-4) Measuring Membrane Potential Changes in Target Cells Using the "NanoTouch Method" Another method for measuring membrane potential changes in target cells is the "NanoTouch method" (Saito, 2019) (International Publication No. WO2018 / 199334), which the inventors previously developed. The "NanoTouch" method involves penetrating conductive nanoparticles into the cell membrane and using them as intracellular electrodes. Using a method (nanoCharge) that combines this method with a capacitive potential measurement device, spontaneous firing of action potentials in cultured neurons or cardiac muscle is recorded. Specifically, the cells are cultured on conductive glass, and polyethyleneimine and conductive magnetic nanoparticles (gold magnetic nanoparticles) are mixed. The mixture is then applied to the cells, which have been washed with PBS (-), and left in a 37°C incubator for 15 minutes. Next, this mixture is replaced with physiological saline or culture medium. The conductive glass on which the cells are cultured is connected to the positive electrode, and a thin metal film (e.g., aluminum foil) is placed on the underside of the conductive glass on which cells are not cultured and connected to the negative electrode. This conductive glass is then placed on a 180-200 mT magnet. This magnetic force attracts the conductive magnetic nanoparticles already introduced into the cells toward the cell membrane in contact with the glass surface, penetrating the cell membrane and conducting the intracellular potential to the conductive glass, where it is measured. This device utilizes the principle of a capacitive potential measurement device, forming a capacitor between the conductors on the top and bottom of the conductive glass. This allows changes in the intracellular potential to be captured as a charge and detected by the conductor on the opposite side of the conductive glass. Since the charge (Q) has the relationship Q = CV, the potential (V) can be measured in proportion to the capacitance (C) of the electrode glass. By using this method, it is possible to record intracellular potentials without using techniques such as the patch clamp method, and to measure the activating effects of Aβ peptides or sweet amino acids or umami substances in CSF on nerves or myocardium, as well as the effects of inhibitors.
[0108] (2-5) A method for observing the frequency of action potentials in cultured neural cells using extracellular recording. Multielectrode arrays (MEAs, etc.) can observe the frequency of cellular action potentials, but they cannot observe the waveform of action potentials or slow changes in synaptic potentials, as with the nanoTouch method described above. When using an MEA, each target cell is seeded and cultured on an MEA probe embedded with a recording electrode, and extracellular recording is performed using the MEA device. The neuronal activity of Aβ peptides and the inhibitory effects can be observed using fluorescent membrane potential-sensitive reagents or fluorescent intracellular calcium-sensitive reagents, as in the above experiments. Cells that spontaneously fire the above-mentioned action potentials (note that "spontaneous firing" refers to the spontaneous generation of action potentials rather than in response to an external stimulus; typical "spontaneously firing cells" are neurons and cardiac muscle cells, with neurons in particular having a high spontaneous firing activity) are seeded and cultured, and in the case of a calcium-sensitive reagent, the reagent mixture is administered and then the cells are cultured in an incubator at 37°C for 60-90 minutes, and in the case of a fluorescent membrane potential reagent, measurements are taken using the same measuring equipment. The fluorescent wavelength will differ depending on the reagent used, so follow the specifications for that reagent.
[0109] (2-6) Method for screening compounds that modify / inhibit changes induced by Aβ peptides or sweet amino acids or umami substances in CSF: Cell impedance (resistance) measurement. The measured impedance of a cell sheet fluctuates, reflecting the state of ATP and actin polymerization. This change is linked to changes in cell morphology. Because the actin cytoskeleton is an important downstream effector of GPCRs, the activation state of GPCRs can be sensitively measured as an increase or decrease in impedance, reflecting the adhesion state of cells seeded on an electrode substrate and changes in cell morphology due to the expansion of the adhesion area. It has been reported that the GPCR pathway that activates the G protein Gαi increases impedance upon activation; the pathway that activates Gαq initially shows a transient decrease in impedance, followed by a large increase; and the pathway that activates Gαs results in a decrease in impedance (Scott and Matthew, 2010).
[0110] GPCR activity is measured as changes in cell morphology caused by cytoskeletal changes, as changes in the impedance of a cell sheet. This is typically done using measuring instruments such as the ×CELLigence System (ACEA Biosciences) or CellKey (Molecular Devices). Specifically, cells are cultured in a sheet form on an electrode plate, such as gold foil or conductive glass, and changes in the impedance of the cell sheet can be measured by applying an electrical current between the conductive glass covering the cell surface and the extracellular solution. By culturing cells in a sheet form, the electrode surface is completely covered by the cells and isolated from the extracellular solution. Therefore, by passing a current (I) between the extracellular solution and the electrode plate and measuring the resulting potential difference (V), the resistance (R) of the entire cell sheet can be calculated using Ohm's law (V = IR > R = V / I). Since impedance is the reciprocal of resistance, the measured impedance is 1 / R. Here, GPCR activity causes changes in the cytoskeleton, leading to changes in cell morphology and changes in gap junctions connecting cells. This weakens the adhesion between cells, allowing current to flow more easily, resulting in a decrease in resistance, i.e., an increase in impedance. First, Aβ peptides (or sweet amino acids or umami substances in CSF) are exposed to ligands for sweet and umami receptors (T1Rs), which are agonists of type I taste receptors, and the changes in impedance are measured as described above. Then, which G protein (Gαi, Gαq, or Gαs) is stimulated is identified. Various Aβ peptides (or sweet amino acids or umami substances in CSF) are exposed to T1Rs GPCR, and the resulting impedance changes are analyzed. This experimental system is used to screen for compounds that modify / inhibit the changes induced by Aβ peptides (or sweet amino acids or umami substances in CSF). That is, compounds that inhibit or modify the changes in the cytoskeleton caused by Aβ peptides (or sweet amino acids or umami substances in CSF) upon administration of the test substance are searched for.This invention demonstrates that T1R GPCRs expressed on the cell membrane, when given an agonist, alter the function of effectors such as VGSCs through changes in the polymerization state of cytoskeleton components such as actin and tubulin. In addition to the impedance assay, another effective method for primary screening is to monitor intracellular calcium concentrations using cells endogenously expressing T1R GPCRs, such as HEK cells. This discovery revealed that Aβ1-40 and Aβ1-42 exhibit distinct patterns of intracellular calcium changes. Furthermore, by accumulating response patterns induced by other lengths of Aβ peptides, umami, and sweet substances, we believe that linking the response patterns to the relevant T1R GPCR subunits and combining these results with the screening methods described below will enable accurate drug discovery. It is also effective to perform this method as an initial screening method, followed by the previously described screening methods (e.g., effects on the polymerization state of fluorescently labeled actin and tubulin, effects on cell excitability using the "nanoTouch" method, MEA, etc., and detailed analysis of effects using voltage clamp). It is known that the measurable impedance changes depending on the activity of GPCR expressed on the cell surface.
[0111] (3) In vivo screening method: (Method using experimental animals with humanized T1Rs genes) In vivo screening requires the use of experimental animals, such as mice, with humanized T1Rs genes. This is because compounds such as lactisole, which inhibit ligand-induced conformational changes in T1R3, respond differently in mice and rats than in humans. Lactisole suppresses umami and sweetness perception only in humans, but this effect is not confirmed in mice or rats (Jiang et al. (2005)). Furthermore, Toda et al. (2018) reported the allosteric regulation of T1R1 / T1R3 by methional, which acts as a positive allosteric modulator (PAM) in humans but as a negative allosteric modulator (NAM) in mice. Additionally, the sweet protein thaumatin is detectable in humans but not in mouse T1R3. Gymnemic acid is also effective on human T1R2 but not on mouse T1R2. In experiments using Nav1.6-expressing HEK cells using the patch clamp method, thaumatin was confirmed to enhance VGSC currents in the same way as Aβ peptides (data not shown). Based on these findings, in addition to in vivo drug discovery screening using mice, mouse experiments to analyze the function of taste receptors require the use of humanized mice, such as knockout (KO) of mouse-derived related genes or insertion of human T1Rs genes.
[0112] The present invention will now be described in more detail with reference to examples, but the present invention is not limited thereto. Other terms and concepts used in the present invention are based on the meanings of terms commonly used in the relevant field. The various techniques used to implement the present invention, except for those specifically cited, can be easily and reliably implemented by those skilled in the art based on known literature. Furthermore, various analyses were performed according to the methods described in the instruction manuals and catalogs of the analytical instruments, reagents, and kits used. The contents of the technical literature, patent publications, and patent application specifications cited herein are to be construed as the contents of the present invention. Furthermore, the term "cells" used in the present invention simply refers to human-derived cells, but it also includes cells derived from any animal that endogenously express a human Type I taste receptor, or cells in which a Type I taste receptor with a human-specific amino acid sequence is expressed by gene transfer or other methods. Typical animals that have cells that endogenously express human Type I taste receptors are apes such as chimpanzees, gorillas, orangutans, long-tailed macaques, baboons, and rhesus monkeys, but are not limited to these animals as long as the cells are derived from animals with similar properties.
[0113] Experimental Methods Used in This Example 1. Electrophysiological Experiments Electrophysiological experiments in this example were performed using the patch clamp method (voltage clamping, current clamp). Patch clamp experiments were performed using an Axopatch 200A (Axon Instruments Inc., Union City, CA) amplifier, and digitization was performed using a Data Digidata 1332a (Axon Instruments Inc.). Voltage control and data acquisition were performed using Clampex Software (pClamp 9.0, Axon Instruments Inc.). Data digitized by Clampex were analyzed using Clampfit 10.6.2.2 (Molecular Devices, San Jose, CA). Statistical processing was performed using Microsoft Excel. The Boltzmann equation and Hill plot analysis were performed using Curve Expert Professional 2.6.0 (Hyams Development). Specifically, a patch electrode containing intracellular solution connected to an Axopatch amplifier was attached to the cell to be recorded under a microscope. The cell membrane at the opening at the tip of the patch electrode was destroyed, and the intracellular potential was recorded through the patch electrode integrated with the cell interior. Stimulation was repeated at 8- to 10-second intervals until the recording state stabilized. At this point, IV and SS curves were measured and used as a control (baseline). At this point, the test substance was administered again while stimulating repeatedly at 8- to 10-second intervals. Once the effect of the test substance was stably observed, or after 5 minutes or more had elapsed, IV and SS curves were measured again and the results were compared with the control to determine whether or not the test substance had any effect. Note that if the opening at the cell membrane of the patch electrode narrowed during the experiment, resulting in a deterioration in measurement accuracy, the results were excluded from the analysis.
[0114] The solutions used for patch clamp experiments were prepared as follows: Extracellular solution: (in mM) 126 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 24 HEPES, 10 glucose (pH 7.4 adjusted with NaOH). Intracellular solution (electrode solution): (in mM) 130 KCl, 5 MgCl2, 5 EGTA, 4 Tris-ATP, 10 HEPES (pH 7.2 adjusted with KOH). Chemicals used were purchased from Nakalai tescue, Sigma-Aldrich, and Tokyo Chemical Industry Co., Ltd.
[0115] 2. Cell lines used in the present invention and their cell culture conditions: (1) Creation of a HEK cell line stably expressing Nav1.5. HEK293 cells (JCRB bank) were transfected with Nav1.5-pcDNA3.1 (hygromycin, Invitrogen, USA) using Superfect transfection reagent (Qiagen, DE) to create a hygromycin-resistant cell line. The HEK293 cell culture medium used was DMEM (Sigma-Aldrich, St. Louis, MO, USA), 10% FBS (BioWest, FR). Hereinafter, when referring to "HEK293 cells" in this specification, this refers to the "HEK293 cell line stably expressing Nav1.5."
[0116] (2) Cultivation of SH-SY5Y Cell Line and Differentiation into Neuron-like Cells The SH-SY5Y cell culture medium was prepared by mixing DMEM (Sigma-Aldrich) and F-12 (Sigma-Aldrich) in a 1:1 ratio, to which 5% FBS (BioWest), 5% 40 mM L-Glutamine (Fujifilm), and 1% MEM non-essential amino acids (Wako Pure Chemical Industries) were added. To differentiate SH-SY5Y cells into neurons, the FBS content of the above solution was adjusted to 1%, and retinoic acid (Fujifilm) was added at a concentration of 10 μM / ml. The cells were cultured for at least 5 days to differentiate. Hereinafter, the term "SH-SY5Y cells" refers to the "SH-SY5Y cell line differentiated into neuron-like cells."
[0117] 3. Electrophysiological measurement protocols: (1) Activation protocol of voltage-gated sodium channels (VGCS): The membrane potential was set at -80 mV, followed by a prepulse (-120 mV, 500 ms), followed by a final 200 ms depolarizing pulse from -80 mV to 40 mV at 10 mV intervals. Double pulse protocol: This was the same as the activation protocol above, except that after the first pulses, another pulse group was administered with a prepulse of -120 mV.
[0118] (2) Protocol for investigating steady-state inactivation of VGCS: The membrane potential was set to -80 mV, and a pulse of -20 mV (200 ms) was applied first. This was followed by a 10 mV increment change from 0 mV to -120 mV (1 sec) to create an inactivation state. Finally, a test pulse (-20 mV, 200 ms) was applied to examine how the magnitude of VGCS activated by the test pulse was affected by the membrane potential before the test pulse. For Nav1.5 expressed in HEK cells and Nav1.7 and Nav1.3 expressed in SH-SY5Y, different test pulses were used in some experiments. This will be specified in each case.
[0119] (3) Pulse and ramp protocol: A 20 ms, -20 mV depolarization step was performed after the pre-pulse (-120 mV, 320 ms), and the membrane potential was again increased to 2nd A prepulse was applied at -120 mV for 360 ms, followed by a 20 ms ramp from -120 mV to 60 mV, after which the membrane potential was held at 60 mV for 10 ms and then at -40 mV for 100 ms.
[0120] (Experimental Example 1) Confirmation of the Efficacy of the T1R3 Silencing Vector: Proteins were extracted from control HEK cells and HEK cells expressing a T1R3 knockout vector, and the endogenously expressed T1R3 protein levels were examined by Western blotting to determine the effect of T1R3 silencing (Figure 1). The antibodies used for Western blotting were T1R3 antibody LifeSpan Biosciences, Inc. (LSP) LS-C496868-100 and anti-T1R3 / AS1R3 Human (Rabbit) antibody. Specifically, the cells were centrifuged at 6000 rpm at 4°C for 3 minutes to form a cell pellet. The pellet was suspended in 100 μL of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40), protease inhibitor cocktail (Complete Mini; Roche Applied Science), and phosphatase inhibitor cocktail (PhosSTOP; Roche Applied Science), and incubated on ice for 20 minutes. The lysis buffer containing the cells was then centrifuged at 15,000 rpm for 20 minutes at 4°C. The supernatant was then concentrated, and 10 μg of the supernatant was subjected to electrophoresis (7.5% Tris-HCl polyacrylamide gel) and used for Western blotting. Following electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane (Immobilon P; Millipore, Burlington, MA, USA).The primary antibody used was Tas1R3 antibody (LifeSpan Biosciences, Inc. (LSP) LS-C496868), and the secondary antibody used was sheep anti-mouse HRP-conjugated secondary antibody (Amersham Pharmacia Biotech, Buckinghamshire, UK). Visualization was performed using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech).
[0121] (Experimental Example 2) Construction of expression vectors for hT1R1, hT1R2, and hT1R3, and measurement of the expression levels of T1R1, T1R2, and T1R3 endogenously expressed in HEK cells and SH-SY5Y cells by quantitative PCR. cDNAs used and accession numbers hTAS1R1 (BC136515), hTAS1R2 (BC141437), and hTAS1R3 (BC152912) (Kabushiki Kaisha DNAFORM). The purchased cDNA was inserted into the expression vector using the following method. cDNA cloning was performed using Thermo's cloning kit (Gateway® cloning technology). First, the cDNA was ligated to the BamH1 / Xho1 site of the pENTR1.0A (Entry Clone) vector, and then LR reaction (Gateway TM LR Clonase TM II Enzyme mix: Catalog number 11791100) TM pcDN TM The genes were cloned into the 6.2 / EmGFP-Bsd / V5-DEST Vector (Catalog number: V36620). Using quantitative PCR (qPCR), the expression levels of T1R1, T1R2, and T1R3, which are endogenously expressed in HEK cells and SH-SY5Y cells, were examined, and sufficient expression was confirmed. The results of quantitative PCR from HEK cells are shown in Figure 2. It can be seen that T1R3 is significantly more abundantly expressed than T1R1 and T1R2.
[0122] (Experimental Example 3) Preparation of knockdown vector The miRNAs Oligo (Thermofisher) used for silencing was annealed to form double-stranded DNA, which was then ligated to the miR RNAi Expression Vector using T4 DNA ligase to prepare a knockdown vector. Specifically, the knockdown vector was prepared according to the miR RNAi Expression Vector Kit manual (BLOCK-i TM The Pol II miR RNAi Expression Vector Kit with EmGFP (Catalog number: K493600) was used.
[0123] Example 1: VGSC activation by glutamine (Gln) via T1R2 / T1R3, a sweet GPCP-type receptor. Glutamine is a sweet amino acid and is recognized as a taste sensation through the T1R2 / T1R3 receptor. Since glutamine levels in the cerebrospinal fluid of AD patients are known to be significantly elevated compared to healthy controls, we speculated on the possibility of glutamine's effect on VGSCs and investigated whether or not this effect was present. Administration of 0.5-1 mM glutamine resulted in an amplification (10-20%) of VGSC currents. No further enhancement was observed with the addition of glutamine at concentrations higher than 1 mM. Glutamine-induced VGSC enhancement was observed in both SH-SY5Y (n=8) and HEK-Nav1.5 (n=4). Figure 3 shows the recordings from SH-SY5Y. Amplification of VGSC inward currents was confirmed before and after administration of 500 μM glutamine. The left side of Figure 3 shows the actual current waveform from the experiment, and the right side of Figure 3 shows an IV plot (a graph plotting the change in current magnitude in response to the stimulation voltage).
[0124] (Example 2) Activation of VGSCs via T1R2 / T1R3 by Amyloid β Peptide (Aβ25-35) (2-1) Enhancement of VGSC Inward Current by Aβ25-35 Amyloid β peptide is used as a biomarker for diseases such as Alzheimer's disease (AD), dementia with Lewy bodies (Bibl et al. (2007)), and amyotrophic lateral sclerosis (ALS, Lanznaster et al. (2020)). Increased levels of amyloid β peptide in the brain have been reported by immunohistochemistry using Aβ antibodies in these diseases. Clinically, the relationship between amyloid β peptide and neural hyperexcitability has also been studied in ALS patients (Palop et al. (2009), Sperling et al. (2020)). (2009)). It has been suggested that neuronal hyperexcitability due to amyloid beta peptide induces burst-like activity (seizures) in AD or ALS patients, potentially contributing to neurodegeneration (Hartley et al. (1999), Brunet et al. (2020)). It has also been suggested that overexpression of amyloid beta peptide enhances VGSCs such as Nav1.6, resulting in neuronal hyperexcitability (Li et al. (2016), Ciccone et al. (2019), Non-Patent Document 1). Non-Patent Document 1 also demonstrated, using electrophysiological techniques (voltage clamp) to demonstrate that cultured cortical neurons differentiated from iPS cells derived from AD patients exhibited increased neuronal excitability, burst-like neuronal hyperactivity, and simultaneous amplification of VGSCs, which confirms neuronal hyperactivity, compared to controls derived from healthy individuals. Furthermore, this neural hyperactivity and VGSC amplification disappear when a BACE1 inhibitor is administered, suggesting a causal relationship between Aβ peptides and the onset of neural hyperactivity and epileptic seizures in AD patients.
[0125] Amyloid β peptides are formed from amyloid precursors, such as amyloid β1-42 (Aβ1-42) peptides. Among amyloid β peptides, Aβ25-35, which is formed by proteases in the brain, is reported to be the most toxic. Immunohistochemical analysis has shown that amyloid β peptides 25-35 are not found in healthy individuals, but are found in senile plaques of AD patients and in degenerated neurons in the CA1 region of the hippocampus (Kubo et al. (2002)).
[0126] (2-2) Concentration-Dependent Amplification of VGSC Currents by Aβ25-35 Peptide For the above reasons, in this example, we first examined the effects of Aβ25-35 peptide on VGSCs. Specifically, experiments similar to those in Example 1, in which glutamine (Gln) was administered, were performed using 1-6 μM Aβ25-35 peptide. As shown in Figure 4, enhancement of VGSC inward currents was observed in SH-SY5Y cells (n = 5), similar to the effect of glutamine administration. Similar enhancement was also observed in HEK-Nav1.5 (n = 4). We then examined the concentration-dependent effects of various concentrations of Aβ25-35 peptide on VGSC currents in SH-SY5Y cells. At the highest concentration of 6 μM, the magnitude of the VGSC current was amplified 1.65-fold. Next, using the membrane voltage clamp method (perforated patch clamp recording method) described in detail in (2-4) below, the EC 50 , Hill slope was calculated. As a result, EC 50 The obtained values were 86.8 nM and the Hill Slope was 1.33 (Figure 9).
[0127] Next, using current-clamp mode, we applied current stimulation and recorded action potentials from differentiated SH-SY5Y cells (Figure 5, square-wave current stimulation was applied from the bottom row to the top row. The current strength was 6, 8, 10, and 12 pA from bottom to top). Before the Aβ25-35 peptide treatment, no action potentials were induced at stimulation currents of 6 pA and 8 pA, but action potentials were recorded at stronger stimulation currents (10 pA and 12 pA). This suggests that the Aβ25-35 peptide lowered the threshold for generating action potentials. Furthermore, the amplitude of action potentials also increased, suggesting that, just as glutamine's potentiation of VGSC lowers the neuronal excitability threshold, the Aβ25-35 peptide potentiates VGSC, making neurons more susceptible to hyperexcitability.
[0128] Since the Aβ25-35 peptide is said to be the most toxic, we examined the effect of the Aβ1-42 peptide on VGSC currents using voltage clamp with HEK-Nav1.5 to see if it had a similar effect to the Aβ25-35 peptide (Figure 6). Aβ1-42 did not show the same enhancing effect as Aβ25-35 (n=4). Rather, unlike the Aβ25-35 peptide, the Aβ1-42 peptide inhibited sodium channel currents in VGSCs. Vitvitsky et al. found that when the Aβ25-35 peptide was applied to astrocytes, intracellular Na + and K. + reported that an increase in Aβ levels occurred, but such an effect was not observed with the Aβ1-42 peptide (Vitvitsky et al. (2012)), which is consistent with the results of this example using VGSCs. Vitvitsky et al. further described that a similar effect was observed with Aβ25-35 and Aβ1-40, but not with Aβ1-42, suggesting that the presence or absence of the amino acid sequence at positions 40-42 may result in some important structural change.
[0129] (2-3) Aβ25-35 peptide enhances VGSC activity via T1R2 / T1R3 (i) Observation by silencing T1R3 or treating with anti-T1R3 antibodies: The experimental results in Example 1 above indicate that the sweet amino acid glutamine acts through sweet taste receptors (T1R2 / T1R3), and it is understood that glutamine's VGSC enhancement lowers the excitability threshold, making action potentials more likely to occur and increasing the amplitude of action potentials. Because the Aβ25-35 peptide produced effects very similar to those of glutamine (enhancing VGSC, lowering the excitability threshold), it is possible that the Aβ25-35 peptide also acts on the T1R2 / T1R3 receptors in the same way as glutamine. Therefore, in this example, T1R3-silenced HEK Nav1.5 cells were used to compare the effect of Aβ25-35 peptide on VGSCs with that of control HEK Nav1.5 cells.
[0130] Figures 7A and 7B show a comparison of VGSCs recorded by voltage clamp from control HEK Nav1.5 cells before and after Aβ25-35 administration. 1 μM Aβ25-35 was confirmed to enhance VGSC currents. (B) shows actual experimental current waveforms (left: control, right: after 1 μM Aβ25-35 administration). (A) shows the IV plot measured from Experiment B. In contrast, no change in VGSCs was observed in T1R3-silenced HEK Nav1.5 cells treated with 2 μM Aβ25-35 peptide at twice the concentration used for control recordings (n = 4). (A) IV plot, (B) VGSC current traces before and after Aβ25-35 peptide administration. In addition to the above observations, VGSCs enhanced by the Aβ25-35 peptide were restored to the VGSCs recorded in the control group before enhancement by 1-1.5 mM lactisole (n = 2) (Figure 7E). Given that lactisole specifically binds to T1R3, this observation also indicates that the Aβ25-35 peptide acts on T1R3. Lactisole, which binds to the TM domain, located carboxy-terminal to the extracellular ligand-binding site (Venus flytrap domain) and close to the G-protein binding site, has been suggested to inhibit T1R3 activation. The suppression of the enhancement by lactisole strongly suggests that the action of Aβ25-35 is mediated by T1R3.
[0131] (ii) Changes in sodium current potentiation in HEK Nav1.5 cells treated with anti-T1R3VFD antibody: We observed changes in sodium current potentiation in HEK Nav1.5 cells pretreated with anti-T1R3VFD antibody (Figure 8). HEK Nav1.5 cells were incubated with 1000-fold diluted anti-T1R3 antibody for 10-20 minutes, and patch clamp experiments were performed to confirm whether the effect of Aβ25-35 peptide on VGSCs could be suppressed. IV and SS curves of VGSC currents recorded from HEK Nav1.5 cells treated with a T1R3 N-terminal-recognizing antibody are shown before and after the Aβ25-35 peptide treatment (n=2). The effect of Aβ25-35 peptide was abolished in experiments in which T1R3 was silenced. Controls without anti-T1R3 antibody pretreatment reproducibly demonstrated a 10-20% increase in VGSC current amplitude, but no enhancement was observed in cells pretreated with anti-T1R3 antibody. This antibody was generated against the amino acid sequence 229-258 of the human T1R3 VFD domain and reacts specifically with human cells. The fact that this antibody inhibits the action of the Aβ25-35 peptide suggests the possibility of species differences (differences with mice) in the action of the Aβ25-35 peptide.
[0132] (iii) Possibility of acting on both T1R2 and T1R3: On the other hand, when T1R3 was treated with an antibody recognizing the N-terminus of T1R3, the potentiation of VGSC currents by the Aβ25-35 peptide was suppressed, but a leftward shift (toward a negative potential) of the IV and SS curves was observed (Figures 8 and 29). Because the leftward shift of the IV and SS curves is observed primarily when a reagent / compound acting on T1R2 is applied, it is believed that T1R2 and T1R3 are closely functionally related. This suggests that T1R2 may function as a low-affinity binding site when the Aβ25-35 peptide is unable to act on T1R3 due to the T1R3 antibody. Therefore, the Aβ25-35 peptide may act on both T1R2 and T1R3, similar to sucrose and sucralose.
[0133] From the above, it was confirmed that the T1R2 / T1R3 heterodimer or the T1R3 / T1R3 homodimer acts as a receptor for the Aβ25-35 peptide, enhancing VGSC through a mechanism similar to that of glutamine, suggesting the possibility that this may be the cause of neural hyperactivity.
[0134] (2-4) Enhancement of T1R3-mediated VGSC currents by Aβ25-35 peptide: Reexamination using the perforated patch-clamp recording method. The enhancement of T1R3-mediated VGSC currents by Aβ25-35 peptide acts on the effector (VGSC) via G protein-mediated intracellular second messengers. The opening in the inner diameter of the whole-cell membrane-fixed patch electrode used in the experiment in Example (2-2) above disrupts the cell membrane, creating a hole that integrates the intracellular and patch electrode interiors, allowing for recording of intracellular potentials, controlling the cell's membrane potential, and measuring ionic currents using voltage clamp. During this process, the solution inside the patch electrode mixes with the intracellular solution. Because the volume of solution inside the patch electrode is greater than the intracellular solution, the intracellular solution and intracellular substances are replaced by the solution inside the patch electrode. For intracellular second messengers to function properly, it is essential to maintain the composition of the intracellular solution and prevent the leakage of intracellular substances such as ATP into the patch electrode. Therefore, we re-examined the effects of the Aβ25-35 peptide using the perforated patch-clamp recording method. The perforated patch-clamp recording method involves adding antibiotics, such as amphotericin B or gramicidin, to the patch electrode solution, which create a pathway for monovalent cations in cholesterol-containing lipid membranes, such as the cell membrane, without creating holes in the cell membrane. This allows recording of VGSC currents using the voltage-clamp method without creating holes in the cell membrane (i.e., without altering the intracellular environment). Application of the Aβ25-35 peptide resulted in an amplification of the VGSC current, similar to that recorded using the standard voltage-clamp method (patch-clamp method). Further increasing the concentration of the Aβ25-35 peptide eliminated the amplification of the VGSC current induced by the Aβ25-35 peptide, and the VGSC current returned to nearly its pre-application level (Figure 10). This phenomenon is thought to be due to desensitization of the VGSC receptor. It is noteworthy that the amplification of the VGSC current was accompanied by an increase in the cell membrane area. When a square-wave voltage is applied during voltage clamp recording, the amplifier charges the capacitance generated by the cell membrane before recording the ionic current.This charge amount is proportional to the size of the cell (size of the cell membrane), and the charge amount (amount of electric charge) is represented by Q and can be measured experimentally. This value Q is expressed by the formula Q = CV. By applying the voltage pulse value (V = 10 mV) used in this experiment and the experimentally measured charge amount (Q) to the formula C = Q / V, the electrical capacitance (C) of the cell membrane can be calculated.
[0135] As shown in (2-2) above (Figure 9), the membrane charge and VGSC current amplitude were measured using the voltage clamp method after Aβ25-35 peptide treatment. We observed an increase in membrane charge capacitance along with the VGSC current. We calculated and analyzed the VGSC current density to determine how the increase in membrane charge correlated with the increase in VGSC current. The current density (pA / pF) was calculated by dividing the VGSC current (pA) by the membrane capacitance (pF) (Figure 11B). We found that not only the VGSC current but also the VGSC current density (pA / pF) increased after Aβ peptide treatment. The increase in membrane capacitance indicates an increase in the membrane area due to Aβ peptide treatment. This indicates the addition of intracellular endosome-like vesicles to the membrane. Furthermore, the increase in VGSC current density after Aβ peptide treatment indicates that the loaded intracellular vesicles contained more VGSC than the VGSC already present on the membrane. When the Aβ peptide concentration was further increased, both the VGSC current and the cell membrane capacitance decreased, returning to almost the control level (FIG. 11A).
[0136] Because the experiments using the perforated patch clamp technique were transient, it is unclear whether VGSCs derived from intracellular vesicles with high VGSC current density induced by Aβ peptides diffuse to non-vesicle-derived plasma membranes. However, because the differential current density also returns to control levels when the cell volume returns to control levels, it is likely that in experiments lasting just over 10 minutes, membrane-inserted VGSCs derived from intracellular vesicles with high VGSC current density are endocytosed into vesicles while maintaining their VGSC current density. Increases and decreases in VGSC current density due to exocytosis or endocytosis were observed not only in HEK Nav1.5 cells (n = 3) but also in RA-differentiated SH-SY5Y neuroblastoma cells (n = 1). Stimulation was applied every 8 seconds. The x-axis in Figure 11C indicates the number of stimulations. Therefore, for example, stimulus 10 means 80 seconds after the start of the experiment.
[0137] (2-5) Comparison of Changes in VGSC Current Density with Increases and Decrease in Aβ25-35 Peptide Concentration Because the mechanisms of AMPA-type glutamate receptor enhancement on the plasma membrane in LTP and Aβ25-35-induced enhancement of VGSC on the plasma membrane are similar, we adapted the method used in LTP studies to evaluate the insertion of VGSC-containing endosomes into the plasma membrane using the voltage-clamp technique (Fig. 12). The results of measurements of T1R3-mediated VGSC current and current density using a perforated patch clamp (Fig. 10 and Fig. 11) obtained in (2-4) above are shown in Fig. 12.
[0138] As shown in Figure 12, the action of Aβ25-35 peptide increased the VGSC current. Further increasing the concentration of Aβ25-35 peptide decreased the VGSC current, returning it to the value before the action of Aβ25-35 peptide. It was observed that the increase and decrease in VGSC current occurred simultaneously with the increase and decrease in cell membrane capacitance. Therefore, the VGSC current (pA) was divided by the cell capacitance (pF) to calculate the current density (pA / pF). It was confirmed that the action of Aβ25-35 peptide increased the VGSC current density, and that an increase in the amount of Aβ25-35 peptide decreased the current density. This suggests that intracellular endosomes expressing VGSC fuse with the cell membrane and migrate to the extracellular surface (increased current density) due to the action of Aβ25-35 peptide, and are then re-introduced into the cell by increasing the amount of Aβ25-35 peptide (decreased current density). Furthermore, when current densities were calculated using only measurements of the current and cell capacitance changes that occurred after Aβ25-35 peptide treatment compared to the current density before treatment, it was confirmed that the change in current density caused by Aβ25-35 peptide was greater than the current density before treatment. The decrease in current density caused by increased amounts of Aβ25-35 peptide was also greater than the increase observed during treatment, even when comparing the current densities before and after treatment with Aβ25-35 peptide. That is, the amount of VGSC contained in the membrane per unit area derived from endosomes newly added to the cell membrane by Aβ25-35 peptide was greater than the VGSC per unit area present on the cell membrane before treatment with Aβ25-35 peptide, and the amount of VGSC absorbed from the cell membrane due to T1R3 desensitization per unit area of membrane was also greater than the VGSC per unit area present on the cell membrane before treatment with Aβ25-35 peptide. From the above, it was concluded that the VGSC current density on the endosome inserted by the Aβ25-35 peptide is larger than the size per unit area (current density) of the VGSC present on the cell membrane surface.
[0139] The enhancement of synaptic currents observed in long-term potentiation (LTP), which is thought to be important in explaining the process of early memory formation, has been reported to occur through the fusion of AMPA-type glutamate receptors expressed on intracellular vesicles to the plasma membrane (Park et al. (2004) Science 24:305(5692):1972-5). This is very similar to the process by which vesicle-localized VGSCs are fused and inserted into the plasma membrane in this discovery. It is thought that Rab11a and Rab5, which are involved in recycling endosome trafficking, are involved in the fusion and retrieval of vesicles expressing AMPA-type glutamate receptors (Park et al. (2004)). Therefore, as shown in (2-4) above, it is possible to measure the current density of VGSCs in intracellular vesicles, or to evaluate the degree / process of vesicular fusion of vesicles expressing labeled VGSCs to the cell membrane by incorporating FITC-dextran, FM1-43 fluorescent reagents, etc. into intracellular vesicles expressing VGSCs. Using the above-described method, it is possible to evaluate the process / degree of VGSC enhancement caused by insertion of VGSCs into the cell membrane by Aβ peptides. This method is effective for screening inhibitors that suppress neuronal hyperactivity caused by Aβ peptides, etc. Furthermore, this technique can be applied to study the effects of many amino acids contained in CSF (spinal cerebrospinal fluid), particularly glutamine (L-Gln) and lysine, which are known to increase in neurodegenerative diseases such as epilepsy and Alzheimer's disease, on neuronal activity.
[0140] (Example 3) VGSC Inhibitory Effect Targeting Sweet Taste Receptors (T1R2 / T1R3 Heterodimer or T1R3 Homodimer) and Its Concentration Dependence (3-1) VGSC Inhibitory Effect Targeting T1R2 / T1R3 or T1R3 / T1R3 Mailliet et al. reported that, as an experimental system in which the response to sweet stimuli can be observed as an increase in intracellular calcium, they expressed T1R2, T1R3, and G16-gust44 (Ueda et al., (2003)), which has the function of converting these receptor responses into an increased reaction of intracellular calcium, in HEK cells, and observed the effect of a T1R3 inhibitor on the sweet stimuli response (Mailliet et al. (2009)). In this case, the artificial sweetener sucralose was used as a stimulant, and the resulting sweet taste receptor (T1R2 / T1R3) response was used as a control. It has been reported that lactisole and its structural analogs, fibrates and phenoxy-herbicides, have an inhibitory effect on this sweet taste response. According to the reported results, the IC 50 The binding efficiencies were 70 μM for lactisol, 28 μM for clofibric acid (a fibrate; a lipid-lowering drug), and 5.3 μM for dichlorprop (2,4DP), a phenoxy-herbicides. Dichlorprop, like lactisol, has been reported to bind to the transmembrane domain of T1R3 (Nagakita et al. (2019)).
[0141] Therefore, in this experiment, sweet taste receptor (T1R2 / T1R3) antagonist-like substances such as clofibrate and dichlorprop, which were found to have inhibitory effects on sweet taste receptor (T1R2 / T1R3) binding in the above-mentioned experimental system conducted by Mailliet et al., were applied to VGSCs, and their IC 50 The IC values obtained in the above experimental results by Mailliet et al. 50In addition, we also observed whether the effects of artificial sweeteners, such as saccharin and sucralose (Non-Patent Document 2), which exhibit agonist-like effects on sweet taste receptors (T1R2 / T1R3), and Gymnema TEA Extract (GTE; Sanematsu et al. (2014) J. of Biol. Chem. 289(37): 25711-20), which exhibit antagonistic effects, on VGSCs were activating or inhibiting.
[0142] The concentration-dependent effects of dichlorprop were observed based on the membrane potential-dependent activation and steady-state inactivation curves of VGSCs (Figure 13). Unlike saccharin, sucralose, and gymnema tea extract (GTE), dichlorprop's concentration-dependent decrease in VGSC currents occurs by shifting the steady-state inactivation curve to the left (hyperpolarization). Therefore, when depolarizing stimulation was performed using a resting membrane potential of approximately -80 mV in normal cells or a holding voltage of -120 mV, which is frequently used in this experiment to activate Nav1.5, the steady-state inactivation curve shifted further to the left (hyperpolarization), and no VGSCs could be activated by depolarizing stimulation, so dichlorprop acts as an inhibitor. However, saccharin, sucralose, and gymnema tea purely inhibit VGSC without affecting the steady-state inactivation curve. From the above, dichlorprop significantly differs from saccharin, sucralose, and gymnema tea extract in that it shifts the steady-state inactivation curve in a parallel manner toward the negative membrane potential, similar to the cases of T1R2 overexpression, T1R2 silencing, and TBB (casein kinase 2 inhibitor). This indicates that dichlorprop, saccharin, and gymnema tea extract all have the same effect of concentration-dependently reducing VGSC activity by acting on sweet taste receptors (T1R2 / T1R3), but their mechanisms of action are different. Specifically, saccharin, sucralose, and gymnema tea may share the same target of action, acting as an agonist or antagonist, in that they increase or decrease VGSC currents without affecting glutamine (L-Gln) or Aβ peptide kinetics, such as inactivation kinetics.
[0143] The steady-state inactivation curves were analyzed using the Boltzmann equation to calculate the slope factor and the prepulse midpoint potential (Vh) required to reduce the current to half its maximum. The slope factor remained stable (Fig. 14A), but the Vh shifted hyperpolarizingly with increasing dicloprop concentrations (Fig. 14B). The analytical results, along with those for clofibrate, are shown in Tables 6 and 7.
[0144] (3-2) Concentration-dependent effects of dichlorprop on VGSC amplitude Next, the concentration-dependent effects of dichlorprop on VGSC amplitude were analyzed. From the steady-state inactivation experiment results recorded at different dichlorprop concentrations, the VGSC current amplitude in response to a test pulse stimulus (-20 mV) of the preconditioning pulse potential and the degree of dichlorprop concentration-dependent inhibition could be analyzed. Therefore, the concentration-dependent inhibitory effects of dichlorprop at pre-pulse potentials of -80 mV, -100 mV, and -120 mV were analyzed (Tables 6 and 7). The more hyperpolarizing the pre-pulse potential, the greater the IC 50 It was found that the value of VGSC increases. In other words, it is highly effective at the resting potential of normal cells (around -80 mV), and when used in treatment aimed at correcting the hyperexcitable state of nerves due to the enhancement of VGSC by the Aβ25-35 peptide shown in Example (2-2) (Figures 3, 4, and 7), a sufficient therapeutic effect can be expected at 100 μM or less. Similar therapeutic effects can be expected not only for epilepsy and ALS, but also as a therapeutic agent for neuropathic pain that occurs with the administration of anticancer drugs (the anticancer drug Taxol also enhances VGSC to a similar extent, like the Aβ25-35 peptide; see Figure 8).
[0145] IC of VGSC inhibition using dicloprop and clofibrate 50The IC was calculated under different pre-pulse conditions and the results are shown in Tables 6 and 7. These results also show that DichlorProp is significantly more effective than clofibrate. 50 The value of was measured by Mailiet et al. (2009) using calcium imaging (dicloprop IC 50 = 5.3 μM, clofibrate IC 50 However, in this experiment, the degree of hyperpolarization of the holding potential (Prepulse) that activates VGSC was large, and the IC 50 It is clear that this has an effect on
[0146]
[0147] Compared with Nav1.6 expressed in SH-SY5Y cells, the steady-state inactivation of Nav1.5 used in this experiment is located in the hyperpolarized direction. Therefore, as mentioned above, the IC 50 The IC value obtained by calcium imaging is expected to be different from the IC value obtained by calcium imaging if the holding voltage is more hyperpolarized. 50 To further explore the difference between the IC values, we used SH-SY5Y cells expressing Nav1.6 to measure the IC value of dicloprop. 50 As a result, when the holding voltage was -60 mV, IC 50 The IC value was 9 μM, which is almost the same as the value of 5.3 μM obtained by calcium imaging. 50 This suggests that dicloprop is highly safe for cardiac function when used as an analgesic or antiepileptic drug. However, the IC value of dicloprop was 50 Since the values are different between HEK Nav1.5 and SH-SY5Y (Nav1.6), the difference in VGSC genes (Nav1.5, Nav1.6) is also related to the IC 50 This is likely to be responsible for the difference in values.
[0148]
[0149] As described above, dicloprop, which is known to bind to T1R3 similarly to clofibrate and lactisole, was confirmed to have the effect of shifting the membrane dependence of the steady-state inactivation curve of VGSCs toward hyperpolarization. This phenomenon is similar to the phenomenon observed in brain trauma, where shear stress or stretching of nerves disrupts the connection between the cytoskeleton and VGSCs, resulting in a shift in the membrane dependence of the steady-state inactivation curve of VGSCs toward hyperpolarization (Wang et al. (2009), Shcherbatko et al. (1999)). This suggests that the GPCR sweet taste receptor (T1R2 / T1R3) may also affect the relationship between the cytoskeleton and VGSCs, thereby regulating VGSC function. As mentioned above, the cytoskeleton binds to VGSCs via Ankyrin G / Spectric, and the presence and extent of phosphorylation by Casein kinase 2 at the Ankyrin G-binding sequence on VGSCs plays an important role in the binding between VGSCs and Ankyrin G.
[0150] Next, in the experimental results of (Table 6) and (Table 7), the pre-pulse potential is IC 50 We considered why this significantly affected the values. According to Nin et al., "hyperpolarization of the membrane potential stabilizes the actin cytoskeleton, strengthening adherens junctions in epithelial cells" (Nin et al. (2009)). Based on this, it is thought that the more hyperpolarized the prepulse potential, the more stabilized the cytoskeleton and the weaker the effect of T1R3 blockers (sweet taste-suppressing compounds). In other words, when neurons are overactive, the membrane potential is more depolarized than the prepulse potentials used in Tables 6 and 7, and therefore the compounds are thought to exert their VGSC inhibitory effect at even lower concentrations. This offers the advantage of selectively acting only on overactive neurons, while having a weak effect on normally functioning neurons.
[0151] Based on the above, it was speculated that inhibiting casein kinase 2 (CK2) would dephosphorylate the ankyrin G binding site of VGSC, weakening the relationship between VGSC and the cytoskeleton, resulting in changes such as a shift in the membrane dependency of the steady-state inactivation curve toward hyperpolarization.
[0152] Example 4: Effect of Dephosphorylation of the Ankyrin G Binding Site of VGSCs Using a Casein Kinase 2 Inhibitor (TBB) on VGSCs (4-1) Inhibition of Concentration-Dependent VGSC Currents by a Casein Kinase 2 Inhibitor (TBB) We discovered that TBB, a known casein kinase 2 inhibitor, reduces the amplitude of VGSC currents. Specifically, membrane potential-dependent VGSC activity is affected by the potential of the pre-pulse. The amplitude of the VGSC current induced by depolarizing stimulation decreases when the pre-pulse is depolarized from -80 mV to -50 mV in 10 mV increments compared to when the pre-pulse is depolarized from -120 mV to -20 mV. Taking advantage of this property, TBB was administered to Nav1.5-expressing HEK cells, and changes in the amplitude of the VGSC current were observed. A TBB concentration-dependent decrease in the peak inward current was observed. This inhibitory effect of TBB was highly dependent on the membrane potential of the pre-pulse. When the pre-pulse was -80 mV, almost complete inhibition was observed at 30 μM, the lowest concentration used (Fig. 15B). The IV curve in Fig. 15A shows the experimental results when the pre-pulse was -120 mV. In the steady-state inactivation (SS) curve shown on the left side of Fig. 15A, 10 μM TBB (open circles) exhibited a hyperpolarized (leftward) shift in the SS curve compared to the control (filled circles), demonstrating that a -80 mV pre-pulse almost completely inhibited the VGSC current. However, the degree of inhibition was weak with a -100 mV pre-pulse, and almost no inhibition was observed with a -120 mV pre-pulse. In the steady-state inactivation curve experiment, the amplitude of the VGSC current activated by a test pulse of -20 mV applied following a pre-pulse of -170 mV, -120 mV, or 0 mV was plotted against the membrane potential. With increasing TBB concentrations, the current gradually shifted to the left (hyperpolarization direction) (Fig. 15A). Figure 15B shows the actual experimental data waveform used for the plot in 15A. Similar experiments were then performed using SH-SY5Y cells, and comparable results were obtained (data not shown).
[0153] The experimental results in Figure 15 indicate that the inhibitory effect of TBB on VGSCs is significantly membrane potential-dependent, which is a result of the shift of the steady-state inactivation curve toward hyperpolarization (leftward) as shown above (Figures 13 and 14).
[0154] Figure 16 shows the IC of the concentration-dependent VGSC current suppression effect of TBB. 50 The values (Fig. 16A) and the hyperpolarizing shift of the steady-state inactivation curve of the concentration-dependent VGSC current by TBB (Fig. 16B) are expressed as the difference in Vh between the control (before TBB treatment) and after TBB treatment.
[0155] Next, similar experiments were performed using SH-SY5Y cells, and comparable results were obtained (data not shown).
[0156] The phenomenon of VGSC inhibition due to the left shift of the S-S of VGSC is very similar to the inhibition of VGSC by T1R2 overexpression and aspartame, which exhibits T1R2 agonist-like action, as described below. This suggests that the inhibitory effect of TBB on VGSC may also be due to the inhibition of VGSC activity via T1R2 or other T1Rs. When VGSC was partially inhibited by TBB, the IC of dicloprop and aspartame 50 If it can be confirmed that this has an effect on VGSC, then the inhibition of VGSC via T1R2 or T1R3 will be related to the degree of inhibition of VGSC phosphorylation by CK2 by TBB, which strongly suggests that the relationship between VGSC and the cytoskeleton, such as Ankyrin G, is related to the mechanism of inhibition of VGSC through T1Rs.
[0157] VGSCs colocalize with the membrane skeletal protein ankyrin G at the axon initial segment (AIS), nodes of Ranvier, and synaptic clefts at mammalian neuromuscular junctions. Zhou et al. reported that ankyrin G is essential for clustering VGSCs at the axon initial segment and is essential for VGSC activity (Zhou, et al., (1998)). Similarly, Brechet et al. reported that VGSCs contain an ankyrin-binding motif, and that CK2 phosphorylation of a serine within this motif is essential for VGSC-ankyrin G binding, and that inhibition of CK2 activity reduces sodium channel accumulation at the axon initial segment (AIS) of neurons (Brechet et al. (2008)). These results suggest that CK2 phosphorylation of VGSCs regulates the degree of ankyrin G-ankyrin G binding to VGSCs. Xu et al. (2015) also reported that phosphorylation of VGSC by CK2 is important for binding to ankyrin G (Non-Patent Document 9).
[0158] When TBB was applied during patch clamp recording of VGSCs, the steady-state inactivation curve (hereafter abbreviated as S-S) of VGSCs shifted significantly toward hyperpolarization (Fig. 15). That is, unless the holding potential (membrane potential set before the application of a stimulation pulse) was set to a significantly hyperpolarized state (<-140 mV) when activating VGSCs, the magnitude of VGSCs was significantly reduced (suppressed).
[0159] (4-2) Delay of VGSC inactivation by MSG Even in this inhibitory state, MSG treatment showed a tendency to restore the magnitude of VGSC current (Fig. 17), confirming that it acts to correct the S-S hyperpolarization shift (Fig. 18). In addition, the MSG effect also occurred in T1R3 knockout (KO) mice, suggesting that the T1R1 umami taste receptor and sweet taste receptor interact cooperatively, but that there are pathways that act on VGSCs through different mechanisms.
[0160] The results in Figure 18 show that the casein kinase 2 (CK2) inhibitor TBB induces a hyperpolarized shift in the VGSC S-S curve, and subsequent application of MSG partially reverses this shift, suggesting that the MSG effect on VGSCs via the T1R1 umami receptor may be independent of the effect induced by CK2. In Figure 18 (left), the S-S curves were stimulated by stepwise changes in the VGSC membrane potential from different steady-state holding voltages to -20 mV. Inhibition of CK2 by TBB significantly shifted the S-S curve toward hyperpolarization (left-pointing arrow). Subsequent application of MSG partially reversed the TBB-induced leftward shift and caused a rightward shift (right-pointing arrow). The current-membrane potential curve (IV curve) on the right side of the S-S curve was measured at a holding potential of -120 mV, so the maximum current depended on the magnitude of the activatable VGSC current at -120 mV due to the effect of the reagent. (Figure 18, right) shows the actual VGSC current traces obtained by measuring the S-S curve. The vertical scale is the same, so the magnitude of the maximum VGSC current due to each reagent can be clearly seen. It can also be seen that the effect of MSG delays the VGSC inactivation process.
[0161] The experimental results (Figure 18) confirmed that inhibition of casein kinase 2 (CK2) by TBB inhibits VGSCs. This was observed by patch clamp observation, showing that CK2 inhibitors shift the membrane potential required for VGSC activity to a more negative potential than the physiologically acceptable membrane potential range of the cell, promoting inactivation and thereby reducing the number of activatable VGSCs within the membrane potential range in which the cell is active. This is the first report to document this finding. Taking into account the findings of the enhancement of VGSCs by paclitaxel (Taxol), a microtubule stabilizer that constitutes the cytoskeleton (described below), the enhancement of VGSCs by colchicine, a microtubule depolymerizing agent, and the inhibition of VGSC currents by latrunculin A, a microfilament polymerization inhibitor, we concluded that the relationship between the cytoskeleton and VGSCs is that stimulation from taste receptors regulates the activity of VGSC currents through the cytoskeleton. In other words, since the relationship between VGSC and cytoskeleton strongly influences the increase and decrease of VGSC current, it is suggested that TBB, a CK2 inhibitor, may also be effective as a therapeutic drug for pain relief, epileptiform seizures, and the like.
[0162] Example 5: Effect on Paclitaxel-Induced Neuropathic Pain. Pain caused by neuronal overactivity, other than that resulting from cranial nerve disease, such as the neuropathic pain caused by paclitaxel (Taxol), an anticancer drug used in breast cancer treatment, is also hypothesized to result from an amplification of VGSC currents. Therefore, we investigated the effect of Taxol on VGSC currents. Specifically, we used HEK Nav1.5 to examine the effect of Taxol on VGSC currents (Figure 19). VGSC currents were recorded from HEK Nav1.5 cells and treated with Taxol at concentrations ranging from 0.4 μM to 2.4 μM. The results were compared before and after administration. Enhancement of VGSCs was confirmed in all experiments (Figure 19, n = 4). These experiments demonstrated that Taxol, like glutamine and Aβ25-35 peptide, enhanced VGSC currents. The results suggest that enhanced VGSC currents may lower the threshold for neuronal action potential generation, making action potential bursts more likely to occur, leading to pain. At the same time, the degree of microtubule polymerization may be involved in VGSC activity. This suggests that VGSCs can be enhanced by directly acting on the cytoskeleton (microtubules) without tasting receptors, similar to sweet amino acids such as L-glutamine and Aβ25-35 peptide. Furthermore, dicloprop shifted the SS curve of VGSC currents toward hyperpolarization (inactivation) even in the presence of taxol, thereby inhibiting / reducing VGSC currents. These findings suggest that compounds that inhibit VGSCs via T1R3 inhibitors may also be useful in treating taxol-induced neuropathic pain.
[0163] (Example 6) Substances with VGSC Inhibitory Effect Targeting T1R3 (6-1) The VGSC Inhibitory Effect of Cinacalcet Is Mediated by T1R3 Mattheisen et al. have reported that cinacalcet, calindol, calhex, and NPS2143, allosteric modulators of the calcium-sensing receptor (CaSR), completely inhibit VGSC in the majority of cultured neocortical neurons in mice. In their report, they reported that the inhibition of VGSC by these agents acts via GPCRs, that PKA and PKC are not involved, and that the inhibitory effect is unaffected by CaSR knockout mice (Non-Patent Document 7). However, the GPCR involved was not identified in this report. In this example, since sweet amino acids affect the function of VGSCs via T1R3 or T1R2 / T1R3 sweet taste (GPCR) receptors, we hypothesized that the effect of the CaSR allosteric modulators used in Mattheisen et al.'s experiments on VGSCs is mediated by sweet taste receptors, and conducted the following experiment. Specifically, among the above-mentioned reagents, cinacalcet, a CaSR agonist, and NPS-2143, an antagonist, were used to act on VGSCs expressed in human-derived HEK Nav1.5 and SH-SY5Y cells, and examined whether similar effects would be observed not only in mouse neurons but also in human-derived cells (GPCRs). As a result, both cinacalcet and NPS-2143 inhibited human VGSCs (NPS-2143 (n=10) and cinacalcet (n=11)). In this study, the concentration required for VGSC inhibition was 5 μM, and the relatively long time required for complete inhibition, 3 to 5 minutes, was consistent with the report by Mattheisen et al. (Non-Patent Document 7). An experimental example showing the inhibitory effect of 5 μM NPS-2143 on VGSC of HEK Nav1.5 is shown in Figure 20, and an experimental example showing the effect of 5 μM cinacalcet on SH-SY5Y is shown in Figure 21. SH-SY5Y endogenous VGSC current and the subsequent outward potassium channel current can be confirmed in Figure 21A. After the action of cinacalcet, both the VGSC current and the potassium channel current were inhibited.The changes in VGSC current and potassium channel current after the action of cinacalcet are shown in time series in FIG. 21B. Cinacalcet completely inhibited not only the VGSC current but also the potassium channel current over approximately the same time course.
[0164] (6-2) Analgesic Effect by T1R3-Mediated VGSC Inhibition To test the hypothesis that the above reagents act via sweet taste receptors, lactisole (Nakagita et al. (2019)), which specifically binds to T1R3 and has sweet taste-inhibiting properties, was pretreated at a concentration of 1-1.5 mM before the application of cinacalcet. This confirmed the inhibition of cinacalcet-induced VGSCs in HEK Nav1.5 (n = 3, data not shown). These experimental results strongly suggested that the inhibitory effect of cinacalcet may be mediated by T1R3.
[0165] To further confirm these experimental results, we performed a similar experiment using HEK Nav1.5 cells in which T1R3 expression was silenced (Figure 22). VGSC currents were measured in HEK Nav1.5 cells in which T1R3 expression was silenced. Stimulation was repeated every 8 seconds. In control HEK Nav1.5 cells, cinacalcet, which completely inhibits cinacalcet at 5 μM, was not affected even after repeated exposure to 20 μM. These results confirmed that suppressing T1R3 expression nullified the inhibitory effect of cinacalcet (n=7).
[0166] (6-3) Observation of the Inhibitory Effect of Cinacalcet on VGSCs in Cells with Altered Cytoskeleton Polymerization State. Based on the results of (6-2) above, it was inferred from the above observations that the polymerization state of the cytoskeleton influences the inhibition of T1R3-mediated VGSC currents by cinacalcet. Therefore, the inhibitory effect of cinacalcet on VGSCs was observed in cells treated with cytochalasin D, a compound that affects the polymerization state of microfilaments, or colchicine, which affects the polymerization state of microtubules (Figure 23). The bottom panel of Figure 23A shows VGSC currents from control, after cytochalasin D treatment, and after cinacalcet treatment, from left to right. The top panel of Figure 23A shows IV plots and SS curves under each recording condition. The effect of cinacalcet was inhibited by cytochalasin D treatment. This indicates that cinacalcet acts by controlling the polymerization state of microfilaments. In Figure 23B, cinacalcet was applied to cells in which microtubules had been depolymerized with colchicine. Cinacalcet inhibited VGSC currents similarly to cells not treated with colchicine. This suggests that microtubules are not involved in the inhibition of VGSC currents by cinacalcet. Based on these results, we conclude that cinacalcet-induced inhibition of VGSCs is mediated by T1R3, at least in HEK cells and SH-SY5Y neuroblastoma cells.
[0167] (6-4) Inhibitory Effect of NPS-2143, a CaSR Antagonist, on VGSCs. Meanwhile, NPS-2143, a CaSR antagonist, also inhibited VGSC currents, similar to cinacalcet. However, although NPS-2143 inhibited VGSCs similarly to cinacalcet, one important difference was observed between the two reagents. After administration of NPS-2143, when VGSC inhibition was nearly complete, a leak current with no selectivity for outward or inward currents occurred in many cases. This phenomenon was not observed with cinacalcet. Conversely, cinacalcet was confirmed to reduce the leak current (Figure 24). Figure 24A shows the time series of NPS-2143 inhibition of VGSC currents. The upper panel of Figure 24B shows actual VGSC current traces. Black symbols indicate peak VGSC currents, and white symbols indicate baseline values. The lower plot in Figure 24B shows the VGSC current and baseline values after the action of NPS-2143 and cinacalcet in time series. It was confirmed that the baseline leak current increased at the timing when the VGSC current was almost completely suppressed. Therefore, since this does not occur with cinacalcet, we confirmed whether this leak current could be reversed by applying cinacalcet after NPS-2143. As expected, the leak current decreased with cinacalcet.
[0168] This suggests that NPS-2143 and cinacalcet have similar effects in terms of inhibiting VGSC, but have opposite effects in terms of maintaining the integrity of the cytoskeleton and cell membrane. In other words, it suggests that cinacalcet may promote microfilament polymerization, while NPS-2143 may conversely inhibit it.
[0169] Example 7: Application of Cinacalcet as a Local Anesthetic and Analgesic for Neuropathic Pain It is known that only uncharged (non-ionized) local anesthetics effectively diffuse across cell (lipid) membranes. However, because the pKa values of almost all local anesthetics are greater than pH 7.6 at 37°C, under inflammatory acidic conditions, most local anesthetics exist in a charged (ionized) form, and only a portion of the local anesthetic maintains membrane permeability and activity. Therefore, the efficacy of local anesthetics is significantly reduced under inflammatory acidic conditions (Tsuchiya, (2008)). Therefore, we hypothesized that compounds such as cinacalcet that target the extracellular sweet taste receptor GPCR, rather than local anesthetics that act directly on VGSCs, would effectively inhibit VGSCs and exert analgesic effects even under inflammatory acidic conditions. Therefore, we measured the VGSC inhibitory effect of cinacalcet using extracellular fluid adjusted to an acidic pH of 6. As a result, it was confirmed that cinacalcet exhibited VGSC inhibitory activity even at a concentration of 5 μM under acidic conditions (pH 6) caused by inflammation, demonstrating its effectiveness as a local anesthetic. Pain during terminal cancer metastasis is also relieved by H released from invasive cancer cells. + It is thought that this is due to the acidic environment caused by the acidity of the acid. Therefore, it may be used as a pain reliever for terminal cancer.
[0170] When cinacalcet is used to treat hypercalcemia, its plasma concentration is said to be 50 nM (Padhi, Harris (2009)). The concentration of 5 μM used in this experiment is nearly 100 times higher, but because local anesthetics are usually injected locally at the same time as vasoconstrictors such as epinephrine, its effect is limited to the injection site and it is unlikely to diffuse widely into the surrounding area. For these reasons, cinacalcet is a promising candidate for local anesthetics.
[0171] Example 8: Analgesic Effects of Artificial Sweeteners In this example, the effects of the artificial sweeteners saccharin, aspartame, and sucralose on VGSCs were investigated. All artificial sweeteners used shifted steady-state inactivation to the left (negative) in a concentration-dependent manner. Figure 26 shows the results of an experiment in which saccharin was administered. Compared to the control, administration of 2 mM and 4 mM saccharin resulted in a decrease in amplitude without significant changes in the VGSC waveform. From this, it was concluded that the use of appropriate concentrations can suppress hyperactivity and correct neural activity to normal.
[0172] This is because VGSCs become inactivated within a short period of time after activation, preventing current transmission (the generation of transient currents). If the membrane potential is not maintained at a negative value (e.g., -120 mV) to allow sufficient recovery from inactivation, the number of VGSCs that can be activated by depolarizing stimuli decreases, resulting in a smaller VGSC current that can be activated by polarizing stimuli. Saccharin reduces VGSC current and shifts the steady-state inactivation curve to the left, presumably preventing VGSCs from fully recovering at -120 mV. Similar changes were observed with aspartame, but the concentration required to produce a similar shift was approximately one-fifth that of saccharin, demonstrating its greater effectiveness.
[0173]
[0174] The effective concentration of aspartame was calculated using the inhibition of VGSC as an index. 50 The IC value was <17 μM (49.7 μM for Nav1.5 when the membrane potential was set to a hyperpolarized −100 mV). 50The values were calculated by Masuda et al. (2012) using a calcium assay of T1R2 / T1R3 by overexpressing G16-gust44. The effective concentration (IC value) was calculated based on the increase in intracellular calcium caused by aspartame. 50 Not E.C. 50 ) is the E.C. 50 The value was 756 μM, which was more than 10 times higher than the value obtained using VGSC as an indicator. The mechanism by which VGSC inhibits is thought to be different from the pathway by which artificial sweeteners are perceived as sweet.
[0175] We simultaneously transfected T1R2 and T1R3 genes to test whether stimulation by artificial sweeteners was enhanced, but no significant changes were observed in the response of endogenous sweet receptors. Therefore, we expressed T1R2 alone, and obtained a reproducible shift in the steady-state inactivation curve toward hyperpolarization. (Figure 27) shows recordings from cells expressing T1R2 in HEK Nav1.5. While VGSC currents were very small in these cells, overexpression of T1R2 resulted in a large leftward shift in the steady-state inactivation curve, similar to that observed when artificial sweeteners, which are T1R2 antagonists, were applied. Specifically, VGSCs were completely suppressed when a stimulation pulse was applied at a holding voltage of -100 mV. However, when the pre-pulse holding voltage was set to -120 mV, -140 mV, or -180 mV, the amplitude of the VGSC current in response to the stimulation significantly increased and recovered (n = 3). Since the inhibitory effect disappeared when the holding voltage was set to a hyperpolarizing voltage, it is thought that the principle of VGSC inhibition by artificial sweeteners via the T1R2 sweet receptor is due to the promotion of the steady-state inactive state of VGSCs.
[0176] Example 9: Antihyperactivity Effect of Gymnema Tea Extract. Gymnema tea extract has been used as a folk medicine in India for over 2,000 years to treat diabetes and obesity. Similar experiments were conducted using gymnema tea extract (GTE) in the same way as saccharin. Gymnema tea (Gymnema TEA) is obtained from Gymnema sylvestre, a tropical plant with antisweetening properties, and its active ingredients are gymnemic acids. Gymnema sylvestre is currently being recognized in Western countries as an alternative therapy for treating obesity, as the antisweetening substances in plants such as gymnema lower hyperglycemia (Mailiet et al. (2009)). Similar to saccharin, experiments using gymnema tea extract (GTE) resulted in a leftward shift in the steady-state inactivation curve. This experiment was also performed on SH-SY5Y cells and NG108-15 cells in addition to HEK Nav1.5. The negative shift of the midpoint of the membrane potential between the peak of the steady-state inactivation curve (Vh) and the zero response current, as well as the decrease in the peak current, were analyzed before and after GTE administration. The values are summarized in the table in Figure 28 (n=2). These results suggest that GTE may have a therapeutic effect on AD similar to that of dicloprop.
[0177] Example 10: Suppression of VGSC hyperactivity caused by Aβ25-35 peptide using anti-T1R3 antibody (10-1) Suppression of the potentiation of VGSC inward currents by Aβ peptides by anti-T1R3 antibody. HEKNav1.5 cells seeded on cover glasses were preincubated for at least 10 minutes in culture medium containing a 1:1,000 dilution of anti-T1R3 antibody. The HEK Nav1.5-seeded cover glasses were then transferred to recording solution (HBPS), and VGSC currents were recorded using a patch clamp. After the magnitude of the VGSC currents stabilized, Aβ peptide was administered and its effects / effects were measured. In cells treated with anti-T1R3 antibody, the magnitude of the VGSC currents was not enhanced at concentrations of Aβ peptide that amplify the VGSC currents, but a shift to the left (hyperpolarization) of the threshold for VGSC activation occurred. The cells were cultured in a medium containing Aβ25-35 peptide, and VGSC inward currents were measured as described above (Example 2-1, Figures 4, 6, and 7). A similar experiment was performed using SH-SY5Y cells, and the effect of anti-T1R3 antibody on VGSC current enhancement by Aβ25-35 was similarly suppressed when anti-T1R3 antibody was applied (Figure 29). In contrast, in both SH-SY5Y and HEK Nav1.5 cells, the effect of anti-T1R3 antibody was insufficient when incubated with anti-T1R3 antibody for 5 or 7 minutes, and the effect of Aβ25-35 peptide on VGSCs still occurred.
[0178] (10-2) Inhibition of Aβ peptide binding to neurons by anti-T1R3 antibodies. We confirmed that SH-SY5Y cells were fluorescently labeled when fluorescently labeled Aβ25-35 peptide (FL-Aβ25-35) was applied to SH-SY5Y cells for 20-30 minutes. Next, we used the fluorescently labeled Aβ25-35 peptide (FL-Aβ25-35) to examine whether the binding of the Aβ25-35 peptide itself to SH-SY5Y cells by T1R3 antibodies changed. Fluorescence from the FL-Aβ25-35 peptide was almost nonexistent in cells pretreated with T1R3 antibodies. (Figure 30, left) shows the control, and (Figure 30, right) shows that the binding of FL-Aβ25-35 to cells pretreated with anti-T1R3 antibodies was inhibited compared to the control. The anti-T1R3 antibody not only inhibited the amplification of VGSC currents by the Aβ25-35 peptide, but also tended to inhibit the binding of FL-Aβ25-35 peptide to SH-SY5Y cells. These findings suggest that the anti-T1R3 antibody may be a potential therapeutic agent that prevents the binding of Aβ peptide to neurons and prevents VGSC-mediated neuronal hyperexcitation.
[0179] (10-3) Enhancement of VGSC currents by colchicine, which has microtubule-degrading ability, and reduction of VGSC currents by latrunculin A, which has microfilament-degrading ability. Colchicine, which disassembles microtubules, enhances VGSC, while latrunculin A, which degrades microfilaments, reduces VGSC. We confirmed that enhancement of VGSC by Aβ25-35 also occurs in the presence of latrunculin A. Similar to TBB, artificial sweeteners, and dichlorprop, 12.6 μM latrunculin A suppressed VGSC currents by shifting the S-S curve in the hyperpolarized direction. In addition, suppression of the magnitude of the VGSC current itself was also observed. Under this condition, application of 12.5 μM Aβ25-35 doubled the magnitude of the VGSC current, which had been reduced by latrunculin A (Figure 31). This suggests that the polymerization state of microfilaments does not play an important role in the mechanism by which Aβ25-35 enhances VGSC currents. In particular, it is thought that the enhancement by Aβ25-35 is suppressed (regulated) through microtubules in cells in which the polymerization state of microfilaments is not artificially affected (normal state).
[0180] Next, to examine how the microtubule polymerization state affects the kinetics of VGSCs, we examined whether Aβ25-35 potentiated VGSC currents in the presence of the microtubule polymerization inhibitor colchicine. 2.25 μM colchicine was applied. In these cells, colchicine slightly shifted the IV curve toward hyperpolarization. At −20 mV, the change in VGSC current was limited, but at −40 mV, the magnitude of the VGSC current nearly doubled. Addition of 12.5 nM Aβ25-35 did not further enhance VGSC currents (Figure 32). In these cells, colchicine's potentiation of VGSC currents was relatively small, but the potentiation by Aβ25-35 was completely inhibited. These results suggest that Aβ25-35-induced potentiation of VGSC currents is dependent on the microtubule polymerization state. Although the results of an experiment using different cells are shown in FIG. 32E, an example of the increasing effect of colchicine on VGSC currents is shown.
[0181] Example 11: Screening method for inhibitors of the effects of Aβ peptides on cellular proteins, including VGSCs, using GFP-Tubulin-induced changes in microtubule fibrillar structure as an indicator. Patch clamp experiments demonstrated that the effect of Aβ peptides (Aβ25-35 peptides) on VGSC currents was observed even after the action of latrunculin A, which degrades microfilaments. This suggests that the polymerization state of cytoskeletal fibers (including microtubules), such as microfilaments, may be affected by Aβ peptides. Therefore, GFP-Tubulin was expressed in HEK Nav1.5, and the polymerization state of microtubules induced by Aβ peptides was observed. While the microtubule fibrillar structure was clearly visible in the control state, it was observed that this fibrillar structure disappeared upon treatment with Aβ peptides. Based on these findings, we concluded that observing the filamentous structure of microtubules in cells labeled with GFP-tubulin is a useful method for screening inhibitors of the effects of Aβ peptides on cellular proteins, including VGSCs (Figure 33A). To confirm that the structural changes in the microtubule structure are mediated by Type I taste receptors rather than by the direct action of Aβ peptides on microtubules, we treated cells with MSG, a ligand for the umami receptor, and demonstrated that structural changes in the microtubule structure were induced (Figure 33B). After the treatment with 5 mM MSG, the filamentous structure disappeared due to depolymerization of microtubules (tubulin).
[0182] Similar to TBB, artificial sweeteners, and dichlorprop, latrunculin A significantly inhibited VGSC currents by shifting the S-S curve toward hyperpolarization. Furthermore, the inhibitory effect of cinacalcet on VGSC currents was abolished by cytochalasin D, a compound that affects the microfilament polymerization state. Therefore, we investigated the effects of cinacalcet and Aβ1-42 peptide on the microfilament fibrillar structure in cells labeled with GFP-Actin (Figure 34). In this experiment, GFP-Actin did not clearly form a fibrillar structure compared with GFP-Tubulin. However, GFP-Actin condensation was observed in both cinacalcet and Aβ1-42 peptide-treated cells. These findings suggest that the kinetics of VGSC currents is influenced by the state of microfilament and microtubule polymerization. The above experimental method can be used to screen for compounds that regulate the activity of proteins that control ion channels and neural activity, including VGSC inhibition (analgesia, epilepsy, and suppression of neural hyperactivity), by labeling microtubules and microfilaments with GFP-tubulin, GFP-actin, etc. Furthermore, tubulin and actin can be simultaneously labeled with different fluorescent proteins. In this case, after fixing the test cells, visualization of tubulin and actin filaments can be achieved using fluorescently labeled antibodies or fluorescent phalloidin.
[0183] Since the present invention has demonstrated that changes in the cytoskeleton filament structure enhance or inhibit ion channels, screening methods using cells labeled with GFP-Tublin, GFP-Actin, etc. are effective in eliminating substances that directly or indirectly affect the cytoskeleton structure to ensure safety in the drug discovery process. This screening method is particularly effective in cardiac safety testing, where changes in VGSC function have a significant impact.
[0184] (Example 12) Screening method for developing highly safe artificial sweeteners - Artificial sweeteners and migraine - A relationship between migraine and Nav1.1 VGSC mutants has been reported. Migraine mutants of Nav1.1 have been reported to be of a type that induces a seizure-like hyperactive state and a type that reduces Nav1.1 expression. Since aspartame inhibits VGSC, it is speculated that excessive intake of aspartame contained in diet drinks, etc. may make attacks more likely to be induced in people with a genetic background prone to migraines. Other artificial sweeteners such as sucralose and saccharin also inhibit VGSC, so there is a possibility that they may pose a similar risk of inducing attacks. From the above, it is possible to develop highly safe artificial sweeteners (ICs that inhibit VGSCs) 50 and EC of sweetness perception 50 Since the presence or absence of an inhibitory effect on VGSCs is important for screening artificial sweeteners, the presence or absence of an inhibitory effect on VGSCs is essential when investigating sweetness perception. 50 and the IC required for VGSC suppression in this test. 50 The results of the comparison are shown below (Table 9).
[0185]
[0186] Judging from this table, IC that suppresses VGSC 50 EC of sweetness perception against concentration 50Among the compounds tested, saccharin had the lowest concentration, indicating that VGSC inhibition does not occur at the concentration required for sweetness perception. Other compounds, particularly aspartame, inhibited VGSC at concentrations one order of magnitude lower than the concentration required for taste perception. Thus, when developing safe artificial sweeteners, screening methods must be incorporated to examine the effects of cytoskeleton using GFP-actin and GFP-tubulin, in addition to the presence or absence of VGSC inhibition (Figures 33 and 34). At the same time, when developing analgesics or antiepileptic drugs, substances with minimal impact on taste, such as aspartame, are effective for inhibiting VGSC.
[0187] (Example 13) Investigation of Screening Methods T1Rs proteins (especially T1R3 and T1R2) act as receptors for amyloid β peptides and affect the magnitude and kinetic properties of the VGSC current. Therefore, as drug discovery screening methods for substances that prevent the binding of amyloid β peptides to T1Rs proteins (such as T1R3 antibodies), substances that suppress functional changes in VGSCs caused by the binding of amyloid β peptides to T1Rs proteins, and substances that bind to amyloid β peptides and prevent their binding to T1Rs proteins (amyloid β peptide antibodies), there are a method of observing functional changes in VGSC currents using the patch clamp method, and a method of measuring changes in cell membrane capacitance caused by amyloid β peptides (a method of measuring changes in cell membrane capacitance caused by amyloid β peptides (at low concentrations (< In the enhancement of VGSC current by amyloid β peptide (100 nM), endosomes containing VGSC are inserted into the cell membrane by exocytosis, increasing the overall cell membrane area and therefore the cell membrane capacitance. When the receptor is desensitized at high concentrations of amyloid β peptide, this process is reversed, and the endosome-derived cell membrane added by exocytosis is absorbed by endocytosis, reducing the cell membrane area containing VGSC. As a result, the overall cell area decreases, resulting in a decrease in cell membrane capacitance. The above-mentioned measurement methods, such as the nanoTouch method, a method using MEA or the like to observe changes in the excitability of cultured neurons as an indicator, and a method using the binding of fluorescently labeled amyloid β peptide to the cell membrane as a marker and observing inhibition of that binding (a method for screening substances (e.g., T1R3 antibodies)), can be used as screening methods using the present invention.
[0188] In addition, this patented invention has discovered that the function of ion channels, particularly VGSCs, is controlled by the polymerization state of the cytoskeleton. (Cytochalasin D, which stabilizes microfilaments, inhibits the action of Cinacalcet; Latrunculin A inhibits actin polymerization, inhibiting the structure of microfilaments promotes VGSC inactivation, reducing the number of active VGSCs in the physiological membrane potential range and thereby reducing VGSC activity in the whole cell; and colchicine, which inhibits microtubule polymerization, and taxol, which promotes polymerization, both enhance VGSCs.) Therefore, since drugs that may modify the cytoskeleton can cause harmful side effects, testing for the effect of cytoskeleton polymerization or depolymerization using cells marked with fluorescent substances or other agents is a safety screening method that should be performed in the early stages of drug discovery to ensure safety. The cytoskeleton's control of ion channel activity has also been reported in many cell types other than neurons. One example is the epithelial sodium channel expressed in epithelial cells (Chifflet et al. (2012)).
[0189] Example 14: Delay in the inactivation process of VGSC currents by monosodium glutamate (MSG) Monosodium glutamate (MSG) acts on the kinetics of Nav1.5 expressed in HEK and Nav1.2 and Nav1.7 VGSCs endogenously expressed in SH-SY5Y via T1R1 / T1R3 receptors, but this effect is more pronounced in HEK Nav1.5 VGSCs than in SH-SY5Y VGSCs. Monosodium glutamate acts on metabotropic glutamate receptors as well as T1R1 receptors. However, only T1R1 responds to the purine nucleotide monophosphates 5'IMP (inosine 5'-monophosphate) and 5'GMP (guanosine 5'-monophosphate). Furthermore, a study using intracellular calcium changes has revealed that the response to monosodium glutamate is synergistically enhanced by IMP (inosine monophosphate) and GMP (guanosine monophosphate) (Zhao et al. (2003)). From these findings, it can be concluded that the action of MSG on VGSCs is mediated by the T1R1 Type I taste receptor, not by metabotropic glutamate receptors.
[0190] In this example, we performed voltage-clamp experiments in HEK Nav1.5 cells to examine the effect of 5 mM monosodium glutamate (MSG) on the kinetics of VGSC currents. The inactivation process of transient currents was significantly delayed, and the amplitude of persistent VGSC currents was enhanced (Fig. 35). The effect of ramp stimulation on the inactivation process was observed in the -40 mV pulse following the ramp, with a slowly recovering tail current observed after MSG administration, which was not observed in controls. This suggests that in addition to slowing the inactivation process, the closing process of VGSCs at -40 mV was also delayed. (n = 3)
[0191] Specifically, we performed voltage-clamp experiments to examine the effect of 5 mM glutamate (MSG) on the kinetics of VGSC currents in HEK Nav1.5 neurons. Transient activation was examined using square-wave stimulation (Figure 35, top left), and persistent currents were examined using ramp stimulation (Figure 35, top right). The changes in current waveforms after MSG administration are shown for each experimental condition compared to the control (pre-treatment). While the inactivation process of the transient current was significantly delayed, MSG did not significantly alter the response of the persistent current to ramp stimulation. This suggests that while MSG delayed the inactivation of the transient current, it had no significant effect on the persistent current, which already had a less pronounced inactivating property. Interestingly, a tail current appeared after MSG administration at a −40 mV pulse following the ramp stimulation that induced persistent currents. This suggests that in addition to the delayed inactivation process, the closing process of VGSCs at −40 mV was also delayed. The IT (current amplitude vs. time) plots (Fig. 35, bottom) show the experimental results measured using square-wave stimulation (Fig. 35, top left). In this experiment, MSG had no effect on the amplitude of the transient current, but it delayed the inactivation process and amplified the amplitude of the sustained current over time. The X-axis shows the number of stimulations applied. Stimulation was performed every 8 seconds.
[0192] MSG administration delayed the inactivation of VGSC currents expressed in SH-SY5Y cells, but the extent of the delay was smaller than in HEK Nav1.5 cells. It is noteworthy that SH-SY5Y differentiated cells express action potentials similar to neurons. Therefore, it is possible to observe the effect of MSG on outward potassium currents in addition to inward (downward) VGSC currents. As a result, in SH-SY5Y neuronally differentiated cells, MSG reduced not only VGSC channel currents but also outward potassium currents (Figure 36A). As shown in Figure 37, the Aβ1-42 peptide, unlike Aβ25-35, which targets T1R3, inhibited VGSC currents by acting on T1R1 (Figure 37D, E). Therefore, to test the possibility that MSG's inhibitory effect on potassium currents is also mediated by the T1R1 umami Type I taste receptor, we expressed Kv1.2, which is predominantly expressed in neurons, in HEK cells and observed the effects of Aβ1-42. The results confirmed that Aβ1-42 inhibited Kv1.2 potassium currents in a concentration-dependent manner (Figure 36B). The upper panel shows the process of Aβ1-42 inhibition of Kv1.2 currents, and the lower panel shows the time series of this inhibition.
[0193] Actual voltage-clamp experiments using SH-SY5Y cells differentiated with retinoic acid (RA) are shown in Figure 36A (top panel) before and after (right panel) administration of 5 mM monosodium glutamate (MSG). The membrane potential was clamped at -120 mV (holding voltage), and voltage stimuli were applied from -70 mV to 60 mV in 10 mV intervals. Because the transient cation in the intracellular solution is potassium, an upward outward potassium current was also recorded (Figure 36A (top panel)). Because the recordings after MSG administration were taken more than 5 minutes later, its effect is considered complete. MSG administration delayed the inactivation of VGSC currents, but the extent of this delay was smaller than in the HEK Nav1.5 cells shown in Figure 35. It is noteworthy that in addition to the inward (downward) VGSC cu...
Claims
1. A ligand composition for controlling an activation current of a voltage-dependent ion channel in a neuron or cardiomyocyte via a Type I taste receptor present on the cell surface, comprising: A composition comprising a Type I taste receptor ligand that specifically binds to the Type I taste receptor and exerts an agonist-like or antagonist-like effect.
2. The composition of claim 1, wherein the voltage-dependent ion channel is a voltage-dependent sodium channel (VGSC), a voltage-dependent potassium channel (VGKC) or a voltage-dependent calcium channel (VGCC), and the Type I taste receptor is T1R1, T1R2 or T1R3, or a homodimer or heterodimer thereof.
3. The composition according to claim 2, wherein the Type I taste receptor ligand is a T1R3 ligand selected from lactisol, clofibrate and dicloprop, and structural analogs thereof, which specifically bind to the T1R3 and exert an antagonistic effect thereby inhibiting the activation current of the VGSC.
4. The composition according to claim 2 , wherein the Type I taste receptor ligand is an anti-human T1R3 antibody that inhibits the activation current of the VGSC by specifically binding to the T1R3 or T1R2 / T1R3.
5. The anti-human T1R3 antibody is (1) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least a sequence of 8 consecutive amino acids in the 229-258 aa region (SEQ ID NO: 5) of human T1R3 protein, thereby inhibiting the binding of Aβ25-35 peptide (SEQ ID NO: 1) to said region and suppressing activated VGSC current; (2) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least a continuous 8 amino acid sequence in the 303-396 aa region (SEQ ID NO: 6) of human T1R3 protein, thereby inhibiting the binding of Aβ1-40 peptide (SEQ ID NO: 3) to said region, and that acts on human T1R2 to suppress activated VGSC current; or (3) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least a continuous 8 amino acid sequence in the 400-570 aa region (SEQ ID NO: 7) of human T1R3 protein, thereby inhibiting the binding of Aβ1-42 peptide (SEQ ID NO: 4) to said region and suppressing activated VGSC current; The composition according to claim 4, characterized in that it is any one of the following:
6. The composition according to claim 3, wherein the Type I taste receptor ligand is a T1R2 ligand or a T1R2 / T1R3 ligand selected from saccharin, aspartame, sucralose, and Gymnema tea extract, and structural analogs thereof, characterized in that the ligand specifically binds to the T1R2 or T1R2 / T1R3 and exerts an antagonistic effect thereby inhibiting the activated current of the VGSC.
7. The composition according to claim 2, wherein the Type I taste receptor ligand is a T1R1 ligand that specifically binds to the T1R1 or T1R1 / T1R3 to exert an agonist-like effect, thereby shifting the IV curve of the VGSC-activated current to the left, or delaying inactivation, or inhibiting the VGKC-activated current.
8. A pharmaceutical composition for preventing and / or treating a disease caused by the amplifying or inhibiting effect of VGSC and / or VGKC currents, which is generated when a sweet amino acid or umami substance, or Aβ peptide binds to an endogenous Type I taste receptor on the surface of a neuronal cell or cardiomyocyte, the pharmaceutical composition comprising as an active ingredient a Type I taste receptor ligand that specifically binds to T1R1, T1R2 or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect.
9. The pharmaceutical composition described in claim 8, wherein the Aβ peptide is an Aβ peptide having the amino acid sequence shown in SEQ ID NO:1, or a mixture thereof.
10. The pharmaceutical composition according to claim 9, wherein the Aβ peptide or a mixture thereof is any Aβ peptide selected from Aβ25-35 peptide, Aβ1-38 peptide, Aβ1-40 peptide and Aβ1-42 peptide, or a mixture thereof, or Aβ1-42 and Aβ1-40 in the Aβ42 / 40 concentration ratio observed in the cerebral spinal fluid (CSF) or serum of AD patients (AD-D).
11. The pharmaceutical composition according to any one of claims 8 to 10, wherein the disease caused by the amplifying or inhibiting effect of the VGSC and / or VGKC currents described in claim 8 is a neurological disease in which an epileptiform neuronal hyperactivity state is observed.
12. The pharmaceutical composition according to claim 11, wherein the neurological disease in which epileptiform neuronal hyperactivity is observed is selected from the group consisting of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies, focal cranial neurological symptoms of cerebrovascular disease, epilepsy, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, focal cranial neurological symptoms in areas damaged by traumatic brain injury, Huntington's disease, spinocerebellar degeneration, and multiple sclerosis.
13. A pharmaceutical composition for preventing and / or treating neuropathic pain associated with nerve overactivity caused by the amplification of VGSC currents resulting from the binding of sweet amino acids or umami substances, or Aβ peptides to endogenous Type I taste receptors on the surface of nerve cells, the pharmaceutical composition comprising as an active ingredient a Type I taste receptor ligand that specifically binds to T1R1, T1R2 or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect.
14. The pharmaceutical composition according to claim 13, wherein the neuropathic pain is selected from the group consisting of peripheral neuropathy caused by administration of an anticancer drug, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and diabetic polyneuropathy.
15. A pharmaceutical composition described in claim 8 or claim 13, wherein the Type I taste receptor ligand described in claim 8 or claim 13 is a ligand that specifically binds to T1R2 or T1R2 / T1R3 and exerts an antagonist-like effect, and is a ligand selected from saccharin, aspartame, sucralose, and Gymnema tea extract and structural analogues thereof.
16. The pharmaceutical composition according to claim 8 or claim 13, wherein the Type I taste receptor ligand according to claim 8 or claim 13 is a ligand that specifically binds to T1R3 and exerts an antagonist-like effect, and is a ligand selected from cinacalcet, NPS-2143, lactisol, clofibrate, dicloprop, and structural analogs thereof.
17. The Type I taste receptor ligand according to claim 8 or claim 13 is an anti-human T1R3 antibody that is a ligand that specifically binds to T1R3 or T1R2 / T1R3 and exerts an antagonistic effect, (1) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least a sequence of 8 consecutive amino acids in the 229-258 aa region of human T1R3, thereby inhibiting the binding of Aβ25-35 peptide to said region and suppressing the active current of VGSCs amplified by the Aβ25-35 peptide; (2) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least 8 consecutive amino acids in the 303-396 aa region of human T1R3 and acts on human T1R2 to inhibit the binding of Aβ1-40 peptide to the region and suppress the active current of VGSCs amplified by Aβ1-40 peptide; or (3) an anti-human T1R3 antibody that specifically binds to an epitope comprising at least a sequence of 8 consecutive amino acids in the 400-570 aa region of human T1R3, thereby inhibiting the binding of Aβ1-42 peptide to said region and suppressing the active current of VGSCs amplified by the Aβ1-42 peptide; The pharmaceutical composition according to claim 8 or claim 13, characterized in that it is any one of the following:
18. A pharmaceutical composition for preventing and / or treating an epileptiform neuronal hyperactivity state caused by amplification of VGSC current enhanced via endogenous Type I taste receptors due to a decrease in the difference in the ratio of Aβ1-42 / Aβ1-40 contained in neurospinal fluid (CSF), or a neurological disease in which cell barrier dysfunction or decreased neuronal plasticity is observed, the pharmaceutical composition comprising as an active ingredient a Type I taste receptor ligand that specifically binds to T1R1, T1R2 or T1R3, or a homodimer or heterodimer thereof, and exerts an antagonistic effect.
19. The pharmaceutical composition described in claim 18, wherein the neurological disease is Alzheimer's disease (AD).
20. The pharmaceutical composition of claim 18, wherein the Type I taste receptor ligand is β-alanine.
21. A measurement cell for measuring and evaluating a change in the amplification or inhibition of VGSC and / or VGKC activation current caused via a human Type I taste receptor by an auto patch clamp membrane voltage clamp method, the measurement cell being a suspension cell selected from the following (i) or (ii): (i) a human suspension cell endogenously expressing VGSC and / or VGKC together with a Type I taste receptor; or (ii) A blood cell-derived suspended cell or an animal cell that has been made into a suspended cell, in which a human-derived Type I taste receptor gene and a human-derived VGSC and / or VGKC gene are forcibly expressed.
22. A method for screening for a substance that physically inhibits binding of an Aβ peptide to a human Type I taste receptor, which is an Aβ peptide receptor, comprising: A method comprising the following steps (1) to (4): (1) administering a test substance to a culture medium containing cultured cells expressing a human Type I taste receptor on the cell surface; (2) A process of administering fluorescently labeled Aβ peptide to the cells administered with the test substance in (1) and to the control cells not administered with the test substance; (3) A process of washing away excess fluorescently labeled Aβ peptide; (4) When a significant decrease in the fluorescence intensity on the surface of the cultured cells when the test substance is administered is observed or measured compared to the fluorescence intensity on the surface of the control cells, the test substance is selected as a candidate substance having the effect of inhibiting the binding of Aβ peptide to the human Type I taste receptor, which is an Aβ peptide receptor.
23. The method according to claim 22, characterized in that the human Type I taste receptor is human T1R1, T1R2 or T1R3, or a homodimer or heterodimer thereof, and the cultured cells expressing the human Type I taste receptor on their cell surface used in step (1) are cultured human neurons, cultured human cardiomyocytes, or cultured cells of a mouse or other experimental animal having a human Type I taste receptor in which the T1R1, T1R2 or T1R3 gene has been replaced with a human gene.
24. The method according to claim 22 or 23, wherein the human Type I taste receptor is human T1R2 / T1R3, and the Aβ peptide administered to the culture solution in the step (2) is Aβ25-35 peptide, Aβ1-40, Aβ1-42, or a mixture thereof.
25. A method for screening for a substance that inhibits the activity of Aβ peptide, sweet amino acid, or umami substance against Type I taste receptor endogenously expressed in human nerve cells or cardiomyocytes, comprising the following steps (1) to (4): (1) establishing a control value by culturing cultured human nerve cells or cultured cells expressing a human Type I taste receptor on the cell surface in a culture medium containing a calcium-sensitive fluorescent reagent and measuring the intracellular calcium concentration using the fluorescent reagent; (2) administering Aβ peptide, sweet amino acid, or umami substance to a cell culture solution cultured in the same manner as in step (1), and then measuring the calcium concentration in the cells using the same measurement method as in step (1); (3) administering a test substance to a cell culture solution cultured in the same manner as in step (1), and then administering Aβ peptide, a sweet amino acid, or an umami substance to the cell culture solution, and measuring the calcium concentration in the cells using the same measurement method as in step (1); (4) A process for evaluating and selecting the test substance as a substance that inhibits the change in intracellular calcium concentration mediated by the Type I taste receptor caused by Aβ peptide, sweet amino acid, or umami substance, when the intracellular calcium concentration measured in step (3) is significantly decreased compared to the calcium concentration measured in step (2), and as a substance that inhibits the activity of the Aβ peptide, sweet amino acid, or umami substance on the Type I taste receptor.
26. A method for screening candidate compounds for active ingredients of a pharmaceutical composition for preventing and / or treating a disease caused by the amplifying or inhibiting action of VGSC and / or VGKC currents caused by the binding of Aβ peptide, sweet amino acid, or umami substance to a Type I taste receptor endogenously expressed in human nerve cells or cardiomyocytes, the method comprising the following steps (1) to (6): (1) preparing, as measurement cells, cultured human nerve cells expressing human Type I taste receptors on the cell surface, cultured human cardiomyocytes, or human-derived cultured cells forcibly expressing neuronal or cardiomyocyte-type VGSCs and / or VGKCs, or mouse or other cultured animal cells expressing Type I taste receptors in which the T1R1, T1R2, or T1R3 genes have been replaced with human-derived genes, and culturing the cells in a culture medium; (2) measuring the VGSC and / or VGKC currents of the measurement cells using a patch clamp method or other membrane voltage clamp method to establish control values; (3) administering the Aβ peptide, sweet amino acid, or umami substance to the culture medium of the measurement cells, measuring the VGSC and / or VGKC current of the cells using the same method as in step (2), and measuring the VGSC and / or VGKC current generated by binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor; (4) then administering a test substance to the culture solution of the cells and measuring the VGSC and / or VGKC currents of the cells using a method similar to that of step (2); (5) a step of evaluating the test substance as a substance capable of controlling the amplifying or inhibiting action of the Aβ peptide, or a sweet amino acid, or an umami substance on the VGSC and / or VGKC current mediated by the Type I taste receptor in human nerve cells or cardiomyocytes, when the measured value of the VGSC and / or VGKC current measured in the step (4) significantly changes either or both of the amplifying and inhibiting amount of the VGSC and / or VGKC current measured in the step (3); (6) A step of selecting, in the step (5), the test substance evaluated as a compound capable of controlling the amplifying or inhibiting action of the Aβ peptide, or a sweet amino acid, or an umami substance on the VGSC and / or VGKC current mediated by the Type I taste receptor in human nerve cells or cardiomyocytes, as a candidate compound for the active ingredient of the pharmaceutical composition.
27. A screening method for candidate compounds for active ingredients of a pharmaceutical composition for preventing and / or treating a disease caused by the amplifying or inhibiting action of VGSC and / or VGKC currents caused by the binding of Aβ peptide, sweet amino acid, or umami substance to Type I taste receptors endogenously expressed on the surface of human nerve cells or cardiomyocytes, using an auto patch clamp membrane voltage clamp method, the method comprising the following steps (1) to (6): (1) preparing human suspension cells expressing or endogenously expressing human-derived T1R1, T1R2 or T1R3 genes, and neuronal or cardiac VGSC and / or VGKC genes as measurement cells, and culturing the cells in a culture medium; (2) measuring the VGSC and / or VGKC currents of the measurement cells using an auto patch clamp method to establish control values; (3) administering the Aβ peptide, sweet amino acid, or umami substance to the culture medium of the measurement cells, measuring the VGSC and / or VGKC current of the cells using the same method as in step (2), and measuring the VGSC and / or VGKC current generated by binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor; (4) then administering a test substance to the culture solution of the cells and measuring the VGSC and / or VGKC currents of the cells using a method similar to that of step (2); (5) A step of evaluating the test substance as a substance capable of controlling the amplifying or inhibiting action of the Aβ peptide, sweet amino acid, or umami substance on the VGSC and / or VGKC current mediated by the Type I taste receptor in human nerve cells or cardiomyocytes, when the measured value of the VGSC and / or VGKC current measured in the step (4) shows a value that significantly inhibits the amplifying or inhibiting amount of either or both of the VGSC and / or VGKC current measured in the step (3). (6) A step of selecting, in the step (5), the test substance evaluated as a compound capable of controlling the amplifying or inhibiting action of the Aβ peptide, or a sweet amino acid, or an umami substance on the VGSC and / or VGKC current mediated by the Type I taste receptor in human nerve cells or cardiomyocytes, as a candidate compound for the active ingredient of the pharmaceutical composition.
28. The amplifying or inhibiting effect of VGSC and / or VGKC current causing the disease according to claim 26 or claim 27 is caused by the Aβ peptide binding to the Type I taste receptor being at an Aβ42 / 40 concentration ratio observed in CSF or serum of an AD patient (AD-D), The method according to claim 26 or 27, wherein the Aβ peptides administered to the culture solution of the measurement cells in the step (3) are Aβ1-42 and Aβ1-40 adjusted to the Aβ42 / 40 concentration ratio (AD-D).
29. A method for screening a candidate compound for an active ingredient of a pharmaceutical composition for preventing and / or treating a disease caused by the amplification of hyperexcitation of human nerve cells or cardiomyocytes caused by binding of Aβ peptide, sweet amino acid, or umami substance to a Type I taste receptor endogenously expressed in said nerve cells or cardiomyocytes, the method comprising the following steps (1) to (6): (1) preparing cultured human nerve cells expressing human Type I taste receptors on the cell surface, cultured human cardiomyocytes, or mouse or other cultured animal cells expressing Type I taste receptors in which the T1R1, T1R2, or T1R3 gene has been replaced with a human-derived gene, as measurement cells, and culturing the cells in a culture medium; (2) measuring and / or recording the waveforms of spontaneous or stimulus-induced action potentials in the measurement cells by a patch clamp method (current clamp mode), a NanoTouch method, or an MEA method, or a method using a fluorescent membrane potential-sensitive reagent or a fluorescent intracellular calcium-sensitive reagent, and establishing a control value; (3) administering Aβ peptide, sweet amino acid, or umami substance to the culture solution of the cells, and measuring and / or recording the waveform of the action potential generated by the binding of the Aβ peptide, sweet amino acid, or umami substance to the Type I taste receptor using a method similar to that of step (2); (4) then administering a test substance to the culture solution of step (3) and measuring and / or recording the action potential generated by the administration of the test substance using a method similar to that of step (2); (5) evaluating the test substance as a candidate for a substance capable of suppressing the enhanced excitability (hyperactivity) of nerve cells or cardiac muscle cells mediated by Type I taste receptors for Aβ peptides, sweet amino acids, or umami substances in human nerve cells or cardiac muscle cells when the measured value of the occurrence frequency of the action potential or the shape of the waveform measured in step (4) shows a significant change compared to the occurrence frequency of the action potential or the shape of the waveform measured in step (3); (6) A step of selecting the test substance evaluated in step (5) as a candidate substance capable of suppressing the increased excitability (hyperactivity) of nerve cells or cardiac muscle cells mediated by Type I taste receptors of Aβ peptides, sweet amino acids, or umami substances in human nerve cells or cardiac muscle cells, as a candidate compound for the active ingredient of the pharmaceutical composition.
30. A method for screening for a compound having an effect of restoring Aβ1-42 and Aβ1-40 in the Aβ42 / 40 concentration ratio (AD-D) observed in AD patients contained in human cerebrospinal fluid (CSF) or serum, or a compound having an effect of restoring cell barrier dysfunction mediated by Type I taste receptors in the human brain or blood vessels by sweet amino acids or umami substances, the method comprising the following steps (1) to (5): (1) preparing, as measurement cells, human vascular epithelial cells or cultured human cells expressing Type I taste receptors on the cell surface and capable of being formed into sheets, or mouse or other cultured animal cells expressing Type I taste receptors in which the T1R1, T1R2 or T1R3 gene has been replaced with a human-derived gene, and culturing the cells in the form of a sheet on a conductive plate; (2) applying a current or voltage between the extracellular fluid of the cell sheet for measurement and the conductive plate to measure the impedance (resistance) value and determine the control level; (3) a step of acting an Aβ peptide mixture containing Aβ1-42 and Aβ1-40 adjusted to (AD-D), or a sweet amino acid or an umami substance, on the human Type I taste receptor on the surface of the cell sheet for measurement, measuring the impedance (resistance) value, and confirming that a decrease in the impedance value is observed; (4) measuring the impedance value when a test substance is applied to the cell sheet; (5) When the impedance value measured in step (4) is increased compared to the value measured in step (3), it is evaluated that the barrier function in the cell sheet has been restored by the action of the test substance, and the test substance is selected as a candidate compound capable of restoring cell barrier function impairment in CSF or blood vessels mediated by human Type I taste receptors of an Aβ peptide mixture having an Aβ42 / 40 concentration ratio in AD-D, or sweet amino acids or umami substances.
31. A method for screening for a compound having an effect of restoring barrier function impairment of vascular cells or reduced plasticity of nerve cells mediated by a human Type I taste receptor caused by an Aβ peptide, a sweet amino acid, or an umami substance, comprising the following steps (1) to (5): (1) preparing and culturing, as measurement cells, cultured human vascular epithelial cells, cultured human nerve cells, or other human cultured cells that endogenously express human Type I taste receptors on the cell surface, or cultured mouse or other animal cells that express Type I taste receptors in which the T1R1, T1R2, or T1R3 genes have been replaced with human-derived genes; (2) determining a control level of the morphology and dynamics of the test cells; (3) reacting Aβ peptide, sweet amino acid, or umami substance with the human Type I taste receptor on the surface of the measurement cell, and observing changes in the morphology and dynamics of the cell, and / or changes in the area or volume, and / or changes in the contraction and motility of the neurites; (4) then observing changes in the morphology and dynamics of the cells, and / or changes in the area or volume of the cells, and / or changes in the contraction and motility of neurites when a test substance is applied to the cells; (5) If the amount of change in the morphology or dynamics of the cells and / or the amount of change in the area or volume observed in step (4) is significantly reduced compared to the amount of change observed in step (3), or if the contraction or motility of the neurites is restored, it is evaluated that the barrier function of the cells or the plasticity of the nerve cells has been restored by the action of the test substance, and the test substance is evaluated and selected as a candidate compound capable of restoring the cell barrier function impairment or the decrease in the plasticity of the nerve cells mediated by the human Type I taste receptor in the CSF or blood vessels caused by the Aβ peptide, sweet amino acid, or umami substance.
32. The method according to claim 31, wherein the Aβ peptide administered in step (3) of claim 31 is an Aβ peptide mixture containing Aβ1-42 and Aβ1-40 adjusted to the Aβ42 / 40 concentration ratio observed in the CSF or serum of AD patients (AD-D).
33. A method for screening a candidate compound for an active ingredient of a pharmaceutical composition for preventing and / or treating a disease caused by cell barrier dysfunction or decreased neuronal plasticity resulting from binding of Aβ peptide, sweet amino acid, or umami substance to a Type I taste receptor endogenously expressed in human neurons or cardiac muscle cells, comprising: A step of selecting a test substance evaluated by the screening method according to any one of claims 30 to 32 as a candidate compound capable of recovering cell barrier dysfunction or reduced neuronal plasticity mediated by human Type I taste receptors induced by Aβ peptides, sweet amino acids, or umami substances, as a candidate compound for the active ingredient of the pharmaceutical composition.
